EP1047425A1 - Integrin receptor antagonists - Google Patents

Integrin receptor antagonists

Info

Publication number
EP1047425A1
EP1047425A1 EP98962096A EP98962096A EP1047425A1 EP 1047425 A1 EP1047425 A1 EP 1047425A1 EP 98962096 A EP98962096 A EP 98962096A EP 98962096 A EP98962096 A EP 98962096A EP 1047425 A1 EP1047425 A1 EP 1047425A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
aryl
oxo
tetrahydro
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98962096A
Other languages
German (de)
French (fr)
Other versions
EP1047425A4 (en
Inventor
Mark E. Duggan
Robert S. Meissner
James J. Perkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9810182.7A external-priority patent/GB9810182D0/en
Priority claimed from GBGB9811283.2A external-priority patent/GB9811283D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1047425A1 publication Critical patent/EP1047425A1/en
Publication of EP1047425A4 publication Critical patent/EP1047425A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors ⁇ v ⁇ 3, ⁇ v ⁇ 5, and/or ⁇ v ⁇ 6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
  • Integrin receptors are heterodimeric transmembrane receptors through which cells attach and communicate with extracellular matrices and other cells (See S.B. Rodan and G.A. Rodan, "Integrin Function In Osteoclasts", Journal of Endocrinology , Vol. 154, S47- S56 (1997), which is incorporated by reference herein in its entirety).
  • the compounds herein are useful for inhibiting bone resorption.
  • Bone resorption is mediated by the action of cells known as osteoclasts.
  • Osteoclasts are large multinucleated cells of up to about 400 mm in diameter that resorb mineralized tissue, chiefly calcium carbonate and calcium phosphate, in vertebrates.
  • Osteoclasts are actively motile cells that migrate along the surface of bone, and can bind to bone, secrete necessary acids and proteases, thereby causing the actual resorption of mineralized tissue from the bone. More specifically, osteoclasts are believed to exist in at least two physiological states, namely, the secretory state and the migratory or motile state.
  • osteoclasts are flat, attach to the bone matrix via a tight attachment zone (sealing zone), become highly polarized, form a ruffled border, and secrete lysosomal enzymes and protons to resorb bone.
  • the adhesion of osteoclasts to bone surfaces is an important initial step in bone resorption.
  • the osteoclasts migrate across bone matrix and do not take part in resorption until they again attach to bone.
  • Integrins are involved in osteoclast attachment, activation and migration.
  • the most abundant integrin in osteoclasts e.g., in rat, chicken, mouse mid human osteoclasts, is an integrin receptor known as ⁇ v ⁇ 3, which is thought to interact in bone with matrix proteins that contain the RGD sequence.
  • Antibodies to ⁇ v ⁇ 3 block bone resorption in vitro indicating that this integrin plays a key role in the resorptive process.
  • ⁇ v ⁇ 3 ligands can be used effectively to inhibit osteoclast mediated bone resorption in vivo in mammals.
  • osteoporosis hypercalcemia of malignancy
  • osteopenia due to bone metastases
  • periodontal disease hyperparathyroidism
  • hyperparathyroidism hyperparathyroidism
  • periarticular erosions in rheumatoid arthritis Paget's disease
  • immobilization- induced osteopenia and glucocorticoid-induced osteoporosis. All of these conditions are characterized by bone loss, resulting from an imbalance between bone resorption, i.e. breakdown, and bone formation, which continues throughout life at the rate of about 14% per year on the average.
  • the rate of bone turnover differs from site to site; for example, it is higher in the trabecular bone of the vertebrae and the alveolar bone in the jaws than in the cortices of the long bones.
  • the potential for bone loss is directly related to turnover and can amount to over 5% per year in vertebrae immediately following menopause, a condition which leads to increased fracture risk.
  • ⁇ v ⁇ 3 ligands have been found to be useful in treating and/or inhibiting restenosis, i.e. recurrence of stenosis after corrective surgery on the heart valve, atherosclerosis, diabetic retinopathy, macular degeneration, and angiogenesis, i.e. formation of new blood vessels.
  • restenosis i.e. recurrence of stenosis after corrective surgery on the heart valve
  • atherosclerosis CAD
  • diabetic retinopathy macular degeneration
  • angiogenesis i.e. formation of new blood vessels.
  • angiogenesis i.e. formation of new blood vessels.
  • ⁇ v ⁇ 3 antagonists which inhibit angiogenesis can be useful in the treatment of cancer by inhibiting tumor growth (See e.g., Brooks et al., Cell, 79:1157- 1164 (1994), which is incorporated by reference herein in its entirety).
  • compounds of this invention can also inhibit neovascularization by acting as antagonists of the integrin receptor, ⁇ v ⁇ .
  • a monoclonal antibody for v ⁇ has been shown to inhibit VEGF- induced angiogenesis in rabbit cornea and the chick chorioallantoic membrane model (See M.C. Friedlander, et al., Science 270, 1500-1502, (1995), which is incorporated by reference herein in its entirety).
  • compounds that antagonize ⁇ v ⁇ are useful for treating and preventing macular degeneration, diabetic retinopathy, tumor growth, and metastasis.
  • compounds of the instant invention can inhibit angiogenesis and inflammation by acting as antagonists of the integrin receptor, ⁇ v ⁇ 6, which is expressed during the later stages of wound healing and remains expressed until the wound is closed (See Christofidou-Solomidou, et al., "Expression and Function of Endothelial Cell ⁇ v Integrin Receptors in Wound-Induced Human Angiogenesis in Human Skin/SCID Mice. Chimeras. American Journal of Pathology. Vol. 151, No. 4, pp. 975-983 (October 1997), which is incorporated by reference herein in its entirety). It is postulated that ⁇ v ⁇ 6 plays a role in the remodeling of the vasculature during the later stages of angiogenesis.
  • ⁇ v ⁇ 6 participates in the modulation of epithelial inflammation and is induced in response to local injury or inflammation (See Xiao-Zhu Huang, et al., "Inactivation of the Integrin ⁇ 6 Subunit Gene Reveals a Role of Epithelial Integrins in Regulating Inflammation in the Lungs and Skin," Journal of Cell Biology. Vol. 133, No.4, pp. 921-928 (May 1996), which is incorporated by reference herein in its entirety). Accordingly, compounds that antagonize ⁇ v ⁇ 6 are useful in treating or preventing cancer by inhibiting tumor growth and metastasis.
  • certain compounds of this invention antagonize both the ⁇ v ⁇ 3 and ⁇ v ⁇ receptors.
  • These compounds referred to as “dual ⁇ v ⁇ 3/ ⁇ v ⁇ antagonists,” are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, tumor growth, and metastasis.
  • certain compounds of this invention are useful as mixed ⁇ v ⁇ 3, ⁇ v ⁇ , and ⁇ v ⁇ 6 receptor antagonists.
  • the present invention relates to compounds of the formula
  • W is selected from the group consisting of
  • a ⁇ - or 6-membered monocyclic aromatic or nonaromatic ring system having 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, 0, and S wherein the ring nitrogen atoms are ⁇ unsubstituted or substituted with one R ⁇ substituent and the ring carbon atoms are unsubstituted or substituted with one or two Rl substituents, and
  • a 9- to 14-membered polycyclic ring system wherein one or more 10 of the rings is aromatic, and wherein the polycyclic ring system has 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, O, and S, and wherein the ring nitrogen atoms are unsubstituted or substituted with one Rl substituent and the ring carbon atoms are unsubstituted or substituted with one or two R ⁇ l ⁇ substituents;
  • X is selected from the group consisting of
  • any methylene (CH2) carbon atom is either 20 unsubstituted or substituted with one or two R ⁇ substitutents; and a ⁇ - or 6-membered monocyclic aromatic or nonaromatic ring system having 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, 0, and S wherein the ring nitrogen atoms are unsubstituted or substituted with one Rl substituent and the ring carbon ⁇ atoms are unsubstituted or substituted with one or two Rl substituents;
  • Y is selected from the group consisting of
  • l ⁇ Z is a ⁇ membered aromatic or nonaromatic mono- or bicyclic ring system having 0 to 3 heteroatoms selected from the group consisting of N, 0, and S, and wherein the ring system is either unsubstituted or substituted with 0, 1, 2, or 3 oxo or thio substituents, and either unsubstituted or substituted with one or more substituents
  • R ⁇ -O independently selected from the group consisting of R ⁇ -O, R ⁇ , and R*2 ;
  • R ⁇ and R ⁇ are each independently selected from the group consisting of hydrogen, halogen, C ⁇ -10 alkyl, C3-8 cycloalkyl, ⁇ C3-8 cycloheteroalkyl, C3-8 cycloalkyl Ci-6 alkyl,
  • each R3 is independently selected from the group consisting of hydrogen, 10 aryl,
  • C ⁇ -6 alkylsulfonyl 20 C ⁇ _6 alkylsulfonyl C ⁇ -6 alkyl, arylsulfonyl C ⁇ -6 alkyl, aryl C ⁇ _6 alkylsulfonyl, aryl C ⁇ _6 alkylsulfonyl C ⁇ -6 alkyl,
  • each R4 is independently selected from the group consisting of hydrogen, l ⁇ aryl, aminocarbonyl,
  • R5 and R6 are each independently selected from the group consisting of hydrogen", C ⁇ . ⁇ o alkyl, aryl, aryl-(CH 2 )r-0-(CH 2 ) s -, aryl-(CH 2 ) r S(0)p-(CH 2 ) s -, aryl-(CH )r-C(0)-(CH 2 ) s -, aryl-(CH 2 ) r -C(0)-N(R4)-(CH 2 ) s -, aryl-(CH 2 ) r -N(R4)-C(0)-(CH 2 ) s -, aryl-(CH 2 )r-N(R4)-C(0)-(CH 2 ) s -, aryl-(CH 2 )r-N(R4)-(CH 2 ) s -, halogen, hydroxyl,
  • CH 2 CH-(CH 2 ) t -
  • X0 C ⁇ _6 alkyl-CH CH-(CH 2 )t-
  • aryl C ⁇ -8 alkyDpaminocarbonyl, and (aryl C ⁇ _8 alkyDpaminocarbonyl C ⁇ -6 alkyl; or R5 and R6 are taken together with the carbon atom to which they are attached to form a carbonyl group, wherein any of the alkyl groups of ⁇ or R ⁇ are either unsubstituted or substituted with one to three Rl substituents, and provided that each R ⁇ and R ⁇ are selected such that in the resultant compound the carbon atom to which R ⁇ and R ⁇ are attached is itself attached to no more than one heteroatom;
  • R7 and R8 are each independently selected from the group consisting of hydrogen
  • CH CH-(CH 2 ) t -
  • C ⁇ _6 alkyl-CH CH-(CH ) t -
  • C3-7 cycloalkyl-CH CH-(CH 2 ) t -
  • aryl-CH CH-(CH 2 ) t -
  • l ⁇ C ⁇ -6 alkylaryl-CH CH-(CH 2 )t-
  • R9 is selected from the group consisting of hydrogen
  • R O , RU, and Rl2 are each independently selected from the group consisting of hydrogen,
  • C ⁇ _8 alkyl 0 . aryl, halogen, hydroxyl, oxo, aminocarbonyl, C3-8 cycloalkyl, amino C ⁇ -6 alkyl, (aryl)paminocarbonyl, hy dr oxycarb onyl , ⁇ (aryl C ⁇ -5 alkyDpaminocarbonyl, hydroxycarbonyl C ⁇ -6 alkyl, aryl C ⁇ -6 alkyl, (C ⁇ -6 alkyDpamino C ⁇ .6 alkyl, (aryl C ⁇ -6 alkyDpamino C -6 alkyl, 10 C ⁇ -8 alkylsulfonyl,
  • aryl C ⁇ -6 alkyDpamino ⁇ (aryl C ⁇ -6 alkyDpamino C ⁇ -6 alkyl, aryl carbonyl oxy, aryl C ⁇ -6 alkylcarbonyloxy, (C ⁇ -6 alkyl )paminocarbonyloxy, C ⁇ -8 alkylsulfonylamino, 0 arylsulfonylamino,
  • the present invention also relates to pharmaceutical compositions comprising the compounds of the present invention and a pharmaceutically acceptable carrier.
  • the present invention also relates to methods for making ⁇ the pharmaceutical compositions of the present invention.
  • the present invention also relates to methods for eliciting an integrin receptor antagonizing effect in a mammal in need thereof by administering the compounds and pharmaceutical compositions of the present invention.
  • the present invention also relates to methods for inhibiting bone resorption, restenosis, atherosclerosis, inflammation, viral disease, diabetic retinopathy, macular degeneration, angiogenesis, wound healing, tumor growth, and metastasis by administering the compounds and pharmaceutical compositions of the present invention.
  • the present invention also relates to methods for treating osteoporosis by administering the compounds and pharmaceutical compositions of the present invention.
  • the present invention relates to compounds useful as integrin receptor antagonists.
  • Representative compounds of the present invention are described by the following chemical formula:
  • W is selected from the group consisting of
  • a ⁇ - or 6-membered monocyclic aromatic or nonaromatic ring system having 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, 0, and S wherein the ring nitrogen atoms are l ⁇ unsubstituted or substituted with one Rl substituent and the ring carbon atoms are unsubstituted or substituted with one or two l substituents, and
  • a 9- to 14-membered polycyclic ring system wherein one or more 0 of the rings is aromatic, and wherein the polycyclic ring system has 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, O, and S, and wherein the ring nitrogen atoms are unsubstituted or substituted with one Rl substituent and the ring carbon atoms are unsubstituted or substituted with one or two R ⁇ substituents;
  • X is selected from the group consisting of
  • any methylene (CH 2 ) carbon atom is either unsubstituted or substituted with one or two Rl substitutents; and a ⁇ - or 6-membered monocyclic aromatic or nonaromatic ring system having 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, O, and S wherein the ring nitrogen atoms are unsubstituted or substituted with one Rl substituent and the ring carbon atoms are unsubstituted or substituted with one or two Rl substituents;
  • Y is selected from the group consisting of
  • any methylene (CH 2 ) carbon atom in Y, other than in R4, can 0 be substituted by one or two R ⁇ substituents;
  • Z is a ⁇ membered aromatic or nonaromatic mono- or bicyclic ring system having 0 to 3 heteroatoms selected from the group consisting of N, O, and S, and wherein the ring system is either unsubstituted or substituted with 0, 1, 2, or 3 oxo or thio substituents, and either unsubstituted or substituted with one or more substituents independently selected from the group consisting of RlO, RU, and 2 ;
  • Rland R ⁇ are each independently selected from the group consisting of hydrogen, halogen, C ⁇ . ⁇ o alkyl, C3-8 cycloalkyl, C3-8 cycloheteroalkyl, C3-8 cycloalkyl C ⁇ -6 alkyl, C3-8 cycloheteroalkyl C ⁇ -6 alkyl, aryl, aryl C ⁇ -8 alkyl, amino, X0 amino C ⁇ -8 alkyl, C ⁇ -3 acylamino, C ⁇ _3 acylamino C ⁇ -8 alkyl,
  • C ⁇ -6 alkyl nitro, cyano, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, C ⁇ -8 alkyl-S(0)p, (C ⁇ -8 alkyDpaminocarbonyl, C ⁇ -8 alkyloxycarbonylamino, (C ⁇ -8 alkyl )paminocarbonyloxy, (aryl C ⁇ -8 alkyDpamino, (aryl)pamino, aryl C ⁇ -8 20 alkylsulfonylamino, and C ⁇ -8 alkylsulfonylamino; or two Rl substituents, when on the same carbon atom, are taken together with the carbon atom to which they are attached to form a carbonyl group;
  • each R3 is independently selected from the group consisting of hydrogen, aryl,
  • each R4 is independently selected from the group consisting of hydrogen, 0 aryl, aminocarbonyl, C3-8 cycloalkyl, amino C ⁇ -6 alkyl, (aryl)paminocarbonyl, (aryl C ⁇ -5 alkyDpaminocarbonyl, hydroxycarbonyl C ⁇ -6 alkyl, C ⁇ -8 alkyl, aryl C ⁇ -6 alkyl, ⁇ (C ⁇ -6 alkyDpamino C 2 _6 alkyl,
  • R6 are each independently selected from the group consisting of hydrogen, C ⁇ . ⁇ o alkyl, 0 aryl, aryl-(CH 2 ) r -0-(CH 2 ) s -, aryl-(CH2)rS(0)p-(CH 2 ) s -, aryl-(CH 2 )r-C(0)-(CH 2 ) s -, aryl-(CH 2 ) r -C(0)-N(R4)-(CH 2 ) s -, aryl-(CH 2 )r-N(R4)-C(0)-(CH 2 ) s -, aryl-(CH 2 )r-N(R4)-(CH 2 ) s -, halogen, hydroxyl, 5 C ⁇ -8 alkylcarbonylamino, aryl C ⁇ - ⁇ alkoxy, C ⁇ -5 alkoxycarbonyl, (C ⁇ -8 alkyDpaminocarbonyl, C ⁇ -6 alkylcarbonyloxy,
  • aryl C ⁇ -8 alkyDpaminocarbonyl, and 20 aryl C ⁇ -8 alkyDpaminocarbonyl C ⁇ -6 alkyl, or R5 and R6 are taken together with the carbon atom to which they are attached to form a carbonyl group, wherein any of the alkyl groups of R ⁇ or R ⁇ are either unsubstituted or substituted with one to three Rl substituents, and provided that each R ⁇ 5 and R > are selected such that in the resultant compound the carbon atom to which R ⁇ and R ⁇ are attached is itself attached to no more than one heteroatom;
  • R7 and R ⁇ are each independently selected from the group consisting of 0 , hydrogen,
  • C ⁇ -6 alkylcarbonyl 10 C ⁇ -6 alkylcarbonyl C ⁇ -6 alkyl, arylcarbonyl C ⁇ -6 alkyl, aryl C ⁇ -6 alkylcarbonyl, aryl C ⁇ -6 alkylcarbonyl C ⁇ -6 alkyl,
  • R9 is selected from the group consisting of hydrogen, C ⁇ -8 alkyl, aryl, aryl C ⁇ _8 alkyl, C ⁇ -8 alkylcarbonyloxy C ⁇ .4 alkyl, aryl C ⁇ -8 alkylcarbonyloxy C ⁇ -4 alkyl,
  • RlO , RU, and Rl2 are each independently selected from the group consisting of hydrogen,
  • arylpaminosulfonyl (aryl C ⁇ -8 alkyDpaminosulfonyl, C ⁇ -6 alkylsulfonyl, aryl sulfonyl, aryl C ⁇ -6 alkylsulfonyl, ⁇ aryl C ⁇ -6 alkylcarbonyl,
  • C ⁇ -6 alkylaryl-CH CH-(CH 2 ) t -, ⁇ C ⁇ . 6 alkyl-S0 2 -(CH 2 )t-,
  • C ⁇ -6 alkylcarbonyloxy (C ⁇ -6 alkyDpamino, aminocarbonyl C ⁇ -6 alkyl, C ⁇ -6 alkoxy, aryl C ⁇ -6 alkoxy, (aryl)pamino, (aryl)pamino C ⁇ -6 alkyl, (aryl C ⁇ -6 alkyDpamino, ⁇ (aryl C ⁇ -6 alkyDpamino C ⁇ -6 alkyl, arylcarbonyloxy, aryl C ⁇ -6 alkylcarbonyloxy, (C ⁇ -6 alkyl )paminocarbonyloxy, C ⁇ -8 alkylsulfonylamino,
  • W is preferably a 6-membered monocyclic aromatic or nonaromatic ring system having 1 or 2 nitrogen atoms wherein each carbon atom is either unsubstituted or substituted with one Rl substituent, or
  • polycyclic ring system wherein one or more of the rings is aromatic, and wherein the polycyclic ring system has 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, 0, and S
  • W is selected from the group consisting of
  • X is preferably 0 -(CH 2 )v- , wherein any methylene (CH 2 ) carbon atom is either unsubstituted or substituted with one or two Rl substituents. More preferably X is a direct bond, that is, v is 0.
  • Y is preferably selected from the group consisting of
  • Y is selected from the group consisting of
  • any methylene (CH ) carbon atom in Y, other than in R4, can be substituted by one or two R ⁇ substituents.
  • Z is preferably ⁇ selected from the group consisting of
  • Z is selected from the group consisting of
  • Rl and R are preferably selected from the group consisting of hydrogen, halogen, O ⁇ . X0 alkyl, C3-8 cycloalkyl, C3-8 cycloheteroalkyl, hydroxy, nitro, cyano, trifluoromethyl, and trifluoromethoxy.
  • Rl and R2 are selected from the group consisting of hydrogen, halogen, C ⁇ . ⁇ o alkyl, C3-8 cycloalkyl, trifluoromethyl, and trifluoromethoxy.
  • R ⁇ is preferably 10 selected from the group consisting of hydrogen, fluoro, trifluoromethyl, aryl, l ⁇ C ⁇ -8 alkyl, arylC ⁇ -6 alkyl hydroxyl, oxo, arylaminocarbonyl, 20 aryl C ⁇ -5 alkylaminocarbonyl, aminocarbonyl, and aminocarbonyl C ⁇ -6 alkyl.
  • R ⁇ is selected from the group consisting of ⁇ fluoro, aryl,
  • R4 is preferably selected from the group consisting of hydrogen, aryl,
  • R is selected from the group consisting of hydrogen
  • R ⁇ and R ⁇ are ⁇ each independently selected from the group consisting of hydrogen, aryl,
  • CH 2 CH-(CH 2 )t-, and HC ⁇ C-(CH 2 ) t -.
  • ⁇ is hydrogen and R ⁇ is selected from the group consisting of ⁇ hydrogen, aryl,
  • R ⁇ , R?, and R8 are each hydrogen and R ⁇ is selected from the group consisting of 0 hydrogen, aryl,
  • R' and R& are each independently selected from the group consisting of 0 hydrogen, aryl, C ⁇ -8 alkylcarbonylamino, arylcarbonylamino, C ⁇ -8 alkylsulfonylamino, ⁇ arylsulfonylamino,
  • R ⁇ is hydrogen and R ⁇ is selected from the group consisting of consisting of hydrogen, ⁇ aryl,
  • R ⁇ , R6. and R8 are each hydrogen and R is selected from the group consisting of hydrogen
  • R is preferably ⁇ selected from the group consisting of hydrogen, methyl, and ethyl. More preferably, R is hydrogen.
  • R O, RU, and Rl are preferably each independently selected from the group consisting of hydrogen and C ⁇ -8 alkyl. More preferably RlO, RU, and 0 Rl are hydrogen.
  • m is preferably an integer from 0 to 4, more preferably from 0 to 3.
  • n is preferably an integer from 0 to 4, more preferably from 0 to 3.
  • r is preferably an integer from 1 to 2.
  • s is preferably an integer from 0 to 2.
  • t is preferably an integer from 0 to 2, more preferably from 0 to 1.
  • v is preferably 0.
  • the compounds have the formula with the following designated 10 stereochemistry:
  • Illustrative but nonlimiting examples of compounds of the present invention that are useful as integrin receptor antagonists are the following:
  • salts of the compounds of this invention refer to non-toxic “pharmaceutically acceptable salts.”
  • Other salts may, however, be useful in the preparation of the compounds 0 according to the invention or of their pharmaceutically acceptable salts.
  • Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
  • Representative salts include the following: acetate, ⁇ benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, ⁇ isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, oxa
  • suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable l ⁇ organic ligands, e.g., quaternary ammonium salts.
  • the compounds of the present invention can have chiral centers and occur as racemates, racemic mixtures, diastereomeric mixtures, and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention. Therefore,
  • the term "administering" 0 shall encompass the treatment of the various conditions described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, ⁇ for example, in "Design of Prodrugs," ed. H. Bundgaard, Elsevier, 198 ⁇ , which is incorporated by reference herein in its entirety. Metabolites of these compounds include active species produced upon introduction of compounds of this invention into the biological milieu.
  • terapéuticaally effective amount shall mean ⁇ that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher or clinician.
  • integrated receptor antagonist refers to a compound which binds to and antagonizes either the ⁇ v ⁇ 3 10 receptor, the ⁇ v ⁇ receptor, or the ⁇ v ⁇ 6 receptor, or a compound which binds to and antagonizes combinations of these receptors (for example, a dual ⁇ v ⁇ 3/ ⁇ v ⁇ receptor antagonist).
  • alkyl shall mean straight or branched chain alkanes of one to ten total carbon atoms, or any number within this range (i.e., methyl, ethyl, 1-propyl, 2-propyl, n-butyl, s-butyl, t-butyl, etc.).
  • alkenyl shall mean straight or branched chain 20 alkenes of two to ten total carbon atoms, or any number within this range.
  • alkynyl shall mean straight or branched chain alkynes of two to ten total carbon atoms, or any number within this range.
  • cycloalkyl shall mean cyclic rings of alkanes of three to eight total carbon atoms, or any number within this range (i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl).
  • cycloheteroalkyl shall mean a 3- to 8-membered fully saturated heterocyclic ring containing one or two 0 heteroatoms chosen from N, O or S.
  • Examples of cycloheteroalkyl groups include, but are not limited to piperidinyl, pyrrolidinyl, azetidinyl, morpholinyl, piperazinyl.
  • alkoxy refers to straight or branched chain alkoxides of the number of carbon atoms specified (e.g., C ⁇ -5 alkoxy), or any number within this range (i.e., methoxy, ethoxy, etc.).
  • aryl refers to a monocyclic or polycyclic system comprising at least one aromatic ring, wherein the 5 monocylic or polycyclic system contains 0, 1, 2, 3, or 4 heteroatoms chosen from N, 0, or S, and wherein the monocylic or polycylic system is either unsubstituted or substituted with one or more groups independently selected from hydrogen, halogen, C ⁇ . ⁇ o alkyl, C3-8 cycloalkyl, aryl, aryl C ⁇ -8 alkyl, amino, amino C ⁇ -8 alkyl, C ⁇ .3
  • aryl examples include, but are not limited to, phenyl, naphthyl, pyridyl, pyrryl, pyrazolyl, pyrazinyl, pyrimidinyl, imidazolyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, indolyl, thienyl, furyl, dihydrobenzofuryl, benzo(l,3) dioxolane, oxazolyl, isoxazolyl and thiazolyl, which are either unsubstituted or substituted with one or more
  • 20 groups independently selected from hydrogen, halogen, C ⁇ . ⁇ o alkyl, C3-8 cycloalkyl, aryl, aryl C ⁇ -8 alkyl, amino, amino C ⁇ -8 alkyl, C ⁇ -3 acylamino, C ⁇ -3 acylamino C ⁇ -8 alkyl, C ⁇ -6 alkylamino, C ⁇ _6 alkylamino-C ⁇ -8 alkyl, C ⁇ -6 dialkylamino, C ⁇ -6 dialkylamino C ⁇ -8 alkyl, C ⁇ -4 alkoxy, C ⁇ -4 alkoxy C ⁇ -6 alkyl, hydroxycarbonyl, hydroxycarbonyl ⁇ C ⁇ -6 alkyl, C ⁇ .5 alkoxycarbonyl, C ⁇ -3 alkoxycarbonyl C ⁇ -6 alkyl, hydroxycarbonyl C ⁇ -6 alkyloxy, hydroxy, hydroxy C ⁇ -6 alkyl, cyano, trifluoromethyl, oxo or C ⁇ -5 alkylcarbonyloxy.
  • the aryl group is unsubstituted, mono-, di-, tri- or tetra-substituted with one to four of the above-named substituents; more preferably, the aryl group is 0 unsubstituted, mono-, di- or tri-substituted with one to three of the above- named substituents; most preferably, the aryl group is unsubstituted, mono- or di-substituted with one to two of the above-named substituents.
  • alkyl or "aryl” or either of their prefix roots appear in a name of a substituent (e.g., aryl C ⁇ -8 alkyl) it shall be
  • Designated numbers of carbon atoms shall refer independently to the number of carbon atoms in an alkyl or cyclic alkyl moiety or to the alkyl portion of a larger substituent in which alkyl ⁇ appears as its prefix root.
  • arylalkyl and “alkylaryl” include an alkyl portion where alkyl is as defined above and to include an aryl portion where aryl is as defined above.
  • arylalkyl include, but are not limited to, benzyl, fluorobenzyl, chlorobenzyl, phenylethyl, X0 phenylpropyl, fluorophenyl ethyl, chlorophenylethyl, thienylmethyl, thienylethyl, and thienylpropyl.
  • alkylaryl include, but are not limited to, toluene, ethylbenzene, propylbenzene, methylpyridine, ethylpyridine, propylpyridine and butylpyridine.
  • two Rl l ⁇ substituents when on the same carbon atom, can be taken together with the carbon to which they are attached to form a carbonyl group.
  • two R ⁇ substituents when on the same carbon atom, can be taken together with the carbon atom to which they are attached to form a carbonyl group.
  • the limitation, that in the resultant compound the carbon atom or atoms to which B ⁇ is attached is itself attached to no more than one heteroatom, does not apply.
  • two R3 substituents when on the same carbon atom, can be taken together with the carbon atom to which they are ⁇ attached to form a cyclopropyl group.
  • R5 and R ⁇ can be taken together with the carbon atom to which they are attached to form a carbonyl group.
  • halogen shall include iodine, bromine, chlorine, and fluorine.
  • oxy means an oxygen (0) atom.
  • thio means a sulfur (S) atom.
  • ⁇ carbonyl
  • substituted shall be deemed to include multiple degrees of substitution by a named substitutent. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted by one or more of the disclosed or ⁇ claimed substituent moieties, singly or plurally. By independently substituted, it is meant that the (two or more) substituents can be the same or different.
  • Representative compounds of the present invention typically 0 display submicromolar affinity for the integrin receptors, particularly the ⁇ v ⁇ 3, ⁇ v ⁇ , and/or ⁇ v ⁇ 6 receptors.
  • Compounds of this invention are therefore useful for treating mammals suffering from a bone condition caused or mediated by increased bone resorption, who are in need of such therapy.
  • Pharmacologically effective amounts of the compounds, ⁇ including pharamaceutically acceptable salts thereof, are administered to the mammal, to inhibit the activity of mammalian osteoclasts.
  • the compounds of the present invention are administered in dosages effective to antagonize the ⁇ v ⁇ 3 receptor where such treatment is needed, as, for example, in the prevention or treatment of 0 osteoporosis.
  • ⁇ v ⁇ 3 antagonizing effect is selected from inhibition of bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation, viral disease, tumor growth, or metastasis.
  • ⁇ the ⁇ v ⁇ 3 antagonizing effect is the inhibition of bone resorption.
  • an example of the invention is the method wherein the integrin receptor antagonizing effect is an ⁇ v ⁇ antagonizing effect. More specifically, the ⁇ v ⁇ antagonizing effect is selected from inhibition of: restenosis, angiogenesis, diabetic retinopathy, macular
  • Illustrating the invention is the method wherein the integrin receptor antagonizing effect is a dual ⁇ v ⁇ 3/ ⁇ v ⁇ antagonizing effect. More particularly, the dual ⁇ v ⁇ 3/ ⁇ v ⁇ antagonizing effect is selected from inhibition of bone resorption, restenosis, angiogenesis, l ⁇ diabetic retinopathy, macular degeneration, inflammation, viral disease, tumor growth, or metastasis.
  • Illustrating the invention is the method wherein the integrin receptor antagonizing effect is an ⁇ v ⁇ 6 antagonizing effect. More particularly, the ⁇ v ⁇ 6 antagonizing effect is selected from
  • the ⁇ v ⁇ 3 antagonizing effect is selected from inhibition of bone resorption, inhibition of restenosis, inhibition of angiogenesis, inhibition of diabetic retinopathy, inhibition of macular degeneration, inhibition of ⁇ atherosclerosis, inflammation, viral disease, or inhibition of tumor growth or metastasis.
  • the ⁇ v ⁇ 3 antagonizing effect is the inhibition of bone resorption.
  • More particularly illustrating the invention is a pharmaceutical composition comprising any of the compounds 0 . described above and a pharmaceutically acceptable carrier.
  • Another example of the invention is a pharmaceutical composition made by combining any of the compounds described above and a pharmaceutically acceptable carrier.
  • Another illustration of the invention is a process for making a pharmaceutical composition comprising combining any of the compounds described above and a pharmaceutically acceptable carrier.
  • the invention is a method of treating and/or preventing a condition mediated by antagonism of an integrin ⁇ receptor in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds described above.
  • the condition is selected from bone resorption, osteoporosis, restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral
  • the condition is selected from osteoporosis and cancer. Most preferably, the condition is osteoporosis.
  • the invention is a method of eliciting an integrin antagonizing effect in a mammal in need thereof, l ⁇ comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
  • the integrin antagonizing effect is an ⁇ v ⁇ 3 antagonizing effect; more specifically, the ⁇ v ⁇ 3 antagonizing effect is selected from inhibition of bone resorption, 0 inhibition of restenosis, inhibition of atherosclerosis, inhibition of angiogenesis, inhibition of diabetic retinopathy, inhibition of macular degeneration, inhibition of inflammation, inhibition of viral disease, or inhibition of tumor growth or metastasis.
  • the ⁇ v ⁇ 3 antagonizing effect is inhibition of bone resorption.
  • the ⁇ integrin antagonizing effect is an ⁇ v ⁇ antagonizing effect, an ⁇ v ⁇ 6 antagonizing effect, or a mixed ⁇ v ⁇ 3, ⁇ v ⁇ , and ⁇ v ⁇ 6 antagonizing effect.
  • ⁇ v ⁇ antagonizing effects are inhibition of restenosis, atherosclerosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation, viral disease, or tumor growth.
  • Examples 0 of dual ⁇ v ⁇ 6 antagonizing effects are inhibition of angiogenesis, inflammatory response and wound healing.
  • Additional examples of the invention are methods of inhibiting bone resorption and of treating and/or preventing osteoporosis in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
  • Additional illustrations of the invention are methods of treating hypercalcemia of malignancy, osteopenia due to bone ⁇ metastases, periodontal disease, hyperparathyroidism, periarticular erosions in rheumatoid arthritis, Paget's disease, immobilization- induced osteopenia, and glucocorticoid treatment in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical 10 compositions described above.
  • More particularly exemplifying the invention is the use of any of the compounds described above in the preparation of a medicament for -the treatment and/or prevention of osteoporosis in a mammal in need thereof. Still further exemplifying the invention is the l ⁇ use of any of the compounds described above in the preparation of a medicament for the treatment and/or prevention of bone resorption, tumor growth, cancer, restenosis, atherosclerosis, diabetic retinopathy, macular degeneration, inflammation, viral disease, and/or angiogenesis.
  • compositions further comprising an active ingredient selected from the group consisting of a.) an organic bisphosphonate or a pharmaceutically acceptable salt or ester thereof, b.) an estrogen receptor modulator, ⁇ c.) a cytotoxic/antiproliferative agent, d.) a matrix metalloproteinase inhibitor, e.) an inhibitor of epidermal-derived, fibroblast-derived, or platelet-derived growth factors, f.) an inhibitor of VEGF, 0 g.) an inhibitor of Flk-1/KDR, Flt-1, Tck/Tie-2, or Tie-1, h.) a cathepsin K inhibitor, and i.) a prenylation inhibitor, such as a farnesyl transferase inhibitor or a geranylgeranyl transferase inhibitor or a dual farnesyl/geranylgeranyl transferase inhibitor; ⁇ and mixtures thereof.
  • an active ingredient selected from the group consisting of a.) an organic
  • the active ingredient is selected from the group consisting of: a.) an organic bisphosphonate or a pharmaceutically acceptable salt or ester thereof, b.) an estrogen receptor modulator, and 10 c.) a cathepsin K inhibitor; and mixtures thereof.
  • Nonlimiting examples of such bisphosphonates include alendronate, etidronate, pamidronate, risedronate, ibandronate, and pharmaceutically acceptable salts and esters thereof.
  • a particularly preferred bisphosphonate is alendronate, especially alendronate l ⁇ mono sodium trihydrate.
  • Nonlimiting examples of estrogen receptor modulators include estrogen, progesterin, estradiol, droloxifene, raloxifene, and tamoxifene.
  • Nonlimiting examples of cytotoxic/antiproliferative agents 20 are taxol, vincristine, vinblastine, and doxorubicin.
  • Cathepsin K formerly known as cathepsin 02, is a cysteine protease and is described in PCT International Application Publication No. WO 96/13 ⁇ 23, published May 9, 1996; U.S. Patent No. 5,501,969, issued March 3, 1996; and U.S. Patent No. 5,736,3 ⁇ 7, issued April 7, 1998, ⁇ all of which are incorporated by reference herein in their entirety. Cysteine proteases, specifically cathepsins, are linked to a number of disease conditions, such as tumor metastasis, inflammation, arthritis, and bone remodeling. At acidic pH's, cathepsins can degrade type-I collagen.
  • Cathepsin protease inhibitors can inhibit osteoclastic bone 0 resorption by inhibiting the degradation of collagen fibers and are thus useful in the treatment of bone resorption diseases, such as osteoporosis.
  • the present invention is also directed to combinations of the compounds of the present invention with one or more agents useful in the prevention or treatment of osteoporosis.
  • the ⁇ compounds of the instant invention may be effectively administered in combination with effective amounts of other agents such as an organic bisphosphonate, an estrogen receptor modulator, or a cathepsin K inhibitor.
  • Additional illustrations of the invention are methods of ⁇ treating tumor growth in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound described above and one or more agents known to be cytotoxic/antiproliferative. Also, the compounds of the present invention can be administered in combination with radiation therapy for treating
  • the integrin ⁇ v ⁇ 3 antagonist compounds of the present invention may be effectively administered in combination with a growth hormone secretagogue in the therapeutic or prophylactic treatment of disorders in calcium or phosphate metabolism and l ⁇ associated diseases.
  • diseases include conditions which can benefit from a reduction in bone resorption.
  • a reduction in bone resorption should improve the balance between resorption and formation, reduce bone loss or result in bone augmentation.
  • a reduction in bone resorption can alleviate the pain associated with osteolytic
  • osteoporosis including estrogen deficiency, immobilization, glucocorticoid induced and senile
  • osteodystrophy Paget's disease
  • myositis ossificans Bechterew's disease
  • malignant hypercalcemia metastatic bone disease
  • periodontal disease ⁇ cholelithiasis
  • nephrolithiasis urolithiasis
  • urinary calculus hardening of the arteries (sclerosis), arthritis, bursitis, neuritis and tetany.
  • ⁇ v ⁇ 3 receptor antagonist of the present invention and a growth hormone secretagogue, optionally including a third component comprising an organic bisphosphonate, preferably ⁇ alendronate monosodium trihydrate.
  • a third component comprising an organic bisphosphonate, preferably ⁇ alendronate monosodium trihydrate.
  • the individual components of the combination can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or l ⁇ indirectly, from combination of the specified ingredients in the specified amounts.
  • the compounds of the present invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills,
  • powders, granules, elixirs, tinctures, suspensions, syrups and emulsions may also be administered in intravenous (bolus or infusion), intraperitoneal, topical (e.g., ocular eyedrop), subcutaneous, intramuscular or transdermal (e.g., patch) form, all using forms well known to those of ordinary skill in the pharmaceutical ⁇ arts.
  • An effective but non-toxic amount of the compound desired can be employed as an ⁇ v ⁇ 3 antagonist.
  • the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the 0 severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed.
  • An ordinarily skilled physician, veterinarian or clinician can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the ⁇ condition.
  • Oral dosages of the present invention when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg day) to about 100 mg/kg/day, preferably 0.01 to 10 mg/kg/day, and most preferably 0.1 to ⁇ .O mg/kg/day.
  • compositions are preferably provided in the form of tablets containing 0.01, O.O ⁇ , 0.1, O. ⁇ , 1.0, 2. ⁇ , ⁇ .O, 10.0, l ⁇ .0, 2 ⁇ .O, ⁇ .0, 100 and ⁇ OO milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • a medicament typically contains from about 0.01 mg to about ⁇ OO mg of the active
  • compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be l ⁇ administered in divided doses of two, three or four times daily.
  • preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art.
  • the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
  • the compounds herein described in detail can form the active ingredient, and are ⁇ typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as 'carrier' materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
  • the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like;
  • an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like
  • the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture.
  • Suitable ⁇ binders include starch, gelatin, natural sugars such as glucose or beta- lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
  • the compounds of the present invention can also be administered in the form of liposome delivery systems, such as small l ⁇ unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
  • Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the 0 compound molecules are coupled.
  • the compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include poly ⁇ inylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxy- ethylaspartamide-phenol, or polyethyleneoxide-polylysine substituted ⁇ with palmitoyl residues.
  • the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, 0 polyacetals, polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
  • a drug for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, 0 polyacetals, polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
  • CBZ(Cbz) Carbobenzyloxy or benzyloxycarbonyl.
  • CDI Carbonyldiimidazole.
  • CH 2 C1 2 Methylene chloride.
  • CH3CN Acetonitrile
  • CHCI3 Chloroform
  • DIAD Diisopropyl azodicarboxylate.
  • DIBAH or DIBAL-H Diisobutylaluminum hydride.
  • DIPEA Diisopropylethylamine.
  • DMAP 4-Dimethylaminopyridine.
  • l ⁇ DME 1,2-Dimethoxyethane.
  • DMF Dimethylformamide.
  • DMSO Dimethylsulfoxide.
  • DPFN 3, ⁇ -Dimethyl-l-pyrazolylformamidine nitrate.
  • EDC l-(3-Dimethylaminopropyl)-3-ethylcarbodiimide # HC1
  • PCA'HCl Pyrazole carboxamidine hydrochloride.
  • Pd/C Palladium on activated carbon catalyst.
  • Ph Phenyl.
  • pTSA p-Toluenesulfonic acid.
  • ⁇ TEA Triethylamine.
  • TFA Trifluoroacetic acid.
  • THF Tetrahydrofuran
  • TMEDA N,N,N',N'-Tetramethylethylenediamine.
  • TMS Trimethylsilyl.
  • novel compounds of the present invention can be prepared according to the procedure of the following schemes and examples, using appropriate materials and are further exemplified by the following specific examples.
  • the compounds illustrated in the following schemes and examples can be prepared according to the procedure of the following schemes and examples, using appropriate materials and are further exemplified by the following specific examples.
  • N-Benzyl-(R)- ⁇ -methylbenzyl-3(S)-fluorophenyl- ⁇ -alanine ethyl ester (1-3) l ⁇
  • N-benzyl-(R)- ⁇ -methylbenzylamine (33.4 g, l ⁇ 8 mmol) in THF (4 ⁇ 0 mL) at 0°C
  • n-butyllithium (1.6M in hexanes; 99 mL, l ⁇ 8 mmol).
  • the dark violet solution was stirred at 0°C for 30 minutes, cooled to -78°C, and the ester 1 ⁇ (29.2 g, l ⁇ O mmol) in THF (100 mL) was added over ⁇ minutes.
  • Acid 5S ( ⁇ .O g, l ⁇ mmol) was suspended in water (3.5 L), then treated with IN NaOH (15 mL) to afford a clear solution.
  • Penicillin 0 amidase (Sigma, EC 3.5.1.11, 10,000 U) in 0.1 M phosphate buffer was added.
  • the pH of the mixture was adjusted to 7.8 with IN NaOH and the solution was stirred at room temperature for 4 days.
  • the reaction was monitored periodically by HPLC and the reaction stopped once the ⁇ 0% conversion was reached.
  • N-BOC-(L)-aspartic acid-alpha benzyl ester (1.5 g, 4.6 mmol) in THF (20 mL) at 0°C was added N-methylmorpholine (0.61 mL, 5. ⁇ mmol) followed by isobutyl chloroformate (0.66 mL, 5.1 mmol). After 0 30 minutes, a solution of the above crude oxime in DMF (5 mL) was added. The solution was allowed to warm to 2 ⁇ °C and stir for 1 h, then toluene (20 mL) was added and the mixture heated to 110°C, allowing the THF to evaporate. The resulting mixture was heated at reflux for 6 h.
  • 1,4-Cyclohexadiene (2 mL. 21.1 mmol) was then gradually added. The reaction mixture was stirred for 3 hr and filtered through a celite pad.
  • Ethyl 3-(6-methoxypyridin-3-yl)acrylate (19-3) A solution of the ⁇ -bromo-2-methoxypyridine 18-2 (74.3 g, 0.4 mol), ethyl acrylate (150 mL, 1.4 mol), triethylamine (150 mL, 1.08 mol), palladium acetate (10 g, 0.045 mol) and tri-o-tolylphosphine (20 g, 0.066 mol) in 100 mL acetonitrile was degassed with argon for 10 minutes. The mixture was heated at 90°C for 12 hr then the volatiles were removed in vacuo.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors alpha v beta 3 and/or alpha v beta 5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.

Description

TITLE OF THE INVENTION INTEGRIN RECEPTOR ANTAGONISTS
CROSS-REFERENCE TO RELATED APPLICATIONS The present invention is related to U.S. provisional applications Serial No. 60/069,910, filed December 17, 1997; 60/083,251, filed April 27, 1998; and 60/092,588, filed July 13, 1998; the contents of each of which are hereby incorporated by reference.
FIELD OF THE INVENTION
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3, αvβ5, and/or αvβ6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
BACKGROUND OF THE INVENTION
It is beheved that a wide variety of disease states and conditions can be mediated by acting on integrin receptors and that integrin receptor antagonists represent a useful class of drugs. Integrin receptors are heterodimeric transmembrane receptors through which cells attach and communicate with extracellular matrices and other cells (See S.B. Rodan and G.A. Rodan, "Integrin Function In Osteoclasts", Journal of Endocrinology , Vol. 154, S47- S56 (1997), which is incorporated by reference herein in its entirety).
In one aspect of the present invention, the compounds herein are useful for inhibiting bone resorption. Bone resorption is mediated by the action of cells known as osteoclasts. Osteoclasts are large multinucleated cells of up to about 400 mm in diameter that resorb mineralized tissue, chiefly calcium carbonate and calcium phosphate, in vertebrates. Osteoclasts are actively motile cells that migrate along the surface of bone, and can bind to bone, secrete necessary acids and proteases, thereby causing the actual resorption of mineralized tissue from the bone. More specifically, osteoclasts are believed to exist in at least two physiological states, namely, the secretory state and the migratory or motile state. In the secretory state, osteoclasts are flat, attach to the bone matrix via a tight attachment zone (sealing zone), become highly polarized, form a ruffled border, and secrete lysosomal enzymes and protons to resorb bone. The adhesion of osteoclasts to bone surfaces is an important initial step in bone resorption. In the migratory or motile state, the osteoclasts migrate across bone matrix and do not take part in resorption until they again attach to bone.
Integrins are involved in osteoclast attachment, activation and migration. The most abundant integrin in osteoclasts, e.g., in rat, chicken, mouse mid human osteoclasts, is an integrin receptor known as αvβ3, which is thought to interact in bone with matrix proteins that contain the RGD sequence. Antibodies to αvβ3 block bone resorption in vitro indicating that this integrin plays a key role in the resorptive process. There is increasing evidence to suggest that αvβ3 ligands can be used effectively to inhibit osteoclast mediated bone resorption in vivo in mammals. The current major bone diseases of public concern are osteoporosis, hypercalcemia of malignancy, osteopenia due to bone metastases, periodontal disease, hyperparathyroidism, periarticular erosions in rheumatoid arthritis, Paget's disease, immobilization- induced osteopenia, and glucocorticoid-induced osteoporosis. All of these conditions are characterized by bone loss, resulting from an imbalance between bone resorption, i.e. breakdown, and bone formation, which continues throughout life at the rate of about 14% per year on the average. However, the rate of bone turnover differs from site to site; for example, it is higher in the trabecular bone of the vertebrae and the alveolar bone in the jaws than in the cortices of the long bones. The potential for bone loss is directly related to turnover and can amount to over 5% per year in vertebrae immediately following menopause, a condition which leads to increased fracture risk.
In the United States, there are currently about 20 million people with detectable fractures of the vertebrae due to osteoporosis. In addition, there are about 250,000 hip fractures per year attributed to osteoporosis. This clinical situation is associated with a 12% mortality rate within the first two years, while 30% of the patients require nursing home care after the fracture. Individuals suffering from all the conditions listed above would benefit from treatment with agents which inhibit bone resorption.
Additionally, αvβ3 ligands have been found to be useful in treating and/or inhibiting restenosis, i.e. recurrence of stenosis after corrective surgery on the heart valve, atherosclerosis, diabetic retinopathy, macular degeneration, and angiogenesis, i.e. formation of new blood vessels. Moreover, it has been postulated that the growth of tumors depends on an adequate blood supply, which in turn is dependent on the growth of new vessels into the tumor; thus, inhibition of angiogenesis can cause tumor regression in animal models (See Harrison's Principles of Internal Medicine. 12th ed., 1991, which is incorporated by reference herein in its entirety). Therefore, αvβ3 antagonists which inhibit angiogenesis can be useful in the treatment of cancer by inhibiting tumor growth (See e.g., Brooks et al., Cell, 79:1157- 1164 (1994), which is incorporated by reference herein in its entirety). Moreover, compounds of this invention can also inhibit neovascularization by acting as antagonists of the integrin receptor, αvβδ. A monoclonal antibody for vβδ has been shown to inhibit VEGF- induced angiogenesis in rabbit cornea and the chick chorioallantoic membrane model (See M.C. Friedlander, et al., Science 270, 1500-1502, (1995), which is incorporated by reference herein in its entirety). Thus, compounds that antagonize αvβδ are useful for treating and preventing macular degeneration, diabetic retinopathy, tumor growth, and metastasis.
Additionally, compounds of the instant invention can inhibit angiogenesis and inflammation by acting as antagonists of the integrin receptor, αvβ6, which is expressed during the later stages of wound healing and remains expressed until the wound is closed (See Christofidou-Solomidou, et al., "Expression and Function of Endothelial Cell αv Integrin Receptors in Wound-Induced Human Angiogenesis in Human Skin/SCID Mice. Chimeras. American Journal of Pathology. Vol. 151, No. 4, pp. 975-983 (October 1997), which is incorporated by reference herein in its entirety). It is postulated that αvβ6 plays a role in the remodeling of the vasculature during the later stages of angiogenesis. Also, αvβ6 participates in the modulation of epithelial inflammation and is induced in response to local injury or inflammation (See Xiao-Zhu Huang, et al., "Inactivation of the Integrin β6 Subunit Gene Reveals a Role of Epithelial Integrins in Regulating Inflammation in the Lungs and Skin," Journal of Cell Biology. Vol. 133, No.4, pp. 921-928 (May 1996), which is incorporated by reference herein in its entirety). Accordingly, compounds that antagonize αvβ6 are useful in treating or preventing cancer by inhibiting tumor growth and metastasis.
In addition, certain compounds of this invention antagonize both the αvβ3 and αvβδ receptors. These compounds, referred to as "dual αvβ3/αvβδ antagonists," are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, tumor growth, and metastasis.
In addition, certain compounds of this invention are useful as mixed αvβ3, αvβδ, and αvβ6 receptor antagonists.
It is therefore an object of the present invention to provide compounds which are useful as integrin receptor antagonists.
It is another object of the present invention to provide compounds which are useful as αvβ3 receptor antagonists. It is another object of the present invention to provide compounds which are useful as αvβδ receptor antagonists.
It is another object of the present invention to provide compounds which are useful as αvβ6 receptor antagonists.
It is another object of the present invention to provide compounds which are useful as dual αvβ3/αvβδ receptor antagonists. It is another object of the present invention to provide compounds which are useful as mixed αvβ3, αvβδ, and αvβ6 receptor antagonists.
It is another object of the present invention to provide pharmaceutical compositions comprising integrin receptor antagonists. It is another object of the present invention to provide methods for making the pharmaceutical compositions of the present invention.
It is another object of the present invention to provide δ methods for eliciting an integrin receptor antagonizing effect in a mammal in need thereof by administering the compounds and pharmaceutical compositions of the present invention.
It is another object of the present invention to provide compounds and pharmaceutical compositions useful for inhibiting bone 10 resorption, restenosis, atherosclerosis, inflammation, viral disease, diabetic retinopathy, macular degeneration, angiogenesis, tumor growth, and metastasis.
It is another object of the present invention to provide compounds and pharmaceutical compositions useful for treating lδ osteoporosis.
It is another object of the present invention to provide methods for inhibiting bone resorption, restenosis, atherosclerosis, inflammation, viral disease, diabetic retinopathy, macular degeneration, angiogenesis, tumor growth, and metastasis. 20 It is another object of the present invention to provide methods for treating osteoporosis.
These and other objects will become readily apparent from the detailed description which follows.
δ SUMMARY OF THE INVENTION
The present invention relates to compounds of the formula
wherein W is selected from the group consisting of
δ -
a δ- or 6-membered monocyclic aromatic or nonaromatic ring system having 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, 0, and S wherein the ring nitrogen atoms are δ unsubstituted or substituted with one R^ substituent and the ring carbon atoms are unsubstituted or substituted with one or two Rl substituents, and
a 9- to 14-membered polycyclic ring system, wherein one or more 10 of the rings is aromatic, and wherein the polycyclic ring system has 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, O, and S, and wherein the ring nitrogen atoms are unsubstituted or substituted with one Rl substituent and the ring carbon atoms are unsubstituted or substituted with one or two R^ lδ substituents;
X is selected from the group consisting of
-(CH2)V-, wherein any methylene (CH2) carbon atom is either 20 unsubstituted or substituted with one or two R^ substitutents; and a δ- or 6-membered monocyclic aromatic or nonaromatic ring system having 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, 0, and S wherein the ring nitrogen atoms are unsubstituted or substituted with one Rl substituent and the ring carbon δ atoms are unsubstituted or substituted with one or two Rl substituents;
Y is selected from the group consisting of
-(CH2)m-, 0 -(CH2)m-0-(CH2)n-, -(CH2)m-S-(CH2)n-, -(CH2)m-SO-(CH2)n-,
-(CH2)m-S02-(CH2)n-,
-(CH2)m-0-(CH2)n-0-(CH2)p-J -(CH2 O-(CH2)n-NR4-(CH2)p -, δ -(CH2)m-NR4-(CH2)n-NR4-(CH )p -,
-(CH2)m-0-(CH2)n-S-(CH2)p -, -(CH2)m-S-(CH2)n-S-(CH2)p -, -(CH2)m-NR4-(CH2)n-S-(CH2)p -, -(CH2)m-NR4-(CH2)n-0-(CH2)p -, 10 -(CH )m-S-(CH2)n-0-(CH2)p -, and
-(CH2)m-S-(CH2)n-NR4-(CH2)p -, wherein any methylene (CH ) carbon atom in Y, other than in R4, can be substituted by one or two R^ substituents;
lδ Z is a δ membered aromatic or nonaromatic mono- or bicyclic ring system having 0 to 3 heteroatoms selected from the group consisting of N, 0, and S, and wherein the ring system is either unsubstituted or substituted with 0, 1, 2, or 3 oxo or thio substituents, and either unsubstituted or substituted with one or more substituents
20 independently selected from the group consisting of R^-O, R^, and R*2 ;
wherein R^and R^ are each independently selected from the group consisting of hydrogen, halogen, Cχ-10 alkyl, C3-8 cycloalkyl, δ C3-8 cycloheteroalkyl, C3-8 cycloalkyl Ci-6 alkyl,
C3-8 cycloheteroalkyl Ci-6 alkyl, aryl, aryl Ci-8 alkyl, amino, amino Ci-8 alkyl, Ci-3 acylamino, C1-3 acylamino Ci-8 alkyl, (Cχ-6 alkyl )pami no, (Ci-6 alkyl)pamino Cχ-8 alkyl, Cχ-4 alkoxy, Cχ-4 alkoxy Ci-6 alkyl, hydroxycarbonyl, 0 hydroxycarbonyl Cχ-6 alkyl, Cχ-3 alkoxycarbonyl,
Ci-3 alkoxycarbonyl Cχ-6 alkyl, hydroxycarbonyl- Ci-6 alkyloxy, hydroxy, hydroxy Ci-6 alkyl, Ci-6 alkyloxy- Cχ-6 alkyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, Cχ-8 alkyl-S(0)p, (Cχ-8 alkyl)paminocarbonyl, Ci-8 alkyloxycarbonylamino, (Cχ-8 alkyl)paminocarbonyloxy, (aryl Cχ-8 alkyDpamino, (aryl)pamino, aryl Cχ_8- alkylsulfonylamino, and Cχ_8 alkylsulfonylamino; or two Rl substituents, when on the same carbon atom, are taken δ together with the carbon atom to which they are attached to form a carbonyl group;
each R3 is independently selected from the group consisting of hydrogen, 10 aryl,
Cχ.χo alkyl, aryl-(CH2)r-0-(CH2)s-, aryl-(CH2)rS(0)p-(CH2)s-, aryl-(CH )r-C(0)-(CH2)s-, lδ aryl-(CH2)r-C(0)-N(R4)-(CH2)s-, aryl-(CH2)r-N(R4)-C(0)-(CH2)s-, aryl-(CH2)r-N(R4)-(CH2)s-, halogen, hydroxyl, 20 oxo, trifluoromethyl ,
Cχ-8 alkylcarbonylamino, aryl Cχ-5 alkoxy,
Cχ-5 alkoxycarbonyl, δ (Cχ-8 alkyl )paminocarbonyl,
Cχ-6 alkylcarbonyloxy,
C3-8 cycloalkyl,
(Cχ-6 alkyDpamino, amino Cχ-6 alkyl, 0 arylaminocarbonyl, aryl Cχ.5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cχ-6 alkyl, hy dr oxy carb onyl , hydroxycarbonyl Cχ_6 alkyl,
HC≡C-(CH )t-,
Cχ-6 alkyl-C≡C-(CH2)t-,
C3-7 cycloalkyl-C≡C-(CH2)t-, δ aryl-C≡C-(CH2)t-,
Cχ-6 alkylaryl-C≡C-(CH )t-,
CH2=CH-(CH2)t-,
Cχ-6 alkyl-CH=CH-(CH2)t-,
C3-7 cycloalkyl-CH=CH-(CH2)t-, 10 aryl-CH=CH-(CH )t-,
Cχ-6 alkylaryl-CH=CH-(CH2)t-,
Cχ-6 alkyl-S02-(CH2)t-,
Cχ-6 alkylaryl-S02-(CH )t-,
Cχ-6 alkoxy, lδ aryl Cχ-6 alkoxy, aryl Cχ-6 alkyl,
(Cχ-6 alkyDpamino Cχ-6 alkyl,
(aryl)pamino,
(aryl)pamino Cχ-6 alkyl, 20 (aryl Cχ-6 alkyDpamino,
(aryl Cχ_6 alkyDpamino Cχ-6 alkyl, arylcarbonyloxy, aryl Cχ_6 alkylcarbonyloxy, (Cχ-6 alkyDpaminocarbonyloxy, δ Cχ-8 alkylsulfonylamino, arylsulfonylamino, Cχ-8 alkylsulfonylamino Cχ-6 alkyl, arylsulfonylamino Cχ_6 alkyl, aryl Cχ-6 alkylsulfonylamino, 0 aryl Cχ_6 alkylsulfonylamino Cχ-6 alkyl,
Cχ-8 alkoxycarbonylamino, Cχ-8 alkoxycarbonylamino Cχ-8 alkyl, aryloxycarbonylamino Cχ_8 alkyl, aryl Cχ-8 alkoxycarbonylamino, aryl Cχ-8 alkoxycarbonylamino Cχ-8 alkyl,
Cχ-8 alkylcarbonylamino,
Cχ-8 alkylcarbonylamino Cχ-6 alkyl, arylcarbonylamino Cχ_6 alkyl, δ aryl Cχ-6 alkylcarbonylamino, aryl Cχ-6 alkylcarbonylamino Cχ-6 alkyl, aminocarbonylamino Cχ_6 alkyl,
(Cχ-8 alkyDpaminocarbonylamino,
(Cχ-8 alkyl )paminocarbonylamino Cχ-6 alkyl, X0 (aryl)paminocarbonylamino Cχ-6 alkyl,
(aryl Cχ-8 alkyDpaminocarbonylamino,
(aryl Cχ-8 alkyDpaminocarbonylamino Cχ_6 alkyl, amino sulfbnylamino Cχ-6 alkyl,
(Cχ-8 alkyDpaminosulfonylamino, lδ (Cχ-8 alkyDpaminosulfonylamino Cχ-6 alkyl,
(aryl)paminosulfonylamino Cχ-6 alkyl,
(aryl Cχ-8 alkyDpaminosulfonylamino,
(aryl Cχ-8 alkyDpaminosulfonylamino Cχ-6 alkyl,
Cχ-6 alkylsulfonyl, 20 Cχ_6 alkylsulfonyl Cχ-6 alkyl, arylsulfonyl Cχ-6 alkyl, aryl Cχ_6 alkylsulfonyl, aryl Cχ_6 alkylsulfonyl Cχ-6 alkyl,
Cχ-6 alkylcarbonyl, δ Cχ-6 alkylcarbonyl Cχ_6 alkyl, arylcarbonyl Cχ-6 alkyl, aryl Cχ-6 alkylcarbonyl, aryl Cχ-6 alkylcarbonyl Cχ-6 alkyl,
Cχ-6 alkylthiocarbonylamino, 0 Cχ-6 alkylthiocarbonylamino Cχ-6 alkyl, arylthiocarbonylamino Cχ-6 alkyl, aryl Cχ-6 alkylthiocarbonylamino, aryl Cχ-6 alkylthiocarbonylamino Cχ-6 alkyl,
(Cχ-8 alkyDpaminocarbonyl Cχ_6 alkyl, (aryl)paminocarbonyl Cχ_6 alkyl, (aryl Cχ-8 alkyDpaminocarbonyl, and (aryl Cχ_8 alkyDpaminocarbonyl Cχ-6 alkyl, or two R3 substituents, when on the same carbon atom are taken δ together with the carbon atom to which they are attached to form a carbonyl group or a cyclopropyl group, wherein any of the alkyl groups of Η are either unsubstituted or substituted with one to three Rl substituents, and provided that each R^ is selected such that in the resultant 10 compound the carbon atom or atoms to which R^ is attached is itself attached to no more than one heteroatom;
each R4 is independently selected from the group consisting of hydrogen, lδ aryl, aminocarbonyl,
C3.8 cycloalkyl, amino Cχ-6 alkyl,
(aryl)paminocarbonyl, 0 (aryl Cχ.5 alkyDpaminocarbonyl, hydroxycarbonyl Cχ_6 alkyl,
Cχ-8 alkyl, aryl Cχ_6 alkyl,
(Cχ-6 alkyDpamino C2_6 alkyl, δ (aryl Cχ-6 alkyDpamino C2-6 alkyl,
Cχ-8 alkylsulfonyl,
Cχ-8 alkoxycarbonyl, aryloxy carbonyl, aryl Cχ-8 alkoxycarbonyl, 0 Cχ-8 alkylcarbonyl, aryl carbonyl, aryl Cχ-6 alkylcarbonyl,
(Cχ-8 alkyDpaminocarbonyl, aminosulfonyl, Cχ-8 alkylaminosulfonyl, (aryl)paminosulfonyl, (aryl Cχ-8 alkyl )paminosulfonyl, arylsulfonyl, arylCl-6 alkylsulfonyl,
Cχ-6 alkylthiocarbonyl, arylthiocarbonyl, and aryl Cχ-6 alkylthiocarbonyl, wherein any of the alkyl groups of R4 are either unsubstituted or substituted with one to three Rl substituents;
R5 and R6 are each independently selected from the group consisting of hydrogen", Cχ.χo alkyl, aryl, aryl-(CH2)r-0-(CH2)s-, aryl-(CH2)rS(0)p-(CH2)s-, aryl-(CH )r-C(0)-(CH2)s-, aryl-(CH2)r-C(0)-N(R4)-(CH2)s-, aryl-(CH2)r-N(R4)-C(0)-(CH2)s-, aryl-(CH2)r-N(R4)-(CH2)s-, halogen, hydroxyl,
Cχ-8 alkylcarbonylamino, aryl Cχ_5 alkoxy,
Cχ-5 alkoxycarbonyl,
(Cχ-8 alkyDpaminocarbonyl,
Cχ-6 alkylcarbonyloxy,
C3.8 cycloalkyl, (Cχ-6 alkyDpamino, amino Cχ-6 alkyl, arylaminocarbonyl, aryl Cχ-5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cχ-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cχ-6 alkyl,
HC≡C-(CH2)t-, 5 Cχ-6 alkyl-C≡C-(CH2)t-,
C3-7 cycloalkyl-C≡C-(CH2)t-, aryl-C≡C-(CH2)t-,
Cχ-6 alkylaryl-C≡C-(CH2)t-,
CH2=CH-(CH2)t-, X0 Cχ_6 alkyl-CH=CH-(CH2)t-,
C3-7 cycloalkyl-CH=CH-(CH )t-, aryl-CH=CH-(CH2)t-,
Cχ-6 alkylaryl-CH=CH-(CH2)t-,
Cχ-6 alkyl-S02-(CH2)t-, lδ Cχ-6 alkylaryl-S02-(CH2)t-,
Cχ-6 alkoxy, aryl Cχ-6 alkoxy, aryl Cχ_6 alkyl,
(Cχ-6 alkyDpamino Cχ-6 alkyl, 0 (aryl)pamino,
(aryl)pamino Cχ-6 alkyl,
(aryl Cχ-6 alkyDpamino,
(aryl Cχ-6 alkyDpamino Cχ_6 alkyl, arylcarbonyloxy, δ aryl Cχ-6 alkylcarbonyloxy,
(Cχ-6 alkyl )paminocarbonyloxy, Cχ-8 alkylsulfonylamino, arylsulfonylamino, Cχ-8 alkylsulfonylamino Cχ_6 alkyl, 0 arylsulfonylamino Cχ-6 alkyl, aryl Cχ_6 alkylsulfonylamino, aryl Cχ-6 alkylsulfonylamino Cχ-6 alkyl, Cχ-8 alkoxycarbonylamino, Cχ-8 alkoxycarbonylamino Cχ-8 alkyl, aryloxycarbonylamino Cχ_8 alkyl, aryl Cχ-8 alkoxycarbonylamino, aryl Cχ-8 alkoxycarbonylamino Cχ_8 alkyl,
Cχ-8 alkylcarbonylamino, δ Cχ-8 alkylcarbonylamino Cχ-6 alkyl, arylcarbonylamino Cχ_6 alkyl, aryl Cχ-6 alkylcarbonylamino, aryl Cχ_6 alkylcarbonylamino Cχ-6 alkyl, aminocarbonylamino Cχ-6 alkyl, 10 (Cχ-8 alkyDpaminocarbonylamino,
(Cχ-8 alkyDpaminocarbonylamino Cχ-6 alkyl,
(aryl)paminocarbonylamino Cχ_6 alkyl,
(aryl Cχ-8 alkyl)paminocarbonylamino,
(aryl Cχ-8 alkyDpaminocarbonylamino Cχ_6 alkyl, lδ aminosulfonylamino Cχ_6 alkyl,
(Cχ-8 alkyDpaminosulfonylamino,
(Cχ-8 alkyDpaminosulfonylamino C -6 alkyl,
(aryl)paminosulfonylamino Cχ-6 alkyl,
(aryl Cχ-8 alkyDpaminosulfonylamino, 0 (aryl Cχ-8 alkyDpaminosulfonylamino Cχ-6 alkyl,
Cχ-6 alkylsulfonyl,
Cχ_6 alkylsulfonyl Cχ-6 alkyl, arylsulfonyl Cχ-6 alkyl, aryl Cχ-6 alkylsulfonyl, δ aryl Cχ-6 alkylsulfonyl Cχ-6 alkyl,
Cχ-6 alkylcarbonyl,
Cχ-6 alkylcarbonyl Cχ-6 alkyl, arylcarbonyl Cχ-6 alkyl, aryl Cχ-6 alkylcarbonyl, 0 aryl Cχ-6 alkylcarbonyl Cχ-6 alkyl,
Cχ-6 alkylthiocarbonylamino,
Cχ-6 alkylthiocarbonylamino Cχ-6 alkyl, arylthiocarbonylamino Cχ-6 alkyl, aryl Cχ-6 alkylthiocarbonylamino, aryl Cχ-6 alkylthiocarbonylamino Cχ_6 alkyl,
(Cχ-8 alkyDpaminocarbonyl Cχ-6 alkyl,
(aryl)paminocarbonyl Cχ-6 alkyl,
(aryl Cχ-8 alkyDpaminocarbonyl, and (aryl Cχ_8 alkyDpaminocarbonyl Cχ-6 alkyl; or R5 and R6 are taken together with the carbon atom to which they are attached to form a carbonyl group, wherein any of the alkyl groups of Ε or R^ are either unsubstituted or substituted with one to three Rl substituents, and provided that each R^ and R^ are selected such that in the resultant compound the carbon atom to which R^ and R^ are attached is itself attached to no more than one heteroatom;
R7 and R8 are each independently selected from the group consisting of hydrogen,
Cχ.χo alkyl, aryl, aryl-(CH2)r-0-(CH2)s-, aryl-(CH2)rS(0)p-(CH2)s-, aryl-(CH2)r-C(0)-(CH2)s-, aryl-(CH2)r-C(0)-N(R4)-(CH2)s-, aryl-(CH2)r-N(R4)-C(0)-(CH2)s-, aryl-(CH2)r-N(R4)-(CH2)s-, halogen, hydroxyl,
Cχ-8 alkylcarbonylamino, aryl Cχ-5 alkoxy,
Cχ-5 alkoxycarbonyl,
(Cχ-8 alkyDpaminocarbonyl, Cχ-6 alkylcarbonyloxy,
C3.8 cycloalkyl,
(Cχ-6 alkyDpamino, amino Cχ-6 alkyl, arylaminocarbonyl, aryl Cχ-5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cχ-6 alkyl, hydroxycarbonyl, 5 hydroxycarbonyl Cχ-6 alkyl,
HC≡C-(CH2)t-,
Cχ-6 alkyl-C≡C-(CH2)t-,
C3-7 cycloalkyl-C≡C-(CH2)t-, aryl-C≡C-(CH2)t-,
10 Cχ-6 alkylaryl-C≡C-(CH2)t-,
CH =CH-(CH2)t-, Cχ_6 alkyl-CH=CH-(CH )t-, C3-7 cycloalkyl-CH=CH-(CH2)t-, aryl-CH=CH-(CH2)t-, lδ Cχ-6 alkylaryl-CH=CH-(CH2)t-,
Cχ.6 alkyl-S02-(CH2)t-, Cχ-6 alkylaryl-S02-(CH2)t-, Cχ-6 alkoxy, aryl Cχ-6 alkoxy,
20 aryl Cχ_6 alkyl,
(Cχ-6 alkyDpamino Cχ-6 alkyl, (aryl)pamino, (aryl)pamino Cχ.6 alkyl, (aryl Cχ-6 alkyDpamino, δ (aryl Cχ_6 alkyDpamino Cχ_6 alkyl, arylcarbonyloxy, aryl Cχ-6 alkylcarbonyloxy, (Cχ-6 alkyDpaminocarbonyl oxy, Cχ-8 alkylsulfonylamino, 0 arylcarbonylamino, arylsulfonylamino, Cχ-8 alkylsulfonylamino Cχ-6 alkyl, arylsulfonylamino Cχ-6 alkyl, aryl Cχ-6 alkylsulfonylamino, aryl Cχ-6 alkylsulfonylamino Cχ-6 alkyl, Cχ-8 alkoxycarbonylamino, Cχ-8 alkoxycarbonylamino Cχ-8 alkyl, aryloxycarbonylamino Cχ-8 alkyl, δ aryl Cχ_8 alkoxycarbonylamino, aryl Cχ-8 alkoxycarbonylamino Cχ-8 alkyl, Cχ-8 alkylcarbonylamino Cχ-6 alkyl, arylcarbonylamino Cχ-6 alkyl, aryl Cχ-6 alkylcarbonylamino, 10 aryl Cχ-6 alkylcarbonylamino Cχ-6 alkyl, aminocarbonylamino Cχ-6 alkyl, (Cχ-8 alkyDpaminocarbonylamino, (Cχ-8 alkyl )paminocarbonylamino Cχ-6 alkyl, (aryl)paminocarbonylamino Cχ-6 alkyl, lδ arylaminocarbonylamino,
(aryl Cχ-8 alkyDpaminocarbonylamino,
(aryl Cχ-8 alkyDpaminocarbonylamino Cχ-6 alkyl, aminosulfonylamino Cχ-6 alkyl,
(Cχ-8 alkyDpaminosulfonylamino, 0 (Cχ-8 alkyDpaminosulfonylamino Cχ_6 alkyl,
(aryl)paminosulfonylamino Cχ_6 alkyl,
(aryl Cχ-8 alkyDpaminosulfonylamino,
(aryl Cχ_8 alkyDpaminosulfonylamino Cχ-6 alkyl,
Cχ-6 alkylsulfonyl, δ Cχ-6 alkylsulfonyl Cχ-6 alkyl, arylsulfonyl Cχ-6 alkyl, aryl Cχ-6 alkylsulfonyl, aryl Cχ.6 alkylsulfonyl Cχ-6 alkyl,
Cχ-6 alkylcarbonyl, 0 Cχ-6 alkylcarbonyl Cχ-6 alkyl, arylcarbonyl Cχ.6 alkyl, aryl Cχ-6 alkylcarbonyl, aryl Cχ-6 alkylcarbonyl Cχ-6 alkyl,
Cχ-6 alkylthiocarbonylamino, Cχ-6 alkylthiocarbonylamino Cχ-6 alkyl, arylthiocarbonylamino Cχ-6 alkyl, aryl Cχ-6 alkylthiocarbonylamino, aryl Cχ-6 alkyltlnocarbonylamino Cχ.ρ alkyl, δ (Cχ-8 alkyDpaminocarbonyl Cχ-6 alkyl,
(aryl)paminocarbonyl Cχ_6 alkyl,
(aryl Cχ-8 alkyDpaminocarbonyl,
(aryl Cχ-8 alkyDpaminocarbonyl Cχ-6 alkyl, and
C7-20 polycyclyl Cθ-8 alkylsulfonylamino; 10 wherein any of the alkyl groups of R and R^ are either unsubstituted or substituted with one to three Rl substituents, and provided that each R^and R^ are selected such that in the resultant compound the carbon atom to which R^ and R^ are attached is itself attached to no more than one heteroatom; lδ
R9 is selected from the group consisting of hydrogen,
Cχ-8 alkyl, aryl, 20 aryl Cχ-8 alkyl,
Cχ-8 alkylcarbonyloxy Cχ-4 alkyl, aryl Cχ-8 alkylcarbonyloxy Cχ-4 alkyl,
Cχ-8 alkylaminocarbonylmethylene, and
Cχ-8 dialkylaminocarbonylmethylene; δ
R O , RU, and Rl2 are each independently selected from the group consisting of hydrogen,
Cχ_8 alkyl, 0 . aryl, halogen, hydroxyl, oxo, aminocarbonyl, C3-8 cycloalkyl, amino Cχ-6 alkyl, (aryl)paminocarbonyl, hy dr oxycarb onyl , δ (aryl Cχ-5 alkyDpaminocarbonyl, hydroxycarbonyl Cχ-6 alkyl, aryl Cχ-6 alkyl, (Cχ-6 alkyDpamino Cχ.6 alkyl, (aryl Cχ-6 alkyDpamino C -6 alkyl, 10 Cχ-8 alkylsulfonyl,
Cχ-8 alkoxycarbonyl, aryloxycarbonyl, aryl Cχ-8 -alkoxycarbonyl,
Cχ_8 alkylcarbonyl, lδ arylcarbonyl, aryl Cχ-6 alkylcarbonyl, (Cχ-8 alkyDpaminocarbonyl, amino sulfonyl, Cχ_8 alkylaminosulfonyl, 0 (aryl)paminosulfonyl,
(aryl Cχ-8 alkyDpaminosulfonyl, Cχ-6 alkylsulfonyl, aryl sulfonyl, aryl Cχ-6 alkylsulfonyl, δ aryl Cχ-6 alkylcarbonyl,
Cχ-6 alkylthiocarbonyl, aryl thi o carb onyl, aryl Cχ-6 alkylthiocarbonyl, aryl-(CH2)r-0-(CH2)s-, 0 aryl-(CH2)rS(0)p-(CH2)s-, aryl-(CH2)r-C(0)-(CH2)s-, aryl-(CH2)r-C(0)-N(R4)-(CH2)s-, aryl-(CH2)r-N(R4)-C(0)-(CH2)s-, aryl-(CH2)r-N(R4)-(CH2)s-, HC≡C-(CH2)t-,
Cχ-6 alkyl-C≡C-(CH2)t-,
C3-7 cycloalkyl-C≡C-(CH )t-, aryl-C≡C-(CH2)t-, δ Cχ-6 alkylaryl-C≡C-(CH2)t-,
CH2=CH-(CH2)t-,
Cχ-6 alkyl-CH=CH-(CH2)t-,
C3-7 cycloalkyl-CH=CH-(CH2)t-, aryl-CH=CH-(CH2)t-, X0 Cχ-6 alkylaryl-CH=CH-(CH2)t-,
Cχ-6 alkyl-S02-(CH2)t-,
Cχ-6 alkylaryl-S02-(CH )t-,
Cχ-8 alkylcarbonylamino, aryl Cχ.5 alkoxy, lδ Cχ-5 alkoxycarbonyl,
(Cχ-8 alkyDpaminocarbonyl,
Cχ-6 alkylcarbonyloxy,
(Cχ-6 alkyDpamino, aminocarbonyl Cχ-6 alkyl, 0 Cχ-6 alkoxy, aryl Cχ-6 alkoxy,
(aryl)pamino,
(aryl)pamino Cχ-6 alkyl,
(aryl Cχ-6 alkyDpamino, δ (aryl Cχ-6 alkyDpamino Cχ-6 alkyl, aryl carbonyl oxy, aryl Cχ-6 alkylcarbonyloxy, (Cχ-6 alkyl )paminocarbonyloxy, Cχ-8 alkylsulfonylamino, 0 arylsulfonylamino,
Cχ-8 alkylsulfonylamino Cχ-6 alkyl, arylsulfonylamino Cχ-6 alkyl, aryl Cχ-6 alkylsulfonylamino, aryl Cχ-6 alkylsulfonylamino C -6 alkyl, Cχ-8 alkoxycarbonylamino,
Cχ-8 alkoxycarbonylamino Cχ-8 alkyl, aryloxycarbonylamino Cχ-8 alkyl, aryl Cχ-8 alkoxycarbonylamino, δ aryl Cχ-8 alkoxycarbonylamino Cχ-8 alkyl,
Cχ-8 alkylcarbonylamino,
Cχ-8 alkylcarbonylamino Cχ_6 alkyl, arylcarbonylamino Cχ-6 alkyl, aryl Cχ-6 alkylcarbonylamino, X0 aryl Cχ-6 alkylcarbonylamino Cχ-6 alkyl, aminocarbonylamino Cχ-6 alkyl,
(Cχ-8 alkyDpaminocarbonylamino,
(Cχ-8 alkyl )paminocarbonylamino Cχ-6 alkyl,
(aryl)paminocarbonylamino Cχ_6 alkyl, lδ (aryl Cχ-8 alkyDpaminocarbonylamino,
(aryl Cχ-8 alkyDpaminocarbonylamino Cχ-6 alkyl, aminosulfonylamino Cχ-6 alkyl,
(Cχ-8 alkyDpaminosulfonylamino,
(Cχ-8 alkyDpaminosulfonylamino Cχ.ρ alkyl, 20 (aryl)paminosulfonylamino Cχ-6 alkyl,
(aryl Cχ-8 alkyDpaminosulfonylamino,
(aryl Cχ-8 alkyDpaminosulfonylamino Cχ-6 alkyl,
Cχ-6 alkylsulfonyl,
Cχ-6 alkylsulfonyl Cχ-6 alkyl, δ arylsulfonyl Cχ-6 alkyl, aryl Cχ-6 alkylsulfonyl, aryl Cχ_6 alkylsulfonyl Cχ-6 alkyl,
Cχ-6 alkylcarbonyl,
Cχ-6 alkylcarbonyl Cχ-6 alkyl, 0 arylcarbonyl Cχ_6 alkyl, aryl Cχ-6 alkylcarbonyl, aryl Cχ-6 alkylcarbonyl Cχ-6 alkyl,
Cχ-6 alkylthiocarbonylamino,
Cχ-6 alkylthiocarbonylamino Cχ-6 alkyl, arylthiocarbonylamino Cχ-6 alkyl, aryl Cχ_6 alkylthiocarbonylamino, aryl Cχ-6 alkylthiocarbonylamino Cχ.6 alkyl,
(Cχ-8 alkyDpaminocarbonyl Cχ-6 alkyl,
(aryl)paminocarbonyl Cχ_6 alkyl,
(aryl Cχ-8 alkyDpaminocarbonyl, and
(aryl Cχ-8 alkyDpaminocarbonyl Cχ-6 alkyl, wherein any of the alkyl groups of RlO, RU, and R 2 are either unsubstituted or substituted with one to three Rl substituents;
10 wherein each m is independently an integer from 0 to 6; each n is independently an integer from 0 to 6 each p is independently an integer from 0 to 2; lδ each r is independently an integer from 1 to 3; each s is independently an integer from 0 to 3; each t is independently an integer from 0 to 3; and v is independently an integer from 0 to 6;
20 and the pharmaceutically acceptable salts thereof.
The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention and a pharmaceutically acceptable carrier.
The present invention also relates to methods for making δ the pharmaceutical compositions of the present invention.
The present invention also relates to methods for eliciting an integrin receptor antagonizing effect in a mammal in need thereof by administering the compounds and pharmaceutical compositions of the present invention. 0 The present invention also relates to methods for inhibiting bone resorption, restenosis, atherosclerosis, inflammation, viral disease, diabetic retinopathy, macular degeneration, angiogenesis, wound healing, tumor growth, and metastasis by administering the compounds and pharmaceutical compositions of the present invention. The present invention also relates to methods for treating osteoporosis by administering the compounds and pharmaceutical compositions of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to compounds useful as integrin receptor antagonists. Representative compounds of the present invention are described by the following chemical formula:
10 wherein W is selected from the group consisting of
a δ- or 6-membered monocyclic aromatic or nonaromatic ring system having 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, 0, and S wherein the ring nitrogen atoms are lδ unsubstituted or substituted with one Rl substituent and the ring carbon atoms are unsubstituted or substituted with one or two l substituents, and
a 9- to 14-membered polycyclic ring system, wherein one or more 0 of the rings is aromatic, and wherein the polycyclic ring system has 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, O, and S, and wherein the ring nitrogen atoms are unsubstituted or substituted with one Rl substituent and the ring carbon atoms are unsubstituted or substituted with one or two R δ substituents; X is selected from the group consisting of
-(CH2)y-, wherein any methylene (CH2) carbon atom is either unsubstituted or substituted with one or two Rl substitutents; and a δ- or 6-membered monocyclic aromatic or nonaromatic ring system having 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, O, and S wherein the ring nitrogen atoms are unsubstituted or substituted with one Rl substituent and the ring carbon atoms are unsubstituted or substituted with one or two Rl substituents;
10
Y is selected from the group consisting of
-(CH )m-5
-(CH2)m-0-(CH2)n-, lδ -(CH2)m-NR4-(CH2)n-.
-(CH2)m-S-(CH2)n-,
-(CH2)m-SO-(CH2)n-,
-(CH2)m-S0 -(CH2)n-,
-(CH )m-0-(CH2)n-0-(CH2)p-, 0 -(CH2 O-(CH2)n-NR4-(CH2)p -,
-(CH2)m-NR4-(CH2)n-NR4-(CH2)p -,
-(CH2)m-0-(CH2)n-S-(CH2)p -,
-(CH2)m-S-(CH2)n-S-(CH2)p -,
-(CH2)m-NR4-(CH2)n-S-(CH2)p -, δ -(CH2)m-NR4 -(CH2)n-0-(CH2)p -,
-(CH )m-S-(CH )n-0-(CH2)p -, and
-(CH2)m-S-(CH2)n-NR4-(CH2)p -,
wherein any methylene (CH2) carbon atom in Y, other than in R4, can 0 be substituted by one or two R^ substituents;
Z is a δ membered aromatic or nonaromatic mono- or bicyclic ring system having 0 to 3 heteroatoms selected from the group consisting of N, O, and S, and wherein the ring system is either unsubstituted or substituted with 0, 1, 2, or 3 oxo or thio substituents, and either unsubstituted or substituted with one or more substituents independently selected from the group consisting of RlO, RU, and 2 ;
δ wherein Rland R^ are each independently selected from the group consisting of hydrogen, halogen, Cχ.χo alkyl, C3-8 cycloalkyl, C3-8 cycloheteroalkyl, C3-8 cycloalkyl Cχ-6 alkyl, C3-8 cycloheteroalkyl Cχ-6 alkyl, aryl, aryl Cχ-8 alkyl, amino, X0 amino Cχ-8 alkyl, Cχ-3 acylamino, Cχ_3 acylamino Cχ-8 alkyl,
(Cχ-6 alkyDpamino, (Cχ-6 alkyDpamino Cχ-8 alkyl, Cχ-4 alkoxy, Cχ-4 alkoxy Cχ-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cχ-6 alkyl, Cχ-3 alkoxycarbonyl, Cχ-3 alkoxycarbonyl Cχ-6 alkyl, hydroxycarbonyl- lδ Cχ-6 alkyloxy, hydroxy, hydroxy Cχ-6 alkyl, Cχ-6 alkyloxy-
Cχ-6 alkyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, Cχ-8 alkyl-S(0)p, (Cχ-8 alkyDpaminocarbonyl, Cχ-8 alkyloxycarbonylamino, (Cχ-8 alkyl )paminocarbonyloxy, (aryl Cχ-8 alkyDpamino, (aryl)pamino, aryl Cχ-8 20 alkylsulfonylamino, and Cχ-8 alkylsulfonylamino; or two Rl substituents, when on the same carbon atom, are taken together with the carbon atom to which they are attached to form a carbonyl group;
δ each R3 is independently selected from the group consisting of hydrogen, aryl,
Cχ.χo alkyl, aryl-(CH2)r-0-(CH2)s-, 0 aryl-(CH2)rS(0)p-(CH2)s-, aryl-(CH2)r-C(0)-(CH2)s-, aryl-(CH2)r-C(0)-N(R4)-(CH2)s-, aryl-(CH2)r-N(R4)-C(0)-(CH2)s-, aryl-(CH )r-N(R4)-(CH2)s-, δ halogen,
- 2δ - hydroxyl, oxo, trifluoromethyl, Cχ-8 alkylcarbonylamino, δ aryl Cχ-5 alkoxy,
Cχ-δ alkoxycarbonyl, (Cχ-8 alkyDpaminocarbonyl, Cχ-6 alkylcarbonyloxy, C3.8 cycloalkyl, 10 (Cχ-6 alkyDpamino, amino Cχ-6 alkyl, aryl amino carb onyl , aryl Cχ-5-alkylaminocarbonyl, aminocarbonyl, lδ aminocarbonyl Cχ-6 alkyl, hydroxy carb onyl , hydroxycarbonyl Cχ-6 alkyl,
HC≡C-(CH2)t-,
Cχ-6 alkyl-C≡C-(CH2)t-, 0 C3-7 cycloalkyl-C≡C-(CH )t-, aryl-C≡C-(CH2)t-, Cχ-6 alkylaryl-C≡C-(CH2)t-, CH2=CH-(CH2)t-, Cχ-6 alkyl-CH=CH-(CH2)f, δ C3-7 cycloalkyl-CH=CH-(CH2)t-, aryl-CH=CH-(CH2)t-, Cχ-6 alkylaryl-CH=CH-(CH2)f , Cχ-6 alkyl-S02-(CH2)t-, Cχ-6 alkylaryl-S02-(CH2)t-, 0 Cχ-6 alkoxy, aryl Cχ-6 alkoxy, aryl Cχ-6 alkyl,
(Cχ-6 alkyDpamino Cχ-6 alkyl,
( aryl )p amino, δ (aryl)pamino Cχ-6 alkyl, (aryl Cχ_6 alkyDpamino,
(aryl Cχ-6 alkyDpamino Cχ-6 alkyl, arylcarbonyloxy, aryl Cχ-6 alkylcarbonyloxy, δ (Cχ-6 alkyDpaminocarbonyl oxy,
Cχ-8 alkylsulfonylamino, arylsulfonylamino ,
Cχ-8 alkylsulfonylamino Cχ_6 alkyl, arylsulfonylamino Cχ-6 alkyl, 10 aryl Cχ-6 alkylsulfonylamino, aryl Cχ-6 alkylsulfonylamino Cχ-6 alkyl,
Cχ-8 alkoxycarbonylamino,
Cχ-8 alkoxycarbonylamino Cχ_8 alkyl, aryloxycarbonylamino Cχ_8 alkyl, lδ aryl Cχ-8 alkoxycarbonylamino, aryl Cχ_8 alkoxycarbonylamino Cχ-8 alkyl,
Cχ-8 alkylcarbonylamino,
Cχ-8 alkylcarbonylamino Cχ-6 alkyl, arylcarbonylamino Cχ-6 alkyl, 0 aryl Cχ-6 alkylcarbonylamino, aryl Cχ_6 alkylcarbonylamino Cχ-6 alkyl, aminocarbonylamino Cχ-6 alkyl,
(Cχ-8 alkyDpaminocarbonylamino,
(Cχ.8 alkyDpaminocarbonylamino Cχ-6 alkyl, δ (aryl)paminocarbonylamino Cχ-6 alkyl,
(aryl Cχ-8 alkyDpaminocarbonylamino,
(aryl Cχ-8 alkyDpaminocarbonylamino Cχ-6 alkyl, aminosulfonylamino Cχ-6 alkyl,
(Cχ-8 alkyDpaminosulfonylamino, 0 (Cχ-8 alkyDpaminosulfonylamino Cχ.6 alkyl,
(aryl)paminosulfonylamino Cχ-β alkyl,
(aryl Cχ-8 alkyDpaminosulfonylamino,
(aryl Cχ-8 alkyDpaminosulfonylamino Cχ.6 alkyl,
Cχ-6 alkylsulfonyl, Cχ-6 alkylsulfonyl Cχ-6 alkyl, arylsulfonyl Cχ-6 alkyl, aryl Cχ-6 alkylsulfonyl, aryl Cχ-6 alkylsulfonyl Cχ-6 alkyl, δ Cχ-6 alkylcarbonyl,
Cχ-6 alkylcarbonyl Cχ-6 alkyl, arylcarbonyl Cχ-6 alkyl, aryl Cχ_6 alkylcarbonyl, aryl Cχ-6 alkylcarbonyl Cχ-6 alkyl, X0 Cχ-6 alkylthiocarbonylamino,
Cχ-6 alkylthiocarbonylamino Cχ-6 alkyl, arylthiocarbonylamino Cχ-6 alkyl, aryl Cχ-6 "alkylthiocarbonylamino, aryl Cχ-6 alkylthiocarbonylamino Cχ-6 alkyl, lδ (Cχ-8 alkyDpaminocarbonyl Cχ-6 alkyl,
(aryl)paminocarbonyl Cχ-6 alkyl, (aryl Cχ-8 alkyDpaminocarbonyl, and (aryl Cχ-8 alkyDpaminocarbonyl Cχ_6 alkyl; or two R3 substituents, when on the same carbon atom are taken 20 together with the carbon atom to which they are attached to form a carbonyl group or a cyclopropyl group, wherein any of the alkyl groups of R^ are either unsubstituted or substituted with one to three Rl substituents, and provided that each R^ is selected such that in the resultant δ compound the carbon atom or atoms to which R^ is attached is itself attached to no more than one heteroatom;
each R4 is independently selected from the group consisting of hydrogen, 0 aryl, aminocarbonyl, C3-8 cycloalkyl, amino Cχ-6 alkyl, (aryl)paminocarbonyl, (aryl Cχ-5 alkyDpaminocarbonyl, hydroxycarbonyl Cχ-6 alkyl, Cχ-8 alkyl, aryl Cχ-6 alkyl, δ (Cχ-6 alkyDpamino C2_6 alkyl,
(aryl Cχ_6 alkyDpamino C2-6 alkyl, Cχ_8 alkylsulfonyl, Cχ-8 alkoxycarbonyl, aryloxycarbonyl, 10 aryl Cχ-8 alkoxycarbonyl,
Cχ-8 alkylcarbonyl, arylcarbonyl, aryl Cχ-6 -alkylcarbonyl,
(Cχ_8 alkyDpaminocarbonyl, lδ amino sulfonyl,
Cχ-8 alkylaminosulfonyl,
(aryl)paminosulfonyl,
(aryl Cχ-8 alkyDpaminosulfonyl, aryl sulfonyl, 20 arylCl-6 alkylsulfonyl,
Cχ.6 alkylthiocarbonyl, aryltbiocarbonyl, and aryl Cχ-6 alkylthiocarbonyl, wherein any of the alkyl groups of R4 are either unsubstituted or δ substituted with one to three Rl substituents;
5 and R6 are each independently selected from the group consisting of hydrogen, Cχ.χo alkyl, 0 aryl, aryl-(CH2)r-0-(CH2)s-, aryl-(CH2)rS(0)p-(CH2)s-, aryl-(CH2)r-C(0)-(CH2)s-, aryl-(CH2)r-C(0)-N(R4)-(CH2)s-, aryl-(CH2)r-N(R4)-C(0)-(CH2)s-, aryl-(CH2)r-N(R4)-(CH2)s-, halogen, hydroxyl, 5 Cχ-8 alkylcarbonylamino, aryl Cχ-δ alkoxy, Cχ-5 alkoxycarbonyl, (Cχ-8 alkyDpaminocarbonyl, Cχ-6 alkylcarbonyloxy, 10 C3-8 cycloalkyl,
(Cχ-6 alkyDpamino, amino Cχ-6 alkyl, arylaminόcarbonyl, aryl Cχ-δ alkylaminocarbonyl, lδ aminocarbonyl, aminocarbonyl Cχ-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cχ-6 alkyl,
HC≡C-(CH2)t-, 0 Cχ-6 alkyl-C≡C-(CH2)t-,
C3-7 cycloalkyl-C≡C-(CH2)t-, aryl-C≡C-(CH2)t-,
Cχ-6 alkylaryl-C≡C-(CH2)t-,
CH2=CH-(CH2)t-, δ Cχ-6 alkyl-CH=CH-(CH2)t-,
C3-7 cycloalkyl-CH=CH-(CH2)t-, aryl-CH=CH-(CH2)t-,
Cχ-6 alkylaryl-CH=CH-(CH2)t- ,
Cχ-6 alkyl-S02-(CH2)t-, 0 Cχ-6 alkylaryl-S02-(CH2)t-,
Cχ-6 alkoxy, aryl Cχ-6 alkoxy, aryl Cχ-6 alkyl,
(Cχ-6 alkyDpamino Cχ-6 alkyl, ( aryl )p amino,
(aryl)pamino Cχ-6 alkyl,
(aryl Cχ.6 alkyDpamino,
(aryl Cχ_6 alkyDpamino Cχ_6 alkyl, δ arylcarbonyloxy, aryl Cχ.β alkylcarbonyloxy,
(Cχ-6 alkyDpaminocarbonyloxy,
Cχ-8 alkylsulfonylamino, arylsulfonylamino,
10 Cχ-8 alkylsulfonylamino Cχ-6 alkyl, arylsulfonylamino Cχ-6 alkyl, aryl Cχ-6 alkylsulfonylamino, aryl Cχ-6 -alkylsulfonylamino Cχ-6 alkyl, Cχ-8 alkoxycarbonylamino, lδ Cχ-8 alkoxycarbonylamino Cχ-8 alkyl, aryloxycarbonylamino Cχ-8 alkyl, aryl Cχ-8 alkoxycarbonylamino, aryl Cχ-8 alkoxycarbonylamino Cχ-8 alkyl, Cχ-8 alkylcarbonylamino,
20 Cχ-8 alkylcarbonylamino Cχ-6 alkyl, arylcarbonylamino Cχ_6 alkyl, aryl Cχ-6 alkylcarbonylamino, aryl Cχ-6 alkylcarbonylamino Cχ-6 alkyl, ami nocarbonylamino Cχ-6 alkyl, δ (Cχ-8 alkyDpaminocarbonylamino,
(Cχ-8 alkyDpaminocarbonylamino Cχ_6 alkyl,
(aryl)paminocarbonylamino Cχ-6 alkyl,
(aryl Cχ-8 alkyDpaminocarbonylamino,
(aryl Cχ-8 alkyDpaminocarbonylamino Cχ-6 alkyl, 0 aminosulfonylamino Cχ-6 alkyl,
(Cχ_8 alkyDpaminosulfonylamino, (Cχ-8 alkyDpaminosulfonylamino C .6 alkyl, (aryl)paminosulfonylamino Cχ_6 alkyl, (aryl Cχ-8 alkyDpaminosulfonylamino, (aryl Cχ-8 alkyDpaminosulfonylamino Cχ_6 alkyl,
Cχ-6 alkylsulfonyl,
Cχ-6 alkylsulfonyl Cχ-6 alkyl, arylsulfonyl Cχ_6 alkyl, δ aryl Cχ-6 alkylsulfonyl, aryl Cχ-6 alkylsulfonyl Cχ-6 alkyl,
Cχ-6 alkylcarbonyl,
Cχ-6 alkylcarbonyl Cχ-6 alkyl, arylcarbonyl Cχ_6 alkyl, 10 aryl Cχ-6 alkylcarbonyl, aryl Cχ-6 alkylcarbonyl Cχ-6 alkyl,
Cχ-6 alkylthiocarbonylamino,
Cχ-6 alkylthiocarbonylamino Cχ-6 alkyl, arylthiocarbonylamino Cχ-6 alkyl, lδ aryl Cχ-6 alkylthiocarbonylamino, aryl Cχ-6 alkylthiocarbonylamino Cχ-6 alkyl,
(Cχ_8 alkyDpaminocarbonyl Cχ-6 alkyl,
(aryl)paminocarbonyl Cχ_6 alkyl,
(aryl Cχ-8 alkyDpaminocarbonyl, and 20 (aryl Cχ-8 alkyDpaminocarbonyl Cχ-6 alkyl, or R5 and R6 are taken together with the carbon atom to which they are attached to form a carbonyl group, wherein any of the alkyl groups of R^ or R^ are either unsubstituted or substituted with one to three Rl substituents, and provided that each R^ 5 and R > are selected such that in the resultant compound the carbon atom to which R^ and R^ are attached is itself attached to no more than one heteroatom;
R7 and Rδ are each independently selected from the group consisting of 0 , hydrogen,
Cχ.χo alkyl, aryl, aryl-(CH2)r-0-(CH2)s-, aryl-(CH2)rS(0)p-(CH2)s-, aryl-(CH2)r-C(0)-(CH2)s-, aryl-(CH2)r-C(0)-N(R4)-(CH )s-, aryl-(CH2)r-N(R4)-C(0)-(CH2)s-, aryl-(CH2)r-N(R4)-(CH2)s-,
5 halogen, hydroxyl,
Cχ-8 alkylcarbonylamino, aryl Cχ-5 alkoxy, Cχ-5 alkoxycarbonyl, 10 (Cχ-8 alkyDpaminocarbonyl,
Cχ-6 alkylcarbonyloxy, C3-8 cycloalkyl, (Cχ-6 alkyDpamino, amino Cχ.β alkyl, lδ arylaminocarbonyl, aryl Cχ-5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cχ_6 alkyl, hydroxycarbonyl , 0 hydroxycarbonyl Cχ-6 alkyl,
HC≡C-(CH2)t-,
Cχ-6 alkyl-C=C-(CH2)t-,
C3-7 cycloalkyl-C- -(CH2)t-, aryl-C=C-(CH2)t-, δ Cχ-6 alkylaryl-C≡C-(CH2)t-,
CH2=CH-(CH )t-, Cχ-6 alkyl-CH=CH-(CH2)t-, C3.7 cycloalkyl-CH=CH-(CH2)t-, aryl-CH=CH-(CH2)t-, 0 Cχ_6 alkylaryl-CH=CH-(CH2)t-, Cχ-6 alkyl-S02-(CH2)t-, Cχ-6 alkylaryl-S02-(CH2)t-, Cχ-6 alkoxy, aryl Cχ.6 alkoxy, aryl Cχ-6 alkyl, (Cχ-6 alkyDpamino Cχ-6 alkyl, (aryl)pamino, (aryl)pamino Cχ-6 alkyl, δ (aryl Cχ-6 alkyDpamino,
(aryl Cχ_6 alkyDpamino Cχ-6 alkyl, arylcarbonyloxy, aryl Cχ-6 alkylcarbonyloxy, (Cχ-6 alkyDpaminocarbonyl oxy, X0 Cχ-8 alkylsulfonylamino, arylsulfonylamino,
Cχ-8 alkylsulfonylamino Cχ-6 alkyl, arylsulfonylamino Cχ-6 alkyl, aryl Cχ-6 alkylsulfonylamino, lδ aryl Cχ-6 alkylsulfonylamino Cχ-6 alkyl,
Cχ-8 alkoxycarbonylamino,
Cχ-8 alkoxycarbonylamino Cχ-8 alkyl, aryloxycarbonylamino Cχ-8 alkyl, aryl Cχ-8 alkoxycarbonylamino, 20 aryl Cχ-8 alkoxycarbonylamino Cχ_8 alkyl,
Cχ-8 alkylcarbonylamino,
Cχ-8 alkylcarbonylamino Cχ-6 alkyl, arylcarbonylamino Cχ-6 alkyl, aryl Cχ_6 alkylcarbonylamino, δ aryl Cχ_6 alkylcarbonylamino Cχ-6 alkyl, aminocarbonylamino Cχ-6 alkyl,
(Cχ-8 alkyDpaminocarbonylamino,
(Cχ-8 alkyl )paminocarbonylamino Cχ-6 alkyl,
(aryl)paminocarbonylamino Cχ_6 alkyl, 0 (aryl Cχ-8 alkyl)paminocarbonylamino,
(aryl Cχ-8 alkyDpaminocarbonylamino Cχ-6 alkyl, aminosulfonylamino Cχ-6 alkyl,
(Cχ-8 alkyDpaminosulfonylamino,
(Cχ-8 alkyDpaminosulfonylamino Cχ-6 alkyl, (aryl)paminosulfonylamino Cχ.6 alkyl,
(aryl Cχ-8 alkyDpaminosulfonylamino,
(aryl Cχ-8 alkyDpaminosulfonylamino Cχ-6 alkyl,
Cχ-6 alkylsulfonyl, δ Cχ-6 alkylsulfonyl Cχ-6 alkyl, arylsulfonyl C -6 alkyl, aryl Cχ_6 alkylsulfonyl, aryl Cχ-6 alkylsulfonyl Cχ-6 alkyl,
Cχ-6 alkylcarbonyl, 10 Cχ-6 alkylcarbonyl Cχ-6 alkyl, arylcarbonyl Cχ-6 alkyl, aryl Cχ-6 alkylcarbonyl, aryl Cχ-6 alkylcarbonyl Cχ-6 alkyl,
Cχ-6 alkylthiocarbonylamino, lδ Cχ-6 alkylthiocarbonylamino Cχ_6 alkyl, arylthiocarbonylamino Cχ.β alkyl, aryl Cχ_6 alkylthiocarbonylamino, aryl Cχ-6 alkylthiocarbonylamino Cχ_6 alkyl,
(Cχ-8 alkyDpaminocarbonyl Cχ_6 alkyl, 20 (aryl)paminocarbonyl Cχ-6 alkyl,
(aryl Cχ-8 alkyDpaminocarbonyl,
(aryl Cχ-8 alkyDpaminocarbonyl Cχ.6 alkyl, and
C7-20 polycyclyl Cθ-8 alkylsulfonylamino; wherein any of the alkyl groups of R^and R° are either unsubstituted or δ substituted with one to three Rl substituents, and provided that each R^and R^ are selected such that in the resultant compound the carbon atom at which R" and R° are attached is itself attached to no more than one heteroatom;
0 R9 is selected from the group consisting of hydrogen, Cχ-8 alkyl, aryl, aryl Cχ_8 alkyl, Cχ-8 alkylcarbonyloxy Cχ.4 alkyl, aryl Cχ-8 alkylcarbonyloxy Cχ-4 alkyl,
Cχ-8 alkylaminocarbonylmethylene, and
Cχ-8 dialkylaminocarbonylmethylene; δ
RlO , RU, and Rl2 are each independently selected from the group consisting of hydrogen,
Cχ-8 alkyl,
10 aryl, halogen, hydroxyl, oxo, aminocarbonyl, lδ C3-8 cycloalkyl, amino Cχ-6 alkyl,
(aryl)paminocarbonyl, hy droxycarb onyl ,
(aryl Cχ-5 alkyDpaminocarbonyl, 0 hydroxycarbonyl Cχ-6 alkyl, aryl Cχ-6 alkyl,
(Cχ-6 alkyDpamino Cχ-6 alkyl,
(aryl Cχ-6 alkyDpamino C2-6 alkyl,
Cχ-8 alkylsulfonyl, δ Cχ-8 alkoxycarbonyl, aryloxycarbonyl, aryl Cχ-8 alkoxycarbonyl,
Cχ-8 alkylcarbonyl, arylcarbonyl, 0 aryl Cχ-6 alkylcarbonyl,
(Cχ-8 alkyDpaminocarbonyl, amino sulfonyl,
Cχ-8 alkylaminosulfonyl,
(aryl)paminosulfonyl, (aryl Cχ-8 alkyDpaminosulfonyl, Cχ-6 alkylsulfonyl, aryl sulfonyl, aryl Cχ-6 alkylsulfonyl, δ aryl Cχ-6 alkylcarbonyl,
Cχ-6 alkylthiocarbonyl, arylthiocarbonyl, aryl Cχ-6 alkylthiocarbonyl, aryl-(CH2)r-0-(CH2)s-,
10 aryl-(CH2)rS(0)p-(CH2)s-, aryl-(CH2)r-C(0)-(CH2)s-, aryl-(CH2)r-C(0)-N(R4)-(CH2)s-, aryl-(CH2)r-N(R4)-C(0)-(CH2)s-, aryl-(CH2)r-N(R4).(CH )s-, lδ HC≡C-(CH2)t-,
Cχ_6 alkyl-C≡C-(CH2)t-,
C3-7 cycloalkyl-C≡C-(CH2)t-, aryl-C≡C-(CH2)t-,
Cχ_6 alkylaryl-C≡C-(CH2)t-,
20 CH2=CH-(CH2)t-,
Cχ_6 alkyl-CH=CH-(CH2)t-,
C3.7 cycloalkyl-CH=CH-(CH2)t-, aryl-CH=CH-(CH2)t-,
Cχ-6 alkylaryl-CH=CH-(CH2)t-, δ Cχ.6 alkyl-S02-(CH2)t-,
Cχ.6 alkylaryl-S02-(CH2)t-, Cχ-8 alkylcarbonylamino, aryl Cχ-5 alkoxy, Cχ-5 alkoxycarbonyl, 0 (Cχ-8 alkyDpaminocarbonyl,
Cχ-6 alkylcarbonyloxy, (Cχ-6 alkyDpamino, aminocarbonyl Cχ-6 alkyl, Cχ-6 alkoxy, aryl Cχ-6 alkoxy, (aryl)pamino, (aryl)pamino Cχ-6 alkyl, (aryl Cχ-6 alkyDpamino, δ (aryl Cχ-6 alkyDpamino Cχ-6 alkyl, arylcarbonyloxy, aryl Cχ-6 alkylcarbonyloxy, (Cχ-6 alkyl )paminocarbonyloxy, Cχ-8 alkylsulfonylamino,
X0 arylsulfonylamino,
Cχ-8 alkylsulfonylamino Cχ-6 alkyl, arylsulfonylamino Cχ-6 alkyl, aryl Cχ-6 'alkylsulfonylamino, aryl Cχ-6 alkylsulfonylamino Cχ_6 alkyl, lδ Cχ-8 alkoxycarbonylamino,
Cχ-8 alkoxycarbonylamino Cχ-8 alkyl, aryloxycarbonylamino Cχ-8 alkyl, aryl Cχ_8 alkoxycarbonylamino, aryl Cχ_8 alkoxycarbonylamino Cχ-8 alkyl, 0 Cχ-8 alkylcarbonylamino,
Cχ-8 alkylcarbonylamino Cχ-6 alkyl, arylcarbonylamino Cχ-6 alkyl, aryl Cχ-6 alkylcarbonylamino, aryl Cχ_6 alkylcarbonylamino Cχ-6 alkyl, δ aminocarbonylamino Cχ-6 alkyl,
(Cχ-8 alkyDpaminocarbonylamino, (Cχ-8 alkyDpaminocarbonylamino Cχ-6 alkyl, (aryl)paminocarbonylamino Cχ-6 alkyl, (aryl Cχ-8 alkyDpaminocarbonylamino, 0 (aryl Cχ-8 alkyDpaminocarbonylamino Cχ-6 alkyl, aminosulfonylamino Cχ-6 alkyl, (Cχ-8 alkyDpaminosulfonylamino, (Cχ-8 alkyDpaminosulfonylamino Cχ-6 alkyl, (aryl)paminosulfonylamino Cχ-6 alkyl, (aryl Cχ-8 alkyDpaminosulfonylamino,
(aryl Cχ-8 alkyDpaminosulfonylamino Cχ_6 alkyl,
Cχ-6 alkylsulfonyl,
Cχ_6 alkylsulfonyl Cχ-6 alkyl, δ arylsulfonyl Cχ-6 alkyl, aryl Cχ.β alkylsulfonyl, aryl Cχ-6 alkylsulfonyl Cχ-6 alkyl,
Cχ-6 alkylcarbonyl,
Cχ-6 alkylcarbonyl Cχ-6 alkyl, 10 arylcarbonyl Cχ-6 alkyl, aryl Cχ-6 alkylcarbonyl, aryl Cχ-6 alkylcarbonyl Cχ-6 alkyl,
Cχ-6 alkylthiocarbonylamino,
Cχ-6 alkylthiocarbonylamino Cχ-6 alkyl, lδ arylthiocarbonylamino Cχ-6 alkyl, aryl Cχ_6 alkylthiocarbonylamino, aryl Cχ-6 alkylthiocarbonylamino Cχ_6 alkyl,
(Cχ-8 alkyDpaminocarbonyl Cχ-6 alkyl,
(aryl)paminocarbonyl Cχ-6 alkyl, 20 (aryl Cχ-8 alkyDpaminocarbonyl, and
(aryl Cχ-8 alkyDpaminocarbonyl Cχ-6 alkyl, wherein any of the alkyl groups of RlO, RU, and Rl2 are either unsubstituted or substituted with one to three Rl substituents;
δ wherein each m is independently an integer from 0 to 6; each n is independently an integer from 0 to 6 each p is independently an integer from 0 to 2; each r is independently an integer from 1 to 3; 0 each s is independently an integer from 0 to 3; each t is independently an integer from 0 to 3; and v is independently an integer from 0 to 6;
and the pharmaceutically acceptable salts thereof. In the compounds of the present invention, W is preferably a 6-membered monocyclic aromatic or nonaromatic ring system having 1 or 2 nitrogen atoms wherein each carbon atom is either unsubstituted or substituted with one Rl substituent, or
a 9- to 14-membered polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system has 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, 0, and S
10 wherein the ring nitrogen atoms are unsubstituted or substituted with one Rl substituent and the ring carbon atoms are unsubstituted or substituted with one or two Rl substituents.
More preferably, W is selected from the group consisting of
Most preferably W is
In the compounds of the present invention, X is preferably 0 -(CH2)v- , wherein any methylene (CH2) carbon atom is either unsubstituted or substituted with one or two Rl substituents. More preferably X is a direct bond, that is, v is 0. In the compounds of the present invention, Y is preferably selected from the group consisting of
δ -(CH2)m-,
-(CH2)m-0-(CH2)n-,
-(CH2)m-S-(CH )n-,
-(CH2)m-SO-(CH2)n-, 10 -(CH )m-S02-(CH2)n-,
-(CH2)m-0-(CH2)n-0-(CH2)p-,
-(CH2)m-0-(CH2)n-NR4-(CH2)p-,
-(CH2)m-NR4-(CH2)n-NR4-(CH2)p-, and
-(CH2)m-NR4-(CH2)n-0-(CH2)p-, lδ wherein any carbon atom in Y, other than in R , can be substituted by one or two R^ substituents.
More preferably Y is selected from the group consisting of
0 (CH2)m, (CH2)m-S-(CH2)n, and (CH2)m-NR4-(CH2)n,
wherein any methylene (CH ) carbon atom in Y, other than in R4, can be substituted by one or two R^ substituents.
In the compounds of the present invention, Z is preferably δ selected from the group consisting of
More preferably Z is selected from the group consisting of
Most preferably Z is
In the compounds of the present invention, Rl and R are preferably selected from the group consisting of hydrogen, halogen, Oχ. X0 alkyl, C3-8 cycloalkyl, C3-8 cycloheteroalkyl, hydroxy, nitro, cyano, trifluoromethyl, and trifluoromethoxy. δ More preferably, Rl and R2 are selected from the group consisting of hydrogen, halogen, Cχ.χo alkyl, C3-8 cycloalkyl, trifluoromethyl, and trifluoromethoxy.
In the compounds of the present invention, R^ is preferably 10 selected from the group consisting of hydrogen, fluoro, trifluoromethyl, aryl, lδ Cχ-8 alkyl, arylCχ-6 alkyl hydroxyl, oxo, arylaminocarbonyl, 20 aryl Cχ-5 alkylaminocarbonyl, aminocarbonyl, and aminocarbonyl Cχ-6 alkyl.
More preferably, R^ is selected from the group consisting of δ fluoro, aryl,
Cχ-8 alkyl, arylCχ-6 alkyl hydroxyl, 0 oxo, and arylaminocarbonyl.
In the compounds of the present invention, R4 is preferably selected from the group consisting of hydrogen, aryl,
C3-8 cycloalkyl, Cχ-8 alkyl, δ Cχ-8 alkylcarbonyl, aryl carbonyl, Cχ-6 alkylsulfonyl, aryl sulfonyl, arylC χ-6alkylsulfonyl, 10 arylCχ-6alkylcarbonyl,
C X-8alkylaminocarbonyl, arylCx-δalkylaminocarbonyl, arylCχ-8alkoxycarbonyl, and
C χ-8alkoxycarbonyl. lδ More preferably, R is selected from the group consisting of hydrogen,
Cχ-8 alkyl,
Cχ-8 alkylcarbonyl, arylcarbonyl, 20 arylCχ-6alkylcarbonyl,
Cχ-6 alkylsulfonyl, arylsulfonyl, and arylC χ-6alkylsulfonyl.
In one embodiment of the present invention, R^ and R^ are δ each independently selected from the group consisting of hydrogen, aryl,
Cχ-8 alkyl, aryl-C≡C-(CH2)t-, 0 aryl Cχ-6 alkyl,
CH2=CH-(CH2)t-, and HC≡C-(CH2)t-.
In a class of this embodiment of the present invention, ^ is hydrogen and R^ is selected from the group consisting of δ hydrogen, aryl,
Cχ-8 alkyl, aryl-C≡C-(CH2)t-, aryl Cχ-6 alkyl, δ CH =CH-(CH2)t-, and
HC≡C-(CH )f.
In a subclass of this class of the present invention, R^, R?, and R8 are each hydrogen and R^ is selected from the group consisting of 0 hydrogen, aryl,
Cχ-8 alkyl, aryl-C≡C-(CH2)t-, aryl Cχ-6 alkyl, 5 CH =CH-(CH2)t-, and
HC≡C-(CH2)t-.
In another embodiment of the present invention, R' and R& are each independently selected from the group consisting of 0 hydrogen, aryl, Cχ-8 alkylcarbonylamino, arylcarbonylamino, Cχ-8 alkylsulfonylamino, δ arylsulfonylamino,
Cχ-8 alkylsulfonylamino Cχ-6 alkyl, arylsulfonylamino Cχ-6 alkyl, aryl Cχ-6 alkylsulfonylamino, aryl Cχ-6 alkylsulfonylamino Cχ-6 alkyl, 0 Cχ-8 alkoxycarbonylamino,
Cχ-8 alkoxycarbonylamino Cχ-8 alkyl, aryloxycarbonylamino Cχ-8 alkyl, aryl Cχ-8 alkoxycarbonylamino, aryl Cχ-8 alkoxycarbonylamino Cχ-8 alkyl, δ Cχ-8 alkylcarbonylamino Cχ-6 alkyl,
- 4δ - arylcarbonylamino Cχ.β alkyl, aryl Cχ-6 alkylcarbonylamino, aryl Cχ-6 alkylcarbonylamino Cχ-6 alkyl, aminocarbonylamino Cχ-6 alkyl, 5 (Cχ-8 alkyDpaminocarbonylamino,
(Cχ-8 alkyDpaminocarbonylamino Cχ-6 alkyl,
(aryl)paminocarbonylamino Cχ-6 alkyl,
(aryl Cχ-8 alkyl)paminocarbonylamino,
(aryl Cχ-8 alkyDpaminocarbonylamino Cχ-6 alkyl, 10 aminosulfonylamino Cχ-6 alkyl,
(Cχ-8 alkyDpaminosulfonylamino,
(Cχ-8 alkyDpaminosulfonylamino Cχ-6 alkyl,
(aryl)paminosulfonylamino Cχ-6 alkyl,
(aryl Cχ-8 alkyDpaminosulfonylamino, lδ (aryl Cχ-8 alkyDpaminosulfonylamino Cχ_6 alkyl,
Cχ-6 alkylthiocarbonylamino,
Cχ-6 alkylthiocarbonylamino Cχ-6 alkyl, arylthiocarbonylamino Cχ.6 alkyl, aryl Cχ-6 alkylthiocarbonylamino, and 0 aryl Cχ-6 alkylthiocarbonylamino Cχ-6 alkyl.
In a class of this embodiment of the present invention, R^ is hydrogen and R^ is selected from the group consisting of consisting of hydrogen, δ aryl,
Cχ-8 alkylcarbonylamino, aryl Cχ-6 alkylcarbonylamino, arylcarbonylamino, Cχ-8 alkylsulfonylamino, 0 aryl Cχ-6 alkylsulfonylamino, aryl sulfonyl amino ,
Cχ-8 alkoxycarbonylamino, aryl Cχ-8 alkoxycarbonylamino, arylaminocarbonylamino, (Cχ-8 alkyDpaminocarbonylamino, (aryl Cχ-8 alkyDpaminocarbonylamino,
(Cχ-8 alkyDpaminosulfonylamino, and
(aryl Cχ-8 alkyDpaminosulfonylamino. δ
In a subclass of this class of the present invention, R^, R6. and R8 are each hydrogen and R is selected from the group consisting of hydrogen,
10 aryl,
Cχ-8 alkylcarbonylamino, aryl Cχ_6 alkylcarbonylamino, arylcarbonylamino , Cχ-8 alkylsulfonylamino, Xδ aryl Cχ-6 alkylsulfonylamino, arylsulfonylamino ,
Cχ-8 alkoxycarbonylamino, aryl Cχ-8 alkoxycarbonylamino, arylaminocarbonylamino, 20 (Cχ-8 alkyDpaminocarbonylamino,
(aryl Cχ-8 alkyDpaminocarbonylamino, (Cχ-8 alkyDpaminosulfonylamino, and (aryl Cχ-8 alkyDpaminosulfonylamino.
In the compounds of the present invention, R is preferably δ selected from the group consisting of hydrogen, methyl, and ethyl. More preferably, R is hydrogen.
In the compounds of the present invention, R O, RU, and Rl are preferably each independently selected from the group consisting of hydrogen and Cχ-8 alkyl. More preferably RlO, RU, and 0 Rl are hydrogen.
In the compounds of the present invention, m is preferably an integer from 0 to 4, more preferably from 0 to 3.
In the compounds of the present invention, n is preferably an integer from 0 to 4, more preferably from 0 to 3. In the compounds of the present invention, r is preferably an integer from 1 to 2.
In the compounds of the present invention, s is preferably an integer from 0 to 2. δ In the compounds of the present invention, t is preferably an integer from 0 to 2, more preferably from 0 to 1.
In the compounds of the present invention, v is preferably 0.
In certain embodiments of the present invention the compounds have the formula with the following designated 10 stereochemistry:
wherein the substituents W, X, Y, Z, Rl, R2, R3, R4, Rδ? R6? R7? R8> R9? RlO, RU, and Rl2, and the subscripts m, n, p, r, s, t, and v are as lδ described above.
Illustrative but nonlimiting examples of compounds of the present invention that are useful as integrin receptor antagonists are the following:
20 Ethyl 3(S)-(3-fluorophenyl)-3-[2-oxo-3(S)-[3-(δ, 6,7,8-tetrahydro- [l,8]naphthyidin-2-yl)-propyl]-pyrrolidin-l-yl]-propionate;
Ethyl 3(S)-(3-fluorophenyl)-3-[2-oxo-3(R)-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyidin-2-yl)-propyl]-pyrrolidin-l-yl]-propionate; δ
Ethyl 3(S)-(2,3-dihydro-benzofuran-6-yl)-3-(2-oxo-3(S)-[3-(δ,6,7,8- tetrahydro-[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionate;
Ethyl 3(S)-(2,3-dihydro-benzofuran-6-yl)-3-(2-oxo-3(R)-[3-(δ,6,7,8- 0 tetrahydro-[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionate; Ethyl 3(S)-(quinoHn-3-yl)-3-(2-oxo-3(R)-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionate;
Ethyl 3(S)-(quinohn-3-yl)-3-(2-oxo-3(S)-[3-(δ,6,7,8-tetrahydro- δ [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionate;
3(S)-(3-Fluorophenyl)-3-[2-oxo-3(R)-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyidin-2-yl)-propyl]-pyrrolidin-l-yl]-propionic acid;
10 3(S)-(3-Fluorophenyl)-3-[2-oxo-3(S)-[3-(δ,6,7,8-tetrahydro-
[l,8]naphth5 din-2-yl)-propyl]-pyrrolidin-l-yl]-propionic acid;
3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(2-oxo-3(R)-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid; lδ
3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(2-oxo-3(S)-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(Quinolin-3-yl)-3-(2-oxo-3(R)-[3-(δ,6,7,8-tetrahydro-[l,8]naphthyridin- 20 2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(Quinolin-3-yl)-3-(2-oxo(S)-3-[3-(δ,6,7,8-tetrahydro-[l,8]naphthyridin- 2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
δ 2(S)-Benzenesulfonylamino-3-[3-(3-[l,8]naphthyridin-2-yl-propyD- [l,2,4]oxadiazol-δ-yl]-propionic acid;
3(S)-(6-Ethoxy-pyridin-3-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid; 0
3(S)-(6-Amino-pyridin-3-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid; 3(S)-(4-Methyl-3-oxo-3,4-dihydro-2H-benzo[l,4]oxazin-7-yl)-3-(2-oxo-3-[3- (δ,6,7,8-tetrahydro-[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)- propionic acid;
δ 3-(6-Methylamino-pyridin-3-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(2-Fluoro-biphenyl-4-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid; 10
3(S)-(2-Oxo-2,3-dihydro-benzoxazol-6-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(4-Ethoxy-3-fluorophenyl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- lδ [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(δ-Ethoxy-pyridin-3-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
0 3(S)-(δ-Methoxy-pyridin-3-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(Ethynyl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro-[l,8]naphthyridin-2-yD- propyl]-p3πrrolidin-l-yl)-propionic acid; δ
3(S)-(6-Methoxy-pyridin-3-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(2-Oxo-2,3-dihydro-lH-4-oxa-l,δ-diaza-naphthalen-7-yl)-3-(2-oxo-3-[3- 0 (δ,6,7,8-tetrahydro-[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)- propionic acid;
3(S)-(2,3-Dihydro-lH-4-oxa-l,δ-diaza-naphthalen-7-yl)-3-(2-oxo-3-[3- (δ,6,7,8-tetrahydro-[l,8]naphthyridin-2-yD-propyl]-pyrrolidin-l-yl)- δ propionic acid;
- δO - 3(S)-(2-Oxo-3,4-dihydro-2H-l-oxa-4,δ-diaza-naphthalen-7-yl)-3-(2-oxo-3-[3- (δ,6,7,8-tetrahydro-[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)- propionic acid; δ
3(S)-(3,4-Dihydro-2H-l-oxa-4,δ-diaza-naphthalen-7-yl)-3-(2-oxo-3-[3- (δ,6,7,8-tetrahydro-[l,8]naphthyri.din-2-yl)-propyl]-pyrrolidin-l-yl)- propionic acid;
10 3-(Furo-[2,3-b]pyridin-6-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro-
[l,8]naphthyridin-2-yl)-propyl]-p3nrrolidin-l-yl)-propionic acid;
3-(2,3-Dihydrofuro[2,3-b]pyridin-6-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid; lδ
3-(Furo-[3,2-b]pyridin-6-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3-(2,3-Dihydrofuro[3,2-b]pyridin-6-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- 0 [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(Benzimidazol-2-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
δ 3(S)-(lH-Imidazo[4,δ-c]pyridin-2-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(Benzoxazol-2-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro-[l,8]naphthyridin- 2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid; 0
3(S)-(l-Methyl-lH-pyrazol-4-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-{2-oxo-3-[3-(δ,6,7,8-tetrahydro-[l,8]naphthyridin-2-yl)-propyl]- δ pyrrolidin-l-yl}-pent-4-enoic acid;
- δl - and the pharmaceutically acceptable salts thereof.
Further illustrative of the present invention are compounds δ selected from the group consisting of
3(S)-(3-Fluorophenyl)-3-[2-oxo-3(R)-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyidin-2-yl)-propyι]-pyrrolidin- l-yl]-propionic acid;
10 3(S)-(3-Fluorophenyl)-3-[2-oxo-3(S)-[3-(δ,6,7,8-tetrahydro-
[l,8]naphthyidin-2-yl)-propyl]-pyrrolidin-l-yl]-propionic acid;
3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(2-oxo-3(R)-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl3-pyrrolidin-l-yl)-propionic acid; lδ
3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(2-oxo-3(S)-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(Quinolin-3-yl)-3-(2-oxo-3(R)-[3-(δ,6,7,8-tetrahydro-[l,8]naphthyridin- 20 2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(Quinolin-3-yl)-3-(2-oxo-3(S)-[3-(δ,6,7,8-tetrahydro-[l,8]naphthyridin- 2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
δ and the pharmaceutically acceptable salts thereof.
For use in medicine, the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts." Other salts may, however, be useful in the preparation of the compounds 0 according to the invention or of their pharmaceutically acceptable salts. Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid. Representative salts include the following: acetate, δ benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, δ isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, sulfate, subacetate, succinate,
10 tannate, tartrate, teoclate, tosylate, triethiodide and valerate.
Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable lδ organic ligands, e.g., quaternary ammonium salts.
The compounds of the present invention can have chiral centers and occur as racemates, racemic mixtures, diastereomeric mixtures, and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention. Therefore,
20 where a compound is chiral, the separate enantiomers or diastereomers, substantially free of the other, are included within the scope of the invention; further included are all mixtures of the two enantiomers. Also included within the scope of the invention are polymorphs and hydrates of the compounds of the instant invention. δ The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound. Thus, in the methods of treatment of the present invention, the term "administering" 0 shall encompass the treatment of the various conditions described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, δ for example, in "Design of Prodrugs," ed. H. Bundgaard, Elsevier, 198δ, which is incorporated by reference herein in its entirety. Metabolites of these compounds include active species produced upon introduction of compounds of this invention into the biological milieu.
The term "therapeutically effective amount" shall mean δ that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher or clinician.
The term "integrin receptor antagonist," as used herein, refers to a compound which binds to and antagonizes either the αvβ3 10 receptor, the αvβδ receptor, or the αvβ6 receptor, or a compound which binds to and antagonizes combinations of these receptors (for example, a dual αvβ3/αvβδ receptor antagonist).
The term "bone resorption," as used herein, refers to the process by which osteoclasts degrade bone, lδ The term "alkyl" shall mean straight or branched chain alkanes of one to ten total carbon atoms, or any number within this range (i.e., methyl, ethyl, 1-propyl, 2-propyl, n-butyl, s-butyl, t-butyl, etc.).
The term "alkenyl" shall mean straight or branched chain 20 alkenes of two to ten total carbon atoms, or any number within this range.
The term "alkynyl" shall mean straight or branched chain alkynes of two to ten total carbon atoms, or any number within this range. δ The term "cycloalkyl" shall mean cyclic rings of alkanes of three to eight total carbon atoms, or any number within this range (i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl).
The term "cycloheteroalkyl," as used herein, shall mean a 3- to 8-membered fully saturated heterocyclic ring containing one or two 0 heteroatoms chosen from N, O or S. Examples of cycloheteroalkyl groups include, but are not limited to piperidinyl, pyrrolidinyl, azetidinyl, morpholinyl, piperazinyl.
The term "alkoxy," as used herein, refers to straight or branched chain alkoxides of the number of carbon atoms specified (e.g., Cχ-5 alkoxy), or any number within this range (i.e., methoxy, ethoxy, etc.).
The term "aryl," as used herein, refers to a monocyclic or polycyclic system comprising at least one aromatic ring, wherein the 5 monocylic or polycyclic system contains 0, 1, 2, 3, or 4 heteroatoms chosen from N, 0, or S, and wherein the monocylic or polycylic system is either unsubstituted or substituted with one or more groups independently selected from hydrogen, halogen, Cχ.χo alkyl, C3-8 cycloalkyl, aryl, aryl Cχ-8 alkyl, amino, amino Cχ-8 alkyl, Cχ.3
10 acylamino, Cχ-3 acylamino Cχ_8 alkyl, Cχ-6 alkylamino, Cχ-6 alkylamino Cχ-8 alkyl, Cχ-6 dialkylamino, Cχ-6 dialkylamino-Cχ-8 alkyl, Cχ-4 alkoxy, Cχ-4 alkoxy Cχ_6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cχ_6 alkyl, Cχ_ 5 alkoxycarbonyl, Cχ_3 alkoxycarbonyl Cχ-6 alkyl, hydroxycarbonyl Cχ-6 alkyloxy, hydroxy, hydroxy Cχ-6 alkyl, cyano, trifluoromethyl, oxo or Oχ. lδ 5 alkylcarbonyloxy. Examples of aryl include, but are not limited to, phenyl, naphthyl, pyridyl, pyrryl, pyrazolyl, pyrazinyl, pyrimidinyl, imidazolyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, indolyl, thienyl, furyl, dihydrobenzofuryl, benzo(l,3) dioxolane, oxazolyl, isoxazolyl and thiazolyl, which are either unsubstituted or substituted with one or more
20 groups independently selected from hydrogen, halogen, Cχ.χo alkyl, C3-8 cycloalkyl, aryl, aryl Cχ-8 alkyl, amino, amino Cχ-8 alkyl, Cχ-3 acylamino, Cχ-3 acylamino Cχ-8 alkyl, Cχ-6 alkylamino, Cχ_6 alkylamino-Cχ-8 alkyl, Cχ-6 dialkylamino, Cχ-6 dialkylamino Cχ-8 alkyl, Cχ-4 alkoxy, Cχ-4 alkoxy Cχ-6 alkyl, hydroxycarbonyl, hydroxycarbonyl δ Cχ-6 alkyl, Cχ.5 alkoxycarbonyl, Cχ-3 alkoxycarbonyl Cχ-6 alkyl, hydroxycarbonyl Cχ-6 alkyloxy, hydroxy, hydroxy Cχ-6 alkyl, cyano, trifluoromethyl, oxo or Cχ-5 alkylcarbonyloxy. Preferably, the aryl group is unsubstituted, mono-, di-, tri- or tetra-substituted with one to four of the above-named substituents; more preferably, the aryl group is 0 unsubstituted, mono-, di- or tri-substituted with one to three of the above- named substituents; most preferably, the aryl group is unsubstituted, mono- or di-substituted with one to two of the above-named substituents. Whenever the term "alkyl" or "aryl" or either of their prefix roots appear in a name of a substituent (e.g., aryl Cθ-8 alkyl) it shall be
- δδ interpreted as including those limitations given above for "alkyl" and "aryl." Designated numbers of carbon atoms (e.g., Cχ.χo) shall refer independently to the number of carbon atoms in an alkyl or cyclic alkyl moiety or to the alkyl portion of a larger substituent in which alkyl δ appears as its prefix root.
The terms "arylalkyl" and "alkylaryl" include an alkyl portion where alkyl is as defined above and to include an aryl portion where aryl is as defined above. Examples of arylalkyl include, but are not limited to, benzyl, fluorobenzyl, chlorobenzyl, phenylethyl, X0 phenylpropyl, fluorophenyl ethyl, chlorophenylethyl, thienylmethyl, thienylethyl, and thienylpropyl. Examples of alkylaryl include, but are not limited to, toluene, ethylbenzene, propylbenzene, methylpyridine, ethylpyridine, propylpyridine and butylpyridine.
In the compounds of the present invention, two Rl lδ substituents, when on the same carbon atom, can be taken together with the carbon to which they are attached to form a carbonyl group. In the compounds of the present invention, two R^ substituents, when on the same carbon atom, can be taken together with the carbon atom to which they are attached to form a carbonyl group. In 0 such instances, the limitation, that in the resultant compound the carbon atom or atoms to which Bβ is attached is itself attached to no more than one heteroatom, does not apply. Also, in the compounds of the present invention, two R3 substituents, when on the same carbon atom, can be taken together with the carbon atom to which they are δ attached to form a cyclopropyl group.
In the compounds of the present invention, R5 and R^ can be taken together with the carbon atom to which they are attached to form a carbonyl group. In such instances, the limitation, that in the resultant compound the carbon atom to which R^ and R^ is attached is 0 itself attached to no more than one heteroatom, does not apply. The term "halogen" shall include iodine, bromine, chlorine, and fluorine.
The term "oxy" means an oxygen (0) atom. The term "thio" means a sulfur (S) atom. The term "oxo" means "=0". The term δ "carbonyl" means "C=0." The term "substituted" shall be deemed to include multiple degrees of substitution by a named substitutent. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted by one or more of the disclosed or δ claimed substituent moieties, singly or plurally. By independently substituted, it is meant that the (two or more) substituents can be the same or different.
Under standard nonmenclature used throughout this disclosure, the terminal portion of the designated side chain is described 10 first, followed by the adjacent functionality toward the point of attachment. For example, a Cχ-5 alkylcarbonylamino Cχ-6 alkyl substituent is equivalent to
O -C1 -6 alkyl-NH-C-C1-5 alkyl .
In choosing compounds of the present invention, one of lδ ordinary skill in the art will recognize that the various substituents, i.e. W,X, Y, Z, Rl, R2, R3, R4, Rδ, R6? R7, R8, R9, R10, R11( and R12; and the subscripts m, n, p, r, s, t and v are to be chosen in conformity with well- known principles of chemical structure connectivity.
Representative compounds of the present invention typically 0 display submicromolar affinity for the integrin receptors, particularly the αvβ3, αvβδ, and/or αvβ6 receptors. Compounds of this invention are therefore useful for treating mammals suffering from a bone condition caused or mediated by increased bone resorption, who are in need of such therapy. Pharmacologically effective amounts of the compounds, δ including pharamaceutically acceptable salts thereof, are administered to the mammal, to inhibit the activity of mammalian osteoclasts.
The compounds of the present invention are administered in dosages effective to antagonize the αvβ3 receptor where such treatment is needed, as, for example, in the prevention or treatment of 0 osteoporosis.
Further exemplifying the invention is the method wherein the integrin receptor antagonizing effect is an αvβ3 antagonizing effect.
- δ7 - An illustration of the invention is the method wherein the αvβ3 antagonizing effect is selected from inhibition of bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation, viral disease, tumor growth, or metastasis. Preferably, δ the αvβ3 antagonizing effect is the inhibition of bone resorption.
An example of the invention is the method wherein the integrin receptor antagonizing effect is an αvβδ antagonizing effect. More specifically, the αvβδ antagonizing effect is selected from inhibition of: restenosis, angiogenesis, diabetic retinopathy, macular
10 degeneration, inflammation, tumor growth, or metastasis.
Illustrating the invention is the method wherein the integrin receptor antagonizing effect is a dual αvβ3/αvβδ antagonizing effect. More particularly, the dual αvβ3/αvβδ antagonizing effect is selected from inhibition of bone resorption, restenosis, angiogenesis, lδ diabetic retinopathy, macular degeneration, inflammation, viral disease, tumor growth, or metastasis.
Illustrating the invention is the method wherein the integrin receptor antagonizing effect is an αvβ6 antagonizing effect. More particularly, the αvβ6 antagonizing effect is selected from
20 inhibition of angiogenesis, inflammatory response, or wound healing. Illustrating the invention is the method wherein the αvβ3 antagonizing effect is selected from inhibition of bone resorption, inhibition of restenosis, inhibition of angiogenesis, inhibition of diabetic retinopathy, inhibition of macular degeneration, inhibition of δ atherosclerosis, inflammation, viral disease, or inhibition of tumor growth or metastasis. Preferably, the αvβ3 antagonizing effect is the inhibition of bone resorption.
More particularly illustrating the invention is a pharmaceutical composition comprising any of the compounds 0 . described above and a pharmaceutically acceptable carrier. Another example of the invention is a pharmaceutical composition made by combining any of the compounds described above and a pharmaceutically acceptable carrier. Another illustration of the invention is a process for making a pharmaceutical composition comprising combining any of the compounds described above and a pharmaceutically acceptable carrier.
Further illustrating the invention is a method of treating and/or preventing a condition mediated by antagonism of an integrin δ receptor in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds described above. Preferably, the condition is selected from bone resorption, osteoporosis, restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral
10 disease, cancer, tumor growth, and metastasis. More preferably, the condition is selected from osteoporosis and cancer. Most preferably, the condition is osteoporosis.
More specifically exemplifying the invention is a method of eliciting an integrin antagonizing effect in a mammal in need thereof, lδ comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above. Preferably, the integrin antagonizing effect is an αvβ3 antagonizing effect; more specifically, the αvβ3 antagonizing effect is selected from inhibition of bone resorption, 0 inhibition of restenosis, inhibition of atherosclerosis, inhibition of angiogenesis, inhibition of diabetic retinopathy, inhibition of macular degeneration, inhibition of inflammation, inhibition of viral disease, or inhibition of tumor growth or metastasis. Most preferably, the αvβ3 antagonizing effect is inhibition of bone resorption. Alternatively, the δ integrin antagonizing effect is an αvβδ antagonizing effect, an αvβ6 antagonizing effect, or a mixed αvβ3, αvβδ, and αvβ6 antagonizing effect. Examples of αvβδ antagonizing effects are inhibition of restenosis, atherosclerosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation, viral disease, or tumor growth. Examples 0 of dual αvβ6 antagonizing effects are inhibition of angiogenesis, inflammatory response and wound healing.
Additional examples of the invention are methods of inhibiting bone resorption and of treating and/or preventing osteoporosis in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
Additional illustrations of the invention are methods of treating hypercalcemia of malignancy, osteopenia due to bone δ metastases, periodontal disease, hyperparathyroidism, periarticular erosions in rheumatoid arthritis, Paget's disease, immobilization- induced osteopenia, and glucocorticoid treatment in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical 10 compositions described above.
More particularly exemplifying the invention is the use of any of the compounds described above in the preparation of a medicament for -the treatment and/or prevention of osteoporosis in a mammal in need thereof. Still further exemplifying the invention is the lδ use of any of the compounds described above in the preparation of a medicament for the treatment and/or prevention of bone resorption, tumor growth, cancer, restenosis, atherosclerosis, diabetic retinopathy, macular degeneration, inflammation, viral disease, and/or angiogenesis. 20 Also exemplifying the invention are compositions further comprising an active ingredient selected from the group consisting of a.) an organic bisphosphonate or a pharmaceutically acceptable salt or ester thereof, b.) an estrogen receptor modulator, δ c.) a cytotoxic/antiproliferative agent, d.) a matrix metalloproteinase inhibitor, e.) an inhibitor of epidermal-derived, fibroblast-derived, or platelet-derived growth factors, f.) an inhibitor of VEGF, 0 g.) an inhibitor of Flk-1/KDR, Flt-1, Tck/Tie-2, or Tie-1, h.) a cathepsin K inhibitor, and i.) a prenylation inhibitor, such as a farnesyl transferase inhibitor or a geranylgeranyl transferase inhibitor or a dual farnesyl/geranylgeranyl transferase inhibitor; δ and mixtures thereof. (See, B. Millauer et al., "Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types in Vivo", Cancer Research. δ6, 161δ-1620 (1996), which is incorporated by reference herein in its entirety), δ Preferably, the active ingredient is selected from the group consisting of: a.) an organic bisphosphonate or a pharmaceutically acceptable salt or ester thereof, b.) an estrogen receptor modulator, and 10 c.) a cathepsin K inhibitor; and mixtures thereof.
Nonlimiting examples of such bisphosphonates include alendronate, etidronate, pamidronate, risedronate, ibandronate, and pharmaceutically acceptable salts and esters thereof. A particularly preferred bisphosphonate is alendronate, especially alendronate lδ mono sodium trihydrate.
Nonlimiting examples of estrogen receptor modulators include estrogen, progesterin, estradiol, droloxifene, raloxifene, and tamoxifene.
Nonlimiting examples of cytotoxic/antiproliferative agents 20 are taxol, vincristine, vinblastine, and doxorubicin.
Cathepsin K, formerly known as cathepsin 02, is a cysteine protease and is described in PCT International Application Publication No. WO 96/13δ23, published May 9, 1996; U.S. Patent No. 5,501,969, issued March 3, 1996; and U.S. Patent No. 5,736,3δ7, issued April 7, 1998, δ all of which are incorporated by reference herein in their entirety. Cysteine proteases, specifically cathepsins, are linked to a number of disease conditions, such as tumor metastasis, inflammation, arthritis, and bone remodeling. At acidic pH's, cathepsins can degrade type-I collagen. Cathepsin protease inhibitors can inhibit osteoclastic bone 0 resorption by inhibiting the degradation of collagen fibers and are thus useful in the treatment of bone resorption diseases, such as osteoporosis. The present invention is also directed to combinations of the compounds of the present invention with one or more agents useful in the prevention or treatment of osteoporosis. For example, the δ compounds of the instant invention may be effectively administered in combination with effective amounts of other agents such as an organic bisphosphonate, an estrogen receptor modulator, or a cathepsin K inhibitor.
Additional illustrations of the invention are methods of δ treating tumor growth in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound described above and one or more agents known to be cytotoxic/antiproliferative. Also, the compounds of the present invention can be administered in combination with radiation therapy for treating
10 tumor growth and metastasis.
In addition, the integrin αvβ3 antagonist compounds of the present invention may be effectively administered in combination with a growth hormone secretagogue in the therapeutic or prophylactic treatment of disorders in calcium or phosphate metabolism and lδ associated diseases. These diseases include conditions which can benefit from a reduction in bone resorption. A reduction in bone resorption should improve the balance between resorption and formation, reduce bone loss or result in bone augmentation. A reduction in bone resorption can alleviate the pain associated with osteolytic
20 lesions and reduce the incidence and/or growth of those lesions. These diseases include: osteoporosis (including estrogen deficiency, immobilization, glucocorticoid induced and senile), osteodystrophy, Paget's disease, myositis ossificans, Bechterew's disease, malignant hypercalcemia, metastatic bone disease, periodontal disease, δ cholelithiasis, nephrolithiasis, urolithiasis, urinary calculus, hardening of the arteries (sclerosis), arthritis, bursitis, neuritis and tetany. Increased bone resorption can be accompanied by pathologically high calcium and phosphate concentrations in the plasma, which would be alleviated by this treatment. Similarly, the present invention would be 0 useful in increasing bone mass in patients with growth hormone deficiency. Thus, preferred combinations are simultaneous or alternating treatments of an αvβ3 receptor antagonist of the present invention and a growth hormone secretagogue, optionally including a third component comprising an organic bisphosphonate, preferably δ alendronate monosodium trihydrate. In accordance with the method of the present invention, the individual components of the combination can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms. The instant δ invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment, and the term "administering" is to be interpreted accordingly. It will be understood that the scope of combinations of the compounds of this invention with other agents useful for treating integrin-mediated conditions includes in principle
10 any combination with any pharmaceutical composition useful for treating osteoporosis.
As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or lδ indirectly, from combination of the specified ingredients in the specified amounts.
The compounds of the present invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills,
20 powders, granules, elixirs, tinctures, suspensions, syrups and emulsions. Likewise, they may also be administered in intravenous (bolus or infusion), intraperitoneal, topical (e.g., ocular eyedrop), subcutaneous, intramuscular or transdermal (e.g., patch) form, all using forms well known to those of ordinary skill in the pharmaceutical δ arts. An effective but non-toxic amount of the compound desired can be employed as an αvβ3 antagonist.
The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the 0 severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician, veterinarian or clinician can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the δ condition. Oral dosages of the present invention, when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg day) to about 100 mg/kg/day, preferably 0.01 to 10 mg/kg/day, and most preferably 0.1 to δ.O mg/kg/day. For oral δ administration, the compositions are preferably provided in the form of tablets containing 0.01, O.Oδ, 0.1, O.δ, 1.0, 2.δ, δ.O, 10.0, lδ.0, 2δ.O, δθ.0, 100 and δOO milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. A medicament typically contains from about 0.01 mg to about δOO mg of the active
10 ingredient, preferably, from about 1 mg to about 100 mg of active ingredient. Intravenously, the most preferred doses will range from about 0.1 to about 10 mg/kg/minute during a constant rate infusion. Advantageously; compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be lδ administered in divided doses of two, three or four times daily.
Furthermore, preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art. To be 0 administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
In the methods of the present invention, the compounds herein described in detail can form the active ingredient, and are δ typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as 'carrier' materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices. 0 For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; δ for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable δ binders include starch, gelatin, natural sugars such as glucose or beta- lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium
10 benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small lδ unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the 0 compound molecules are coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyΥinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxy- ethylaspartamide-phenol, or polyethyleneoxide-polylysine substituted δ with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, 0 polyacetals, polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
In the schemes and examples below, various reagent symbols and abbreviations have the following meanings: AcOH: Acetic acid. δ BH3»DMS: Borane'dimethylsulfide. BOC(Boc): t-Butyloxycarbonyl. BOP: Benzotriazol-l-yloxytris(dimethylamino)- phosphonium hexafluorophosphate.
CBZ(Cbz): Carbobenzyloxy or benzyloxycarbonyl. δ CDI: Carbonyldiimidazole. CH2C12: Methylene chloride.
CH3CN: Acetonitrile CHCI3: Chloroform.
DEAD: Diethyl azodicarboxylate.
10 DIAD: Diisopropyl azodicarboxylate.
DIBAH or DIBAL-H: Diisobutylaluminum hydride. DIPEA: Diisopropylethylamine. DMAP: 4-Dimethylaminopyridine. lδ DME: 1,2-Dimethoxyethane. DMF: Dimethylformamide. DMSO: Dimethylsulfoxide. DPFN: 3,δ-Dimethyl-l-pyrazolylformamidine nitrate. EDC: l-(3-Dimethylaminopropyl)-3-ethylcarbodiimide #HC1
20 EtOAc: Ethyl acetate. EtOH: Ethanol. HOAc: Acetic acid. HO AT: l-Hydroxy-7-azabenzotriazole HOBT: 1-Hydroxyb enzotriazole . δ IBCF: Isobutylchloroformate LDA: Lithium diisopropylamide. MeOH: Methanol. MMNG l,l-methyl-3-nitro-l-nitrosoguanidine NEt3: Triethylamine. 0 NMM: N-methylmorpholine.
PCA'HCl: Pyrazole carboxamidine hydrochloride.
Pd/C: Palladium on activated carbon catalyst.
Ph: Phenyl. pTSA p-Toluenesulfonic acid. δ TEA: Triethylamine. TFA: Trifluoroacetic acid.
THF: Tetrahydrofuran.
TLC: Thin Layer Chromatography.
TMEDA: N,N,N',N'-Tetramethylethylenediamine. δ TMS: Trimethylsilyl.
The novel compounds of the present invention can be prepared according to the procedure of the following schemes and examples, using appropriate materials and are further exemplified by the following specific examples. The compounds illustrated in the
10 examples are not, however, to be construed as forming the only genus that is considered as the invention. The following examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative lδ procedures can be used to prepare these compounds. All temperatures are degrees Celsius unless otherwise noted.
The following Schemes and Examples describe procedures for making representative compounds of the present invention. Moreover, by utilizing the procedures described in detail in PCT
20 International Application Publication Nos. WO9δ/32710, published 7 December 199δ, and W09δ/17397, published 29 June 199δ, both of which are incorporated by reference herein in their entirety, in conjunction with the disclosure contained herein, one of ordinary skill in the art can readily prepare additional compounds of the present invention claimed δ herein. Additionally, for a general review describing the synthesis of β-alanines which can be utilized as the C-terminus of the compounds of the present invention, see Cole, D.C., Recent Stereoselective Synthetic Approaces to β- Amino Acids, Tetrahedron, 1994, 50, 9δl7-9δ82; Juaristi, E, et al., Enantioselective Synthesis of β-Amino Acids, Aldrichimica 0 Ada, 1994, 27, 3. In particular, synthesis of the 3-methyl-β-alanine is taught in Duggan, M.F. et al, J. Med. Chem., 199δ, 38, 3332-3341; the 3- ethynyl-β-alanine is taught in Zablocki, J.A., et al., J. Med. Chem., 199δ, 38, 2378-2394; the 3-(pyridin-3-yl)-β-alanine is taught in Rico, J.G. et al., J. Org. Chem., 1993, 58, 7948-79δl; and the 2-amino- and 2-tosylamino-β- δ alanines are taught in Xue, C-B, et al., Biorg. Med. Chem. Letts., 1996, 6, 339-344. The references described in this paragraph are all also incorporated by reference herein in their entirety.
SCHEME 1
1-1 1-2
P2.
1 -4 Ethyl 3-fluorocinnamate (1-2)
To a solution of 3-fluorobenzaldehyde 1 (18.16 g, 146 mmol) in dichloromethane (δOO mL) was added ethyl (triphenylphosphoranylidene)acetate (61.2 g; 176 mmol), and the δ resulting solution was stirred at room temperature for 18 hr. After evaporation of the solvent, the residue was swirled with ether/hexane and filtered. The filtrate was concentrated and then purified on a plug of silica gel eluting with hexane/EtOAc 9:1. Removal of the solvent afforded the title compound 1^2 as an oil (~9δ% trans) which was used 10 without further purification in the next step.
IH NMR(CDCl3) δ 1.36 (3H, t), 4.28 (2H, q), 6.43 (IH, d), 7.08 (IH, m), 7.2-
7.4 (3H, m), 7.64 (IH, d).
N-Benzyl-(R)-α-methylbenzyl-3(S)-fluorophenyl-β-alanine ethyl ester (1-3) lδ To a solution of N-benzyl-(R)-α-methylbenzylamine (33.4 g, lδ8 mmol) in THF (4δ0 mL) at 0°C was added n-butyllithium (1.6M in hexanes; 99 mL, lδ8 mmol). The dark violet solution was stirred at 0°C for 30 minutes, cooled to -78°C, and the ester 1^ (29.2 g, lδO mmol) in THF (100 mL) was added over δ minutes. The resulting solution was 20 stirred at -78°C for 1 hr., then warmed to room temperature. After 2 hrs, the mixture was poured into water and extracted with EtOAc, washed with water then brine, dried and concentrated in vacuo to give an oil. Column chromatography (silica gel; hexane/EtOAc 1:1 then pure EtOAc) gave the title compound J 3. δ IH NMR (CDC13): δ 1.06 (3H, t), 1.28 (3H, d), 2.δ2 (IH, dd), 2.62 (IH, dd),
3.66 (IH, d), 3.72 (IH, d), 3.9δ (2H, q), 4.44 (IH, dd), 6.9δ (IH, m), 7.1-7.δ (13H, m).
3(S)-Fluorophenyl-β-alanine ethyl ester hvdrochloride (1-4) 0 A solution of the N-benzyl-(R)-α-methylbenzylamine J 3
(28.2 g, 69.6 mmol) in ethanol (300 mL), acetic acid (30 mL) and water (3 mL) was degassed with argon for 30 minutes. Pd(OH)2 on carbon (20% dry weight; 2.6 g) was added and the mixture then stirred under a hydrogen atmosphere (balloon) for 2 hours. The mixture was filtered δ through celite and the solvent removed in vacuo to give an oil. This oil was dissolved in 200 mL ether and to this solution was added 60 mL IN HCl in ether to yield a precipitate. Filtration and washing the solid with ether/hexane then gave the title compound 1 as a white solid. IH NMR(CD3θD) δ 1.21 (3H, t), 3.0-3.2 (2H, m), 4.16 (2H, q), 4.76 (IH, t),
7.2-7.3δ (3H, m), 7.δ (IH, m).
SCHEME 2
2-2
a) LiN(TMS)2, THF b) allyl bromide
SCHEME 2 (CONTINUED)
SCHEME 2 (CONTINUED)
10% Pd/C, ethanol, H2
1 N NaOH, ethanol
δ-(2-methyl-π.31dioxolan-2-yl)-pentanoic acid (2-2)
A mixture of ketone 2Λ (18 g, lOδ mmol), ethylene glycol (3.2 ml, 110 mmol), p-TSA (δO mg, 0.2713 mmol) and toluene (300 mL) was heated to reflux with azeotropic removal of water for 24 hours. The δ reaction mixture was diluted with EtOAc and then washed with sat. NaHC03, brine, dried (MgSθ4), and concentrated. The residue was dissolved in EtOH (200 ml) and then treated with IN NaOH (120 ml, 120 mmol). After 2 h, the reaction was poured into 600 mL 2:1 Et O/10% KHSO4. The organic portion was separated, washed with brine, dried 10 (MgS04) and concentrated to give acid 2^2 as a colorless oil. iH NMR (300 MHz, CDCI3) δ 3.93 (m, 4H), 2.36 (m, 2H), 1.63 (m, 4H), 1.46 (m, 2H), 1.31 (s, 3H).
3-rδ-(2-methyl-ri.31dioxolan-2-yl)-pentanoyll-oxazolidin-2-one (2-3) lδ To a stirred solution of (16.0 g, 8δ.δ mmol), NEt3 (13.1 ml,
94.1 mmol) and THF (400 mL) at -78°C was added pivaloyi chloride (11.6 ml, 94.1 mmol). The mixture was warmed to 0°C for 1.0 h and then recooled to -78°C. To a stirred solution of 2-oxazolidinone (9.3g, 106.9 mmol) and THF (200 ml) at -78°C was added nBuLi (43.0 ml, 106.9 mmol, 0 2.δM in hexanes) dropwise over 10 minutes. After 20 minutes, the lithium reagent was transferred to the mixed anhydride via cannula. After 10 minutes, the reaction was warmed to 0°C for l.Oh. The mixture was diluted with ethyl acetate, washed with sat. NaHCθ3, brine, and dried over MgSθ4. Following evaporative removal of the solvent, the δ residue was chromatographed (silica gel, 40% - δ0% EtOAc/hexanes) to give 2^5 as a colorless foam. TLC Rf = 0.19 (silica, 40% EtOAc/hexanes) iH NMR (300 MHz, CDCI3) δ 4.41 (t, J=8.1 Hz, 2H), 4.02 (t, J=8.1 Hz, 2H), 3.93 (m, 4H ), 3.93 (t, J=7.3 Hz, 2H), 1.66 (m, 4H), 1.48 (m, 2H), 1.31 (s, 0 3H).
3-(2-[3-(2-methyl-[l,3]dioxolan-2-yl)-propyl]-pent-4-enoyl)-oxazolidin-
2-one (2-4)
To a stirred solution of (6.0 g, 23.3 mmol) and THF (12δ δ mL) at -78°C was added LiN(TMS)2 (18.9 mL, 37.8 mmol, 1.0 M in THF) dropwise over 10 minutes. After 20 minutes, allyl bromide was added. After 10 minutes, the reaction was warmed to 0°C. After 4.0 h, the reaction was diluted with EtOAc, washed with sat. NaHCθ3, brine, dried (MgSθ4) and concentrated. Flash chromatography (silica, δ0%
EtOAc/ hexanes) gave 2A as an yellow oil.
TLC Rf = 0.26 (silica, δ0% EtOAc/hexanes) iH NMR (300 MHz, CDCI3) δ δ.76 (m, IH), δ.02 (m, IH), 4.40 (t, J=8.3 Hz,
2H), 4.02 (m, 2H), 3.99 (m, 4H), 2.39 (m, IH), 2.27 (m, IH), 1.72 (m, IH),
1.62 (m, 2H) 1.39 - 1.53 (m, 3H), 1.30 (s, 3H).
10
6-(2-methyl-[l,3]dioxolan-2-yl)-3-(2-oxo-oxazolidine-3-carbonyl)- hexanal (2-δ)
To a stirred solution of 2A (4.0 g, 13. δ mmol), sudan III (10 mg) and CH2C1 (360 mL) at -78°C under argon was bubbled ozone until lδ red solution changed to yellow-orange. The solution was purged with argon for 30 minutes. PPI13 (δ.28g, 20.3 mmol) was added followed by the removal of the cooling bath. After 3.0 h, the reaction was concentrated. Flash chromatography (silica, 20% - δ0% EtOAc/ hexanes) gave δ as a yellow oil. 0 TLC Rf = O.lδ (silica, δ0% EtOAc/hexanes) iH NMR (300 MHz, CDCI3) δ 9.74 (s, IH), 4.43 (m, 2H), 4.1δ (m, IH), 4.03 (m, 2H), 3.91 (m, 4H), 3.04 (m, IH), 2.67 (dd, J=3.9 Hz, 18.6 Hz, lH),1.6δ (m, 3H), 1.45 (m, 3H), 1.29 (s, 3H).
5 3(S)-(3-Muorophenyl)-3-(3-[3-(2-methyl-[l,3]moxolan-2-yl)-propyl]-
2-oxo-Oyrrolidin-l-yl)-propionic acid ethyl ester (2-6)
A mixture of (302 mg, 1.11 mmol), (300 mg, 1.21 mmol), Na(OAc)3BH (321 mg, 1.52 mmol) and NEt3 (0.28 mL, 2.02 mmol) in DCE (10 mL) was stirred for 48 h. The mixture was diluted with ethyl 0 acetate, washed with sat. NaHCθ3, brine, and dried over MgSθ4.
Following evaporative removal of the solvent, the residue was chromatographed (silica gel, δ0:3δ:14:l hexanes/ chloroform ethyl acetate/ MeOH) to give 2^5 as a white solid. TLC Rf = 0.41 (silica, 70:2δ:δ chloroform ethyl acetate/ MeOH) iH NMR (300 MHz, CDCI3) δ 7.30 (m, IH), 7.07 (m, IH), 6.98 (m 3H), δ.68 (m, IH), 4.12 (m, 2H), 3.92 (m, 4H), 3.30 (m, IH), 2.97 (m, 3H), 2.38 (m, IH), 2.14 (m, IH), 1.86 (m, IH), 1.64 (m, 4H), 1.42 (m, 2H), 1.30 (2s, 3H), 1.22 (t, J=7.3Hz, 3H). δ
3(S)-(3- uorophenyl)-3-[2-oxo-3-(4-oxo-pentyl)-pyrrolidin^ ropionic acid ethyl ester (2-7)
A solution of (4δ0 mg, 1.10 mmol), p-TSA (δO mg) and acetone (δO mL) was heated at reflux for 4 hr. The cooled reaction 10 mixture was diluted with EtOAc and then washed with sat. NaHCθ3 and brine, dried (MgSθ4), and concentrated to afford 2 7 as a yellow solid. iH NMR (300 MHz, CDCI3) δ 7.30 (m, IH), 7.06 (m, IH), 6.98 (m, 2H), δ.67
(m, IH), 4.12 (m, 2H), 3.23 (m, IH), 2.97 (m, 2H), 2.33 - 2.49 (m, 3H), 2.14 lδ (2s, 3H), 1.54 -1.86 (m, 5H), 1.33 (m, IH), 1.22 (t, J=7.1Hz, 3H).
3(S)-(3-Fluorophenyl)-3-[3-(3-[l,8]naphthyridin-2-yl-propyl)-2-oxo- pyrrolidin-1-yll-propionic acid ethyl ester (2-8)
A mixture of 22 (430 mg, 1.18 mmol), 2-amino-3-
20 formylpyridine (144 mg, 1.18 mmol; for prep., see JOC 1983,48, 3401) and proline (136 mg, 1.18 mmol) in absolute ethanol (20 mL) was heated at reflux for 12 h. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, δ0% ethyl acetate/ chloroform - 70:2δ:δ chloroform/ethyl acetate/MeOH) to give 2^8 as a yellow solid. δ TLC Rf = 0.30 (70:2δ:δ chloroform ethyl acetate/MeOH). iH NMR (300 MHz, CDCI3) δ 9.08 (m, IH), 8.16 (dd, J=2.0 Hz, 8.0 Hz IH),
8.11 (d, J=8.3 Hz, IH), 7.42 (m, 2H), 7.27 (m, IH), 7.06 (m, IH), 6.97 (m, 2H), δ.66 (m, 1H),4.11 (m, 2H), 3.29 (m, IH), 2.9δ -3.07 (m, 5H), 2.46 (m, IH), 2.18 (m, IH), 1.98 (m, 2H), 1.71 (m, 2H), 1.46 (m, IH), 1.19 (m, 3H). 0
3(S)-(3-Fluorophenyl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro-[l,8]naphthy- ridin-2-yl)-propyll-pyrrolidin-l-yl)-propionic acid ethyl ester (2-9)
A mixture of (340 mg, 0.7991 mmol) and 10% Pd/carbon (170 mg) in EtOH (10 mL) was stirred under a balloon of hydrogen for 4 h. Following filtration and evaporative removal of the solvent, the residue was chromatographed (silica gel, 70:2δ:δ chloroform ethyl acetate/MeOH) to give 2S. as a yellow oil. TLC Rf = 0.16 (70:2δ:δ chloroform/ethyl acetate/MeOH). δ iH NMR (300 MHz, CDCI3) δ 7.29 (m, IH,), 6.98 (m, 4H), 6.33 (m, IH),
5.66 (m, IH), 4.76 (b s, IH), 4.10 (m, 2H), 3.38 (m, 1H),3.28 (m, IH), 2.9δ (m, 3H),2.68 (t, J=6.3 Hz, 2H), 2.δδ (m, 2H), 2.40 (m, IH), 2.13 (m, IH) 1.92 (m, 4H), 1.61 (m, 3H), 1.37 (m, IH), 1.23 (m, 3H).
10 3(S)-(3-Fluorophenyl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro-[l,8]naphthy- ridin-2-yl)-propyll-pyrrolidin-l-yl)-propionic acid (2-10 and 2-11)
To a solution of (300 mg, 0.6614 mmol) in EtOH (3 mL) was added IN NaOH (0.72δ ml, 0.72δ mmol). After stirring for 1 h, the solvents were evaporated and the residue was chromatographed (silica lδ gel, 2δ:10:l:l - 15:10:1:1 ethyl acetate/EtOH/water/NE jOH to give 2-10 and 2-11 as pure diastereomeric white solids. TLC Rf = 0.31 (2-10) (15:10:1:1 ethyl acetate EtOH/water/NH40H). TLC Rf = 0.24 (2-11) (15:10:1:1 ethyl acetate/EtOH/water/NH40H). iH NMR (300 MHz, CD3OD, O) δ 7.44 (d, J=7.3 Hz, IH), 7.37 (m, IH), 20 7.14 (m, IH), 7.06 (m, 2H,), 6.50 (d, J=7.3 Hz, IH,), δ.78 (m, IH), 3.δδ (m, IH), 3.46 (m, 2H), 3.11 (m, IH), 2.61 -2.97 (m, 7H),2.12 (m, IH) 1.74 -1.95 (m, 7H). iH NMR (300 MHz, CD3OD, Ml) δ 7.34 (m, 2H), 7.15 (m, 2H), 7.03 (m,
IH), 6.47 (d, J=7.3 Hz, IH,), 5.δ0 (m, IH), 3.46 (m, 3H), 3.00 (m, 1H),2.79 ' δ (m, 3H), 2.62 (m, 2H),2.δ4 (m, IH), 2.23 (m, IH), 1.93 (m, 2H), 1.69 (m, 5H), 1.44 (m, IH).
SCHEME 3
PPA, PhMe
l-Bromo-3-(2.2-diethoxy-ethoxy)-benzene (3-2)
To a suspension of NaH (2.77 g, llδ.6 mmol) in DMF (100 mL) at 0°C was added a solution of 3-bromophenol 3-1 in DMF (40 mL) over 40 min. After the addition was complete, the solution was stirred δ for an additional 30 min. The solution was then treated with neat bromoacetaldehyde diethyl acetal (17.36 g, llδ.6 mmol). The solution was heated at 100°C for 8 h, cooled to room temperature, and extracted with Et20 (3 x 200 mL). The combined organic extracts were washed with 10% aq. NaOH (100 mL) and brine (100 mL), dried over MgSθ4, 10 filtered and concentrated to give 3^ as a yellow oil. TLC Rf = 0.4 (10% ethyl acetate/hexanes). iH NMR (300 MHz, CHCI3) δ 7.19-7.0δ (m, 3H), 6.8δ (d, IH), 4.81 (t, IH,
J=6.8 Hz), 3.99 (d, 2H, J=6.8 Hz), 3.71 (m, 4H), 1.22 (t, 6H, J=7.1 Hz)
lδ 6-Bromo-benzofuran (3-3)
To a solution of the acetal 3-2 in toluene (200 mL) was added polyphosphoric acid (20 g). The biphasic mixture was heated to 100°C and stirred at this temperature for 4 h. The mixture was cooled to room temperature, poured onto ice, and extracted with Et20 (2 x 200 mL). The 20 combined organic extracts were washed with saturated aq. NaHCθ3 and brine. The solution was dried over MgSθ4, filtered, and concentrated.
The residue was purified by flash chromatography (100% hexanes) to give the product 3^3 as a yellow oil.
TLC Rf = 0.3 (100% hexanes). δ iH NMR (300 MHz, CHCI3) δ 7.68 (s, IH), 7.60 (d, IH, J=2.1 Hz), 7.46 (d,
IH, J=8.4 Hz), 7.36 (dd, IH, J=8.1, l.δ Hz), 6.7δ (dd, IH, J=7.1, 0.9 Hz).
3-(Benzofuran-6-yl)-acrylic acid ethyl ester (3-4)
A mixture of the 6-bromobenzofuran 3^ (1.74 g, 8.79 mmol), 0 ethyl acrylate (1.09 g, 10.98 mmol), Pd(OAc)2 (0.099 g, 0.44 mmol), tri-o- tolylphosphine (0.268 g, 0.880 mmol), and sodium acetate (3.60 g, 43.9 mmol) in DMF (10 mL) was heated to 100°C in a sealed tube for 4 h. The mixture was cooled to room temperature, diluted with water, and extracted with Et 0 (2 x 40 mL). The combined organic extracts were δ washed with brine (30 mL), dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography (10% ethyl acetate/hexanes) to give the ester 3 as an off-white solid. TLC Rf = 0.3 (10% ethyl acetate/hexanes). iH NMR (300 MHz, CHCI3) δ 7.78 (d, IH, J=lδ.9 Hz), 7.68 (d, IH, J=2.4 δ Hz), 7.66 (s, IH), 7.δ9 (d, IH, J=8.4 Hz), 7.43 (dd, IH, J=9.0, 1.5 Hz), 6.78 (m, IH), 6.47 (d, IH, J=15.9 Hz), 4.27 (q, 2H, J=7.2 Hz), 1.34 (t, 3H, J=7.2 Hz).
3(S)-(Benzofuran-6-yl)-3-[benzyl-(l(i?)-phenyl-ethyl)-amino]-propionic 0 acid ethyl ester (3-5)
A solution of N-benzyl-α-(R)-methylbenzylamine (1.32 g, 6.30 mmol) in THF (25 mL) at 0°C was treated with n-BuLi (2.52 mL of a 2.5 M soln in hexanes). The resulting solution was stirred at 0°C for 30 min and then cooled to -78°C. A solution of acrylate <P (0.681 g, 3.15 mmol) in 5 THF (5 mL) was added. After stirring for lδ min at -78°C, satd. aq.
NH4CI soln (δ mL) was added and the cold bath removed. The mixture was warmed to room temperature, and extracted with Et20 (2 x 40 mL).
The combined organic extracts were washed with brine (30 mL), dried over MgSθ4, filtered, and concentrated. The residue was purified by 0 flash chromatography (10% ethyl acetate/hexanes) to give the β- aminoester & as a yellow oil. TLC Rf = 0.8 (10% ethanol/dichloromethane). iH NMR (300 MHz, CHCI3) δ 7.δ8 (m, 3H), 7.41 (m, 2H), 7.22 (m, 9H), 7.59
(s, IH), 4.δ8 (m, IH), 4.0δ (m, IH), 3.91 (q, 2H, J=7.1 Hz), 3.72 (m, 2H), δ 2.62 (m, 2H), 1.21 (d, 3H, J=7.2 Hz), 1.03 (t, 3H, J=7.1 Hz).
3(S)-Amino-3-(2,3-dihydro-benzofuran-6-yl)-propionic acid ethyl ester
(3-6)
A mixture of the dibenzylamine 3J5 (1.19 g, 2.78 mmol) in 0 EtOH/H20/AcOH (26 mL/3 mL/1.0 mL) was degassed with argon and treated with Pd(OH) (1.19 g). The mixture was placed under 1 atm of H2. After stirring for 18 h, the mixture was diluted with EtOAc, and filtered through celite. The filtrate was concentrated and the residue purified by flash chromatography (10% ethyl acetate/dichloromethane) to δ give the ester 3^5 as a white solid. TLC Rf = 0.2δ (10% ethanol/dichloromethane). iH NMR (300 MHz, CD3OD) as the trifluoroacetate salt: δ 7.2δ (d, IH,
J=8.1 Hz), 6.88 (m, IH), 7.66 (s, IH), 6.82 (s, IH), 4.δ8 (m, 3H), 4.12 (m, 2H), 3.30 (m, IH), 3.19 (m, 2H), 2.98 (m, 2H), 1.11 (t, 3H, J=7.2 Hz),
SCHEME 4
SCHEME 4 (CONTINUED)
1N NaOH, ethanol
3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(3-[3-(2-methyl-[l,3]dioxolan-
2-yl)-propyl1-2-oxo-pyrrolidin-l-yl)-propionic acid ethyl ester (4-1)
A mixture of δ (440 mg, 1.6 mmol), 3 (400 mg, l.δ mmol), Na(OAc)3BH (469 mg, 2.2δ mmol) and NEt3 (0.41 mL, 3.0 mmol) in δ dichloroethane (10 mL) was stirred for 48 h. The mixture was diluted with ethyl acetate, washed with sat. NaHCθ3, brine, and dried over MgS04. Followmg evaporative removal of the solvent, the residue was chromatographed (silica gel, δ0:3δ:14:l hexanes/ chloroform/ ethyl acetate/ MeOH) to give as a white solid.
10 TLC Rf = 0.4δ (silica, 70:2δ:δ chloroform ethyl acetate/ MeOH) iH NMR (300 MHz, CDCI3) δ 7.1δ (m, IH), 6.78 (m, IH), 6.70 (m IH), δ.63 (m, IH), 4.δ8 (m, 2H), 4.12 (q, J=7 Hz, 2H), 3.92 (m, 4H), 3.40-2.80 (m, 6H), 2.38 (m, IH), 2.14 (m, IH), 1.86 (m, IH), 1.64 (m, 4H), 1.42 (m, 2H), 1.30 (m, 3H), 1.22 (t, J=7 Hz, 3H). lδ
3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-[2-oxo-3-(4-oxo-pentyD- pyrrolidin-1-yll-propionic acid ethyl ester (4-2)
A solution of 4 (600 mg, 1.4 mmol), p-TSA (20 mg) and acetone (δO mL) was heated at reflux for 4 hr. The cooled reaction
20 mixture was diluted with EtOAc and then washed with sat. NaHCθ3 and brine, dried (MgSθ4), and concentrated to afford 4^2 as a colorless oil.
IH NMR (300 MHz, CDCI3) δ 7.1δ (m, IH), 6.78 (m, IH), 6.70 (m IH), δ.63
(m, IH), 4.δ8 (m, 2H), 4.12 (q, J=7 Hz, 2H), 3.3δ-2.90 (m, 6H), 2.49-2.30 (m, δ 3H), 2.13 (2s, 3H), 1.90-l.δO (m, δH), 1.33 (m, IH), 1.22 (t, J=7 Hz, 3H).
3(S)- (2,3-Dihydro-benzofuran-6-yl)-3-[3-(3-[l,8]naphthyridin-2-yl- propyl)-2-oxo-pyrrolidin-l-v ~l-propionie acid ethyl ester (4-3)
A mixture of 2 (δ40 mg, 1.4 mmol), 2-amino-3- 0 formylpyridine (170 mg, 1.4 mmol; for prep, see JOC 1983,48, 3401) and proline (161 mg, 1.4 mmol) in absolute ethanol (20 mL) was heated at reflux for 12 h. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, δ0% ethyl acetate/ chloroform 70:2δ:δ chloroform/ethyl acetate/MeOH) to give 4^3 as a yellow oil. δ TLC Rf = 0.21 (70:2δ:δ chloroform/ethyl acetate/MeOH). iH NMR (300 MHz, CDCI3) δ 9.08 (m, IH), 8.16 (dd, J=2.0 Hz, 8.0 Hz IH), 8.11 (d, J=8.3 Hz, IH), 7.42 (m, 2H), 7.10 (m, IH), 6.78 (m, IH), 6.70 (m, IH), δ.63 (m, lH),4.δ7 (m, 2H), 4.11 (m 2H), 3.29 (m, IH), 3.30-2.80 (m, 9H), 2.40 (m, IH), 2.18 (m, IH), 1.98 (m, 2H), 1.70-1.50 (m, 2H), 1.46 (m, 5 IH), 1.19 (m, 3H).
3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro-
[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid ethyl ester (4-4)
10 A mixture of (460 mg, 1.0 mmol) and 10% Pd/carbon (300 mg) in EtOH (20 mL) was stirred under a balloon of hydrogen for 3 h. Following filtration and evaporative removal of the solvent, the residue was chromatographed (silica gel, 70:2δ:δ chloroform/ethyl acetate/MeOH) to give 44 as a yellow oil. lδ TLC Rf = 0. lδ (70:2δ:δ chloroform/ethyl acetate/MeOH). iH NMR (300 MHz, CDCI3) δ 7.18 (m, IH,), 7.07 (m, 2H), 6.80 (m, IH),
6.70 (m, IH), 6.37 (m, IH), δ.64 (m, IH), 4.76 (bs, IH), 4.δδ (m, 2H), 4.10 (q, J=7 Hz, 2H), 3.40 (m, 1H),3.28 (m, 2H), 3.28 (m, IH), 3.19 (m, 2H), 3.00 (m, IH), 2.9δ (m, 2H),2.69 (m 2H), 2.δδ (m, 2H), 2.37 (m, IH), 2.13 (m, IH) 1.92 20 (m,3H), 1.75-1.30 (m, 4H), 1.23 (m, 3H).
3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid (4-δ and
4-6) δ To a solution of 44 (380 mg, 0.79 mmol) in EtOH (2 mL) was added IN NaOH (0.93 ml, 0.93 mmol). After stirring for 1 h, the solvents were evaporated and the residue was chromatographed (silica gel, 2δ:10:l:l - lδ:10:l:l ethyl acetate/EtOH/water/NH40H) to give Φδ and
4-6 as pure diastereomeric white solids. 0 TLC Rf = 0.37 (isomer A) (15:10:1:1 ethyl acetate/EtOH/water/NELiOH). TLC Rf = 0.28 (isomer B) (15:10:1:1 ethyl acetate/EtOH/water/NH40H). iH NMR (300 MHz, CD3OD, Isomer A) δ 7.44 (d, J=7 Hz, IH), 7.16 (d, J=7 Hz, IH), 6.80 (d, J=7 Hz, IH,), 6.70 (s, IH), 6.48 (d, J=7 Hz, IH,), δ.46 (m, IH), 4.δ0 (m, 2H), 3.60-2.δ0 (m, 13H), IH), 2.15 -1.70 (m, 8H), iH NMR (300 MHz, CD3OD, Isomer B) δ 7.40 (d, J=7 Hz, IH), 7.13 (d, J=7 Hz, IH), 6.80 (d, J=7 Hz, IH,), 6.68 (s, IH), 6.δ0 (d, J=7 Hz, IH,), δ.72 (m, IH), 4.δ3 (m, 2H), 3.44 (m, 3H), 3.15 (m, 4H), 2.97 (m, IH), 2.70-2.40(m, 6H), 2.20 (m, IH), 2.00-1.40 (m, 6H).
SCHEME δ
3-Quinolin-3-yl-propionic acid (δ-2).
A solution containing quinoline-3-carboxaldehyde δ (δ g,
31.8 mmol), malonic acid (3.6 g, 3δ.O mmol), and ammonium acetate (δ.O g, 63.6 mmol) in anhydrous ethanol (12δ mL) was heated at reflux for 12 δ h. After cooling to room temperature, the resulting white solid was collected by filtration and washed with cold ethanol (lδO mL) and then dried under vacuum to provide | 2 as a white solid (3.84 g, 17.8 mmol,
56%). iH NMR (300 MHz, D20): δ 8.91 (d, J = 2 Hz IH), 8.21 (d, J = 2 Hz, IH), 0 8.12 (d, J = 8 Hz, IH), 7.84 (d, J = 7 Hz, IH), 7.72 (t, J = 7 Hz, IH), 7.54 (t, J = 7 Hz, 1,H), 4.72 (m, IH), 2.73 (m, 2H).
3-Phenylacetylamino-3-(quinolin-3-yl)-propionic (5-3)
A 0° solution of (3.5 g, 16.2 mmol) and NaHCθ3 (2.7 g, 5 32.4 mmol) in 50% aqueous dioxane (100 mL) was treated dropwise with a solution of phenylacetyl chloride (3.00 g, 19.4 mmol) in 25 mL of dioxane. The resulting solution was stirred at 0° for 2.δh., then warmed to room temperature, diluted with H 0 (δO mL) and washed with ether (2 x 100 mL). The aqueous layer was adjusted to pH = 3 with 3N HCl and 0 then extracted with CH2C12 (3 x lδO mL). The pooled organic extracts were dried, filtered and concentrated to afford | 3 as an off-white solid. IH NMR (300 MHz, CD3OD): δ 8.8δ (d, J = 2 Hz IH), 8.20 (d, J = 2 Hz, IH),
8.00 (d, J = 8 Hz, IH), 7.86 (d, J = 7 Hz, IH), 7.76 (t, J = 7 Hz, IH), 7.δ2 (t, J = 7 Hz, 1,H), 7.28 (m, 6H), δ.δ3 (t, J = 6.8 Hz, IH), 3.δ7 (s, 2H), 2. 96 (m, δ 2H).
3(S)-(Quinolin-3-yl)-propionic acid dihydrochloride (δ-6)
Acid 5S (δ.O g, lδ mmol) was suspended in water (3.5 L), then treated with IN NaOH (15 mL) to afford a clear solution. Penicillin 0 amidase (Sigma, EC 3.5.1.11, 10,000 U) in 0.1 M phosphate buffer was added. The pH of the mixture was adjusted to 7.8 with IN NaOH and the solution was stirred at room temperature for 4 days. The reaction was monitored periodically by HPLC and the reaction stopped once the δ0% conversion was reached. Next, the reaction solution was cooled to 0°C δ and adjusted to pH = 3 with 3N HCl. An oily yellow precipitate formed which was collected by filtration, then washed with water to afford crude δ-δ (1.8 g, δ.3 mmol). The filtrate was extracted with CH2C12 (3 x δOO mL) to afford additional δ^δ contaminated by phenylacetic acid. Both batches of crude 5 5 were combined and stirred in 6 N HCl (200 mL) at δ δ0° for 12 h then cooled, washed with ether (2 x 100 mL) and evaporated to afford δ-6.
3(S)-(Quinolin-3-yl)-propionic acid ethyl ester dihydrochloride (δ-7).
The resolved acid j 6 was converted to 5PL by refluxing in
10 ethanolic HCl. iH NMR (300 MHz, CD3OD): δ 9.2δ (d, J = 2 Hz IH), 8.31 (d, J = 2 Hz, IH),
8.1δ (d, J = 8 Hz, IH), 7.84 (d, J =7 Hz, IH), 7.72 (t, J = 7 Hz, IH), 7.δ4 (t, J = 7 Hz, 1,H), 4.72 (m, IH), 4.1δ (q, J = 6 Hz, 2H), 2.73 (m, 2H) 1.18 (t, J= 6 Hz, 3H). lδ
SCHEME 6
SCHEME 6 (CONTINUED)
3(S)-(Quinolin-3-yl)-3-(3-[3-(2-methyl-[l,3]dioxolan-2-yl)-propyl]-2- oxo-pyrrolidin-l-yl)-propionic acid ethyl ester (6-1)
A mixture of (377 mg, 1.3 mmol), 5 (400 mg, 1.3 mmol), Na(OAc)3BH (400 mg, 2.0 mmol) and NEt3 (0.35 mL, 2.6 mmol) in
5 dichloroethane (10 mL) was stirred for 24 h. The mixture was diluted with ethyl acetate, washed with sat. NaHC03, brine, and dried over MgSθ4. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, δ0:3δ:14:l hexanes/ chloroform ethyl acetate/ MeOH) to give 64 as a yellow oil. 10 TLC Rf = 0.47 (silica, 70:2δ:δ chloroform/ ethyl acetate/ MeOH) iH NMR (300, MHz, CDCI3) δ 8.8δ (m, IH), 8.10-7.40 (m, 5H), δ.90 (m, IH),
4.12 (q, J=7 Hz, 2H), 3.90 (m, 4H), 3.38 (m, IH), 3.20-2.9δ (m, 3H), 2.40 (m, IH), 2.14 (m, IH), 1.90 (m, IH), 1.74-1.30 (m, 4H), 1.30 (ds, 3H), 1.22 (t, J=7 Hz, 3H). lδ
3(S)-(Quinolin-3-yl)-3-[2-oxo-3-(4-oxo-pentyl)-pyrrolidin-l-yl]- propionic acid ethyl ester (6-2)
A solution of 6 (380 mg, 1.0 mmol), p-TSA (20 mg) and acetone (δO mL) was heated at reflux for 4 hr. The cooled reaction 0 mixture was diluted with EtOAc and then washed with sat. NaHCθ3 and brine, dried (MgSθ4), and concentrated to afford &2 as a yellow oil. iH NMR (300 MHz, CDCI3) δ 8.74 (m, IH), 8.06-7.40 (m, 5H), 5.90 (m, IH),
4.13 (m, 2H), 3.38 (m, IH), 3.20-2.95 (m, 3H), 2.50-2.10 (m, 4H), 2.13 (d, J=δ Hz, 3H), 1.90-1.20 (m, 6H), 1.22 (t, J=7 Hz, 3H). δ
3(S)-(Quinolin-3-yl)-3-[3-(3-[l,8]naphthyridin-2-yl-propyl)-2-oxo- pyrrolidin-l-yl1-propionic acid ethyl ester (6-3)
A mixture of 62 (396 mg, 1.0 mmol), 2-amino-3- formylpyridine (138 mg, 1.2 mmol; for prep, see JOC 1983,48, 3401) and 0 proline (218 mg, 2.0 mmol) in absolute ethanol (lδ mL) was heated at reflux for 12 h. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, δ0% ethyl acetate/chloroform to 70:2δ:δ chloroform/ethyl acetate/MeOH) to give 6r3 as a yellow oil. TLC Rf = 0.23 (70:2δ:δ chloroform/ethyl acetate/MeOH). iH NMR (300 MHz, CDCI3) δ 9.08 (m, IH), 8.8δ (m, IH), 8.20-7.δ0 (m, 9H), δ.90 (m, IH), 4.11 (m, 2H), 3.40 (m, IH), 3.20-2.90 (m, 6H), 2.60-1.40 (m, 6H), 1.22 (m, 3H).
δ 3(S)-(Quinolin-3-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro-[l,8]naphthy- ridin-2-yl)-propyn-pyrrolidin-l-yl)-propionic acid ethyl ester (6-4)
A mixture of (380 mg, 0.8 mmol) and 10% Pd carbon (200 mg) in EtOH (20 mL) was stirred under a balloon of hydrogen for 6 h. Following filtration and evaporative removal of the solvent, the residue 10 was chromatographed (silica gel, 70:2δ:δ to 70:20:10 chloroform/ethyl acetate/MeOH) to give 6^4 as a yellow oil. TLC Rf = 0.20 (70:20:10 chloroform ethyl acetate/MeOH). iH NMR (300 MHz, CDCI3) δ 8.86 (m, IH), 8.08 (m, 2H), 7.80 (m, IH), 7.72
(m, IH), 7.δ7 (m, IH), 7.03 (m, IH), 6.33 (m, IH), δ.90 (m, IH), 4.11 (m, lδ 2H), 3.40 (m, 3H), 3.15-2.00 (m, 9H), 2.00-1.30 (m, 8H), 1.22 (m, 3H).
3(S)-(Quinolin-3-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro-[l,8]naphthy- ridin-2-yl)-propyll-pyrrolidin-l-yl)-propionic acid (6-5 and 6-6)
To a solution of 64 (300 mg, 0.62 mmol) in EtOH (3 mL) was 20 added IN NaOH (0.68 ml, 0.68 mmol). After stirring for 2 h, the solvents were evaporated and the residue was chromatographed (silica gel, 25:10:1:1 - 15:10:1:1 ethyl acetate/EtOH/water/NH40H) to give and
6-6 as pure diastereomeric white solids.
TLC Rf = 0.32 (isomer A) (10:10:1:1 ethyl acetate/EtOH/water/NILiOH). δ TLC Rf = 0.28 (isomer B) (10:10:1:1 ethyl acetate/EtOH/water/ ELiOH). iH NMR (300 MHz, CD3OD, Isomer A) δ 8.8δ (d, J=2Hz„ IH), 8.33 (bs, IH), 8.00 (m, 2H), 7.78 (m, IH), 7.44 (d, J=7 Hz, IH), 6.50 (d, J=7 Hz, IH,), 6.02 (m, IH), 3.62 (m, IH), 3.48 (m, 2H), 3.20-1.90 (m, 3H), 2.80-2.60 (m, 4H), 2.13 (m, IH), 2.00 -1.70 (m, 8H). 0 iH NMR (300 MHz, CD3OD, Isomer B) δ 8.85 (d, J=2Hz„ IH), 8.33 (bs,
IH), 8.00 (m, IH), 7.95 (m, IH), 7.75 (m, IH), 7.62 (m, IH), 7.33 (d, J=7 Hz, IH), 6.43 (d, J=7 Hz, IH,), 5.74 (m, IH), 3.5δ (m, IH), 3.40 (m, 2H), 3.20- 1.95 (m, 2H), 2.72 (m, 2H), 2.58 (m, 3H), 2.23 (m, IH), 2.00 -1.40 (m, 8H). SCHEME 7
7 _. b) Li (S)-(-)-4-benzyl-2-oxazolidinone
l-(4-(S)-benzyl-2-oxo-oxazolidin-3-yl)-heptane-1.6-dione (7-2)
To a stirred solution of 6-oxo-heptanoic acid 74 (100 g, 694 δ mmol), NEt3 (111.3 ml, 763.4 mmol) and THF (2000 mL) at -78°C was added pivaloyi chloride (98.7 ml, 763.4 mmol). The mixture was warmed to 0°C for 1.0 h and then recooled to -78°C. To a stirred solution of (S)-(-)-4- benzyl-2-oxazolidinone (136g, 763.4 mmol) and THF (2000 ml) at -78°C was added nBuLi (306 ml, 76δ mmol, 2.δM in hexanes) dropwise over 30 10 minutes. After 20 minutes, the lithium reagent was transferred to the mixed anhydride via cannula. After 20 minutes, the reaction was warmed to 0°C for l.Oh. The mixture was diluted with ethyl acetate, washed with sat. NaHC03, brine, and dried over MgSθ4. Following evaporative removal of the solvent, the residue was azeotroped with lδ xylenes to give 2 as a colorless foam.
TLC Rf = 0.26 (silica, 2δ% EtOAc/hexanes) iH NMR (300 MHz, CDCI3) δ 7.27, (m, 5H), 4.66 (m, IH), 4.16 (m, 2H), 3.29 (dd, J=3 Hz, 13 Hz, 1H),2.90 (m, 2H ), 2.75 (m, IH), 2.50 (t, J=7 Hz, 2H), 2.15 (s, 3H), 1.68 (m, 4H).
5 4-(S)-benzyl-3-r5-(2-methyl-ri.31dioxolan-2-yl)-pentanoyll-oxazolidin-2-one
A mixture of ketone £2 (69δ mmol), ethylene glycol (69 ml, 1040 mmol), p-TSA (δOO mg, 2.713 mmol) and benzene (2000 mL) was heated to reflux with azeotropic removal of water for 12 hours. The 10 reaction mixture was diluted with EtOAc and then washed with sat. NaHCθ3, brine, dried (MgSθ4), and concentrated to give 2--3 as a yellow oil.
TLC Rf = 0.2δ (silica, 30% EtOAc/hexanes) iH NMR (300 MHz, CDCI3) δ 7.26 (m, δH), 4.67 (m, 2H), 3.94 (s, 4H), 3.29 lδ (m, IH), 2.9δ (m, 2H), 2.76 (m, IH), 1.71 (m, 4H), 1.50 (m, 2H), 1.32 (s, 3H).
4-(S)-benzyl-3-(R)-f2-r3-(2-methyl-n.31dioxolan-2-yl)-propyn-pent-4-enoyl)- oxazolidin-2-one (7-4) 20 To a stirred solution of £3 (695 mmol) and THF (2000 mL) at -78°C was added LiN(TMS) (91δ mL, 916 mmol, 1.0 M in THF) dropwise over 30 minutes. After 20 minutes, allyl bromide was added. After 20 minutes, the reaction was warmed to 0°C. After 4.0 h, the reaction was diluted with EtOAc, washed with sat. NaHC03, brine, dried (MgSθ4) and 5 concentrated. Flash chromatography (silica, 25% EtOAc/hexanes) gave
74 as a yellow oil.
TLC Rf = 0.27 (silica, 30% EtOAc/hexanes) iH NMR (300 MHz, CDCI3) δ 7.25 (m 5H), δ.81 (m, IH), 5.0δ (m, 2H), 4.67
(m, IH), 4.18 (m, 2H), 3.91 (m, 4H), 3.29 (dd, J=3Hz, 13Hz, IH), 2.67 (m, 0 IH), 2.48 (m, IH), 2.32 (m, 2H), 1.76 (m, IH) 1.63 (m, 2H), 1.55 (m, IH),
1.40 (m, 2H), 1.28 (s, 3H).
3-(R)-(4-(S)-benzyl-2-oxo-oxazolidine-3-carbonyl)-6-(2-methyl- n.31dioxolan-2-yl)-hexanal (7-5) To a stirred solution of 74 (60 g, 15δ mmol), sudan III (20 mg) and CH2C12 (1600 mL) at -78°C under argon was bubbled ozone until red solution changed to yellow-orange. The solution was purged with argon for 30 minutes. PPI13 (61 g, 233 mmol) was added followed by the removal of the cooling bath. After 2.0 h, the reaction was concentrated. Flash chromatography (silica, 20%-40% EtOAc/hexanes) gave iδ as a yellow oil. TLC Rf = O.lδ (silica, 50% EtOAc/hexanes) iH NMR (300 MHZ, CDCL3) δ 7.27 (M 5H), 4.6δ (M, IH), 4.22 (M, 3H), 3.91 (M, 4H), 3.28 (DD, J=3HZ, 13HZ, IH), 3.05 (M, IH), 2.78 (M, 2H), 1.69 (M, 3H), 1.50 (M, 3H), 1.29 (S, 3H).
3(S)-(3-Fluoroph^nyl)-3-(2-oxo-3(R)-r3-(5.6.7.8-tetrahvdro- ri.81naphthyridin-2-yl)-propyll-pyrrolidin-l-yl)-propionic acid (2-10) The title compound was prepared following the synthetic procedure depicted in Scheme 2, but replacing intermediate 2S with the chiral intermediate 7^5, the preparation of which is shown in Scheme 7.
3(S)-(3-Fluorophenyl)-3-(2-oxo-3(S)-r3-(5.6.7.8-tetrahvdro- ri.81naphthyridin-2-yl)-propyll-pyrrolidin-l-yl)-propionic acid (2-11)
The title compound was prepared in a similar fashion as its diastereoisomer 7^6 immediately above, but using the enantiomer of 7-5 prepared in an analogous fashion to that depicted in Scheme 7.
SCHEME 8
proline
8-1 8-2
4-ri.81Naphthyridin-2-yl-butyronitrile (8-2)
A mixture of 5-oxo-hexanenitrile (8-1) (5 ml, 43.8 mmol), 2- amino-3-formylpyridine (7 g, 57 mmol), proline (5.3 g, 43.8 mmol) and ethanol (100 mL) was heated at reflux for 12 hours. Following evaporation of the solvent, the residue was chromatographed (silica gel, ethyl acetate) to give & as a white solid. TLC Rf = 0.21 (silica, ethyl acetate). 5 iH NMR (300 MHz, CDCI3) δ 9.10 (m, IH), 8.19 (m, 2H), 7.47 (m, 2H), 3.24 (t, 2H, J=7 Hz), 2.55 (t, 2H, J=7Hz), 2.39 (m, 2H).
4-(5.6.7.8-Tetrahvdro-ri.81naphthyridin-2-yl)-butyronitrile (8-3)
A mixture of (14 g, 71 mmol), 10% Pd/C (2 g) and ethanol 10 (200 mL) was stirred under a balloon of hydrogen gas for 1 h. Filtration and evaporation produced &3, as a white solid. iH NMR (300 MHz, CDCI3) δ 7.06 (d, IH, J=7 Hz), 6.3δ (d, IH, J=7 Hz),
4.76 (br s, IH), 3-.41 (m, 2H), 2.71 (m, 4H), 2.38 (t, 2H, J=7 Hz), 2.08 (m, 3H), 1.86 (m, 2H), 1.80 (m, IH). lδ
2(S)-tert-Butoxycarbonylamino-3-r3-(3-ri.81naphthyridin-2-yl-propyl)- π.2.41oxadiazol-5-yll-propionic acid benzyl ester (8-δ)
To methanol (20 mL) was added sodium metal (0.86 g, 37 mmol). After 30 minutes, this solution was added to a suspension of
20 hydroxylamine hydrochloride (2.57 g, 37 mmol) in methanol (5 mL). After stirring for 30 min, the mixture was filtered. To this filtrate was added & (δ g, 24.4 mmol), and the mixture stirred for 24 h at 40°C. An additional portion of hydroxylamine (δO mmol, prepared as above) was then added followed by a further 24 h of stirring. The resulting mixture δ was diluted with ethyl acetate, washed with sat. NaHCθ3, brine, and dried over MgSθ4. Evaporation gave crude amide oxime (84). To a solution N-BOC-(L)-aspartic acid-alpha benzyl ester (1.5 g, 4.6 mmol) in THF (20 mL) at 0°C was added N-methylmorpholine (0.61 mL, 5.δ mmol) followed by isobutyl chloroformate (0.66 mL, 5.1 mmol). After 0 30 minutes, a solution of the above crude oxime in DMF (5 mL) was added. The solution was allowed to warm to 2δ°C and stir for 1 h, then toluene (20 mL) was added and the mixture heated to 110°C, allowing the THF to evaporate. The resulting mixture was heated at reflux for 6 h. Following cooling, the mixture was diluted with ethyl acetate, washed δ with sat. NaHCθ3, brine, and dried over MgSθ4. The residue was chromatographed (silica gel, 50-60% ethyl acetate/hexanes) to give 8-5 as a yellow oil.
TLC Rf = 0.63 (silica, ethyl acetate). iH NMR (300 MHz, CDCI3) δ 7.30 (m, 5H), 7.04 (m, IH), 6.34 (m, IH), δ.16 (s, 2H), 4.80 (m, 2H), 3.41 (m, 2H), 2.68 (m, 4H), 2.69 (m, 2H), 2.04 (m, 2H), 1.85 (m, 4H), 1.43 (m, 9H).
2(S)-Benzenesulfonylamino-3-r3-(3-ri.81naphthyridin-2-yl-propyl)- ri.2.41oxadiazol-5-yl"l-propionic acid (8-7) A solution of 4M HCl in dioxane (20 mL) was added to &
(0.7 g, 1.4 mmol). After 30 minutes, the solvent was evaporated to give a white solid. To this solid (0.3 g, 0.64 mmol) was added dichloromethane (10 mL), and NMM (0.7 mL, 6.4 mmol), and the mixture was cooled to 0°C. Phenylsulfonyl chloride (0.081 mL, 0.64 mmol) was added. After 30 minutes, the mixture was diluted with ethyl acetate, washed with sat. NaHC03, brine, and dried over MgSθ4. Evaporation gave the crude ester 8-6. which was dissolved in ethanol (5 mL); sodium hydroxide (0.7 mL, 1 N in water) was added. After 1 hr, the solvent was evaporated, and the residue was chromatographed (silica gel, 26:10:1:1 followed by 15:10:1:1 ethyl acetate /EtOH /water /NH4OH) to give as a white solid. TLC Rf = 0.48 (10:10:1:1 ethyl acetate/EtOH/water/NH40H). iH NMR (300 MHZ, CD3OD) Δ 7.68 (M, 2H), 7.33 (M, 3H), 7.15 (D, IH, J=7 HZ), 6.39 (D, IH, J=7 HZ), 3.91 (M, IH), 3.37 (M, 2H), 3.08 (M, 2H), 2.71 (M, 2H), 2.57 (M, 4H), 1.97 (M, 2H), 1.88 (M, 2H).
5-Bromo-2-ethoxypyridine (9-2)
Sodium metal (4.87 g, 0.212 mol) was added to ethanol (200 mL) and stirred until completely dissolved. To this solution was added 2,5-dibromopyridine 94 (10 g, 0.0424 mol) and the resulting mixture was stirred at reflux for 16 hr. The solvent was removed in vacuo and the residue partitioned between water and EtOAc. After extraction with EtOAc (2x), the organic layer was washed with brine, dried (MgSθ4) and concentrated to give 2t2. as a red-brown solid which was used as such in the next step. NMR (300 MHz, CDClg) δ 1.4 (3H, t), 4.33 (2H, q), 6.63 (IH, d), 7.62
(IH, dd), 8.19 (IH, d).
3(S)-(6-Ethoxypyridin-3-yl)-β-alanine ethyl ester (9-3)
The title compound 9 was prepared from 2 using the procedure described for the synthesis of 19-5 from 19-3. H NMR (300 MHz, CDClg): δ 1.25 (3H, t), 1.39 (3H, t), 2.61 (IH, dd), 2.67
(IH, dd), 4.15 (2H, q), 4.34 (2H, q), 4.40 (IH, dd), 6.71 (IH, d), 7.62 (IH, dd), 8.11 (IH, d).
SCHEME 10
A mixture of 2-amino-5-bromopyridine 10-1 (10 g, 58 mmol), tert-butyl acrylate (50 mL, 344 mmol), triethylamine (50 mL, 359 mmol), tri-o-tolylphosphine (3.0 g, 9.8 mmol) and Pd(OAc)2 (1.0 g, 4.5 mmol) in 150 mL CH3CN was purged with argon for 5 min and subsequently refluxed at 110°C for 20 hr. The mixture was then cooled and concentrated. The residue was purified using silica gel flash chromatography (EtOAc/hexanes 1:1) to afford the desired product 10-2 as a solid.
Rf (silica, EtOAc/hexanes 1:1) = 0.26
3(S)-(6-Amino-pyridin-3-yl)-3-rbenzyl-(l(R)-phenylethvX)-amipo1- propionic acid £ert butyl ester (10-3) To a cooled (0°C) solution of (R)-(+)-N-benzyl-α- methylbenzylamine (4.0 g, 19 mmol) in 50 mL THF was gradually added n-butyllithium (11.3 mL, 2.5 M, 28.2 mmol) over δ min. The mixture was stirred for 30 min at 0°C and cooled to
-78 °C. A solution of J (2.0 g, 9.4 mmol) in 20 mL THF was gradually added. After stirring for 40 min at -78 °C, it was treated with NH4CI
(sat.) at -78°C, warmed to room temperature and extracted three times with EtOAc. The combined organic layers were washed with brine and dried over Na2Sθ4. After solvent evaporation, the residue was purified using silica gel flash chromatography (EtOAc/hexanes 1:2) to afford the desired product 10-3 as an oil.
Rf (silica, EtOAc/hexanes 1:1) = 0.28
3(S)-Amino-3-(6-amino-pyridin-3-yl)-propionic acid ethyl ester* 2 HCl
(10-4) A mixture of J (0.5 g, 1.2 mmol) and 10% Pd/C (0.4 g) in
10 mL AcOH was purged with argon for 5 min and then heated at 78°C.
1,4-Cyclohexadiene (2 mL. 21.1 mmol) was then gradually added. The reaction mixture was stirred for 3 hr and filtered through a celite pad.
The solution was concentrated and the residue was purified using silica gel flash chromatography (EtOAc MeOH/NH4θH 1 :1:0.04) to afford an oil. To the oil (1.2 g) in 20 mL EtOH was introduced HCl gas for 10 min. The mixture was stirred 24 hr and then concentrated to afford the desired product 104 as the HCl salt. iH NMR (400 MHz, CD3OD) δ 8.11 (d, J=9.6 Hz, IH), 8.08 (s, IH), 7.13 (d,
J=9.6 Hz, IH), 4.77 (m, IH), 4.18 (q, J=6.8 Hz, 2H), 3.22-3.02 (m, 2H), 1.24 (t, J=6.8 Hz, 3H).
SCHEME 11
1M 11-7 π-8
3-(3-Hvdroxy-4-nitrophenyl)-acrylic acid ethyl ester (ll-2)
To a stirred solution of aldehyde 11-1 (20.28 g, 132.6 mmol) in CH C12 (400 mL) at room temperature was added
(carbethoxymethylene)triphenylphosphorane (46.12 g, 132.6 mmol) over a 10 min period. The resulting orange solution was stirred at room temperature for 2 h. The solution was concentrated to one-fourth its volume. Flash chromatography (silica gel; 30:70 EtOAc/hexanes) gave the title compound 11-2 as a bright yellow solid. TLC Rf = 0.75 (25:75 EtOAc/hexanes) IH NMR (300 MHz, CDCI3) δ 8.14 (d, IH), 7.60 (d, IH), 7.15 (dd, IH), 6.54
(d, IH), 4.30 (q, 2H), 1.36 (t, 3H).
3-(4-Amino-3-hvdroxyphenyl)-acrylic acid ethyl ester (11-3)
To a stirred suspension of 11-2 (4.64 g, 19.6 mmol), NH4CI (524 mg, 9.8 mmol), EtOH (140 mL) and H20 (70 mL) was added iron dust (2.72 g, 48.9 mmol). The resulting yellow suspension was refluxed for 1.5 h., and then the solution was filtered while hot through celite. The filtrate was concentrated and the residue was partitioned between EtOAc and brine. The layers were separated and the EtOAc layer dried (Na2Sθ4) and concentrated to give 11-3 which was used without further purification in the next step. TLC Rf = 0.2 (25:75 EtOAc/hexanes) IH NMR (300 MHz, CDCI3) δ 7.57 (d, IH), 7.00 (m, 2H), 6.68 (d, IH), 6.20
(d, IH), 4.26 (q, 2H), 4.10 (b, 2H), 1.33 (t, 3H). 3-r4-(2-Chloroacetylamino)-3-hvdroxyphenvnacrylic acid ethyl ester
(l l
To a stirred solution of Ji3 (3.38 g, 16.3 mmol) in CHCI3 (80
5 mL) was added saturated NaHCθ3 (60 mL) and it was then chilled to 0°C. A solution of chloroacetyl chloride (1.94 mL, 24.4 mmol) in CHCI3 (30 mL) was added dropwise to the chilled biphase. Upon addition completion, the reaction was stirred at 0°C for 1 h. The layers were separated and the aqueous layer was extracted twice with EtOAc. The 10 combined organic layers were washed with brine, dried (Na2Sθ4) and concentrated to give 114 which was used without further purification in the next step.
TLC Rf = 0.4 (25:75 EtOAc/hexanes)
IH NMR (300 MHz, CDCI3) δ 10.33 (s, IH), 9.58 (s, IH), 8.02 (d, IH), 7.61 lδ (d, IH), 7.19 (d, IH), 7.12 (s, IH), 6.39 (d, IH), 4.42 (s, 2H), 4.17 (q, 2H), 1.26 (t, 3H).
3-(3-Oxo-3.4-dihvdro-2H-benzori.41oxazin-7-yl) acrylic acid ethyl ester
0 To a stirred solution of 114 (4.28 g, 15.0 mmol) in DMF (50 mL) was added K Cθ3 (4.50 g, 32.6 mmol). The resulting suspension was heated to 50°C for 12 h., after which time the reaction was concentrated. The residue was partitioned between saturated NaΗCθ3 and EtOAc and extracted twice with EtOAc. The combined organic δ layers were washed with brine, dried (Na Sθ4), and concentrated.
Flash chromatography (silica gel; 25:76 EtOAc/hexanes) yielded 11-5 as a beige solid.
TLC Rf = 0.5 (25:75 EtOAc/hexanes).
IH NMR (300 MHz, CDCI3) δ 10.91 (s, IH), 7.54 (d, IH), 7.37 (s, IH), 7.31 0 (d, IH), 6.90 (d, IH), 6.51 (d, IH), 4.60 (s, 2H), 4.16 (q, 2H), 1.24 (t, 3H).
3-(R)-rBenzyl-(l-phenylethyl)-aminol-3-(S)-(3-oxo-3.4-dihvdro-2H- benzoπ.41oxazin-7-yl) propionic acid ethyl ester (11-6) To a stirred solution of (R)-(+)-N-benzyl-α- 5 methylbenzylamine (5.43 g, 25.7 mmol) and anhydrous TΗF (75 mL) at 0°C was added butyllithium (10.3 mL, 2.5 M/hexanes, 25.7 mmol) via syringe. The violet-red solution was stirred at 0°C for 15 minutes and then cooled to -78°C. A solution of 11-5 (2.12 g, 8.6 mmol) in anhydrous THF (50 mL) was added via syringe, and the resulting brown solution was stirred at -78°C for 30 minutes. The brown solution was quenched with saturated NH4CI, the mixture then warmed to room temperature and extracted twice with Et20. The combined organic layers were washed with brine, dried (Na Sθ4), and concentrated. Flash chromatography (silica gel; lδ:85 to 2δ:75 EtOAc/hexanes) yielded 11-6 as a white foam.
TLC Rf = 0.2δ (25:76 EtOAc/hexanes)
IH NMR (300 MHz, CDCI3) δ 10.89 (s, IH), 7.32 (m, 10H), 7.10 (m, 2H),
6.91 (d, IH), 4.62 (s, 2H), 4.39 (m, IH), 4.13 (q, 2H) 3.96 (m, IH), 3.68 (s,
2H), 2.56 (m, 2H), 1.28 (m, 6H).
3-(R)-rBenzyl-(l-phenylethyl)-amino1-3-(S)-(4-methyl-3-oxo-3.4-dihvdro-
2H-benzof4.4"loxazin-7-yl) propionic acid ethyl ester (11-7)
To a stirred suspension of NaΗ (65 mg, 60%, 1.6 mmol) in
DMF (5 mL) under argon was added a solution of 11-6 (650 mg, 1.4 mmol) in DMF (10 mL) via syringe. This yellow solution was stirred at room temperature for 30 minutes. Iodomethane (500 μL, 8.0 mmol) was added and the solution then stirred at room temperature for an additional 30 minutes. The reaction was quenched with saturated NaΗCθ3. The aqueous layer was extracted three times with CH2C12. The combined organic layers were washed with brine, dried (Na2Sθ4) and concentrated. Flash chromatography (silica gel; 25:7δ EtOAc/hexanes) afforded 11-7 as a clear oil.
TLC Rf = 0.6 (25:7δ EtOAc/hexanes)
IH NMR (300 MHz, CDCI3) δ 7.30 (m, 10H), 7.06 (m, 2H), 6.91 (d, IH), 4.62 (s, 2H), 4.39 (m, IH), 4.13 (q, 2H) 3.96 (m, IH), 3.68 (s, 2H), 3.3δ (s, 3H), 2.66 (m, 2H), 1.26 (m, 6H).
3-(S)-Amino-3-(4-methyl-3-oxo-3.4-dihvdro-2H-benzori.41oxazin-7-yl) propionic acid ethyl ester (11-8) A stirred solution of 11 7 (681 mg, 1.2 mmol), MeOH (10 mL), AcOH (1.0 mL), and H20 (0.3 mL) was degassed with argon for 5 minutes. Pd(OH)2 (681 mg) was added and the reaction was placed under 1 atm of H2 for 2.δ h. The reaction was diluted with EtOAc and filtered through celite. The filtrate was concentrated to yield 11-8 as a clear oil.
TLC Rf = 0.3 (5:9δ MeOH/CH2Cl2)
IH NMR (300 MHz, CDCI3) δ 7.04 (m, 2H), 6.93 (dd, IH), 4.61 (s, 2H), 4.39 (m, IH), 4.13 (q, 2H), 3.37 (b, 2H), 3.35 (s, 3H), 2.69 (m, 2H), 1.24 (t, 3H).
SCHEME 12
12-1 12-2 12-3
12-5 12-6
2-£er^Butoxycarbonylamino-5-aminopyridine (12-2)
A solution of 2-amino-4-bromopyridine 12-1 (10.1 g, 68.4 mmol) in 150 mL of melted £-BuOH was treated with di-£eτ -butyl dicarbonate (14.0 g, 64.2 mmol). After the solution was stirred for 12 hr, the solvent was evaporated. The residue was purified using silica gel flash chromatography (CHCl3/hexanes, 5:1) to afford the desired product
12-2 as a solid.
Rf (silica, 100% CHCI3) = 0.56 iH NMR (300 MHz, CDCI3) δ 8.82 (bs, IH), 8.38 (d, IH), 8.78 (d, IH), 7.78 (dd, IH), 1.56 (s, 9H).
2-(^gr^-Butoxycarbonyl-methyl-amino)-5-aminopyridine (12-3) 5 To a solution of l (6.0 g, 22.0 mmol) in 50 mL DMF at 0°C was added NaH gradually. After the mixture was stirred for 40 min, CH3I (3.4 g, 24.0 mmol) was added in one portion. The reaction mixture was stirred for 5 hr, treated with 300 mL water and extracted three times with ethyl ether. The combined organic layers were washed with brine 0 and dried over Na2Sθ4. After solvent removal, the residue was purified by silica gel flash chromatography (CHCl3/hexanes 6:1) to afford the desired product 12-3 as a solid. Rf (silica, 100% CHCI3) = 0.40 iH NMR (300 MHz, CDCI3) δ 8.40 (dd, IH), 7.68 (m, 2H), 3.36 (s, 3H), 1.55 5 (s, 9H).
3-f6-(,:er£-Butoxycarbonyl-methyl-amino)-pyridin-3-yll-acrylic acid ethyl ester (12-4)
A mixture of 1 (6.0 g, 20.9 mmol), ethyl acrylate (6.3 mL, 0 62.7 mmol), triethylamine (17 mL, 126.5 mmol), tri-o-tolylphosphine (1.3 g, 6.2 mmol) and Pd(OAc)2 (0.5 g, 2.1 mmol) in 60 mL CH3CN was purged with argon for δ min and subsequently refluxed at 110°C for 20 hr. The mixture was cooled and concentrated. The residue was purified using silica gel flash chromatography (EtOAc/hexanes 1:3) to afford the δ desired product 124 as an oil. iH NMR (300 MHz, CDCI3) δ 8.47 (bs, IH), 7.82 (m, 2H), 7.64 (d, IH), 6.42
(d, IH), 4.27 (q, 2H), 3.43 (s, 3H), 1.64 (s, 9H), 1.34 (t, 3H).
3-Benzylamino-3-r6-(--er^-butoxycarbonyl-methyl-amino)-pyridin-3-vn- 0 propionic acid ethyl ester (12-δ)
A mixture of 124 (1.7 g, 5.6 mmol) and benzylamine (8 mL, 73.2 mmol) was heated in a sealed- tube at 95 °C for 24 hr. The crude reaction mixture was purified using silica gel flash chromatography (EtOAc/hexanes 1:3 to 1:1) to afford the desired product 12-5 as an oil. Rf (silica, EtOAc/hexanes 1:1) = 0.63.
3-Amino-3-r6-(^e7 -butoxycarbonyl-methyl-amino)-pyridin-3-yll-propionic acid ethyl ester (12-6)
A mixture of 1 (1.5 g 3.6 mmol), 20% Pd(OH)2/C (0.3 g),
AcOH (5.5 mL) and EtOH (50 mL) was purged with argon 3 times under vacuum. The reaction mixture was stirred under balloon hydrogenation condition for 16 hr and filtered through a celite pad. After solvent removal, the desired product 12-6 was obtained as the acetate salt. iH NMR (300 MHz, CDCI3) δ 8.38 (d, IH), 7.70 (m, 2H), 4.50 (dd, IH), 4.15
(q, 2H), 3.40 (s, 3H), 2.80 (m, 2H), 1.25 (t, 3H).
SCHEME 13
3-(2-Fluoro-biphenyl-4-yl)-acrylic acid ethyl ester (13-2) A solution of 2-fluoro-4-bromobiphenyl 13-1 (7.5 gm, 31.8 mmol), ethyl acrylate (4.3 mL), Pd(OAc)2 (0.714 gm, 3.2 mmol), tri-o- tolylphosphine (1.94 gm, 1.5 mmol) and triethylamine (12 mL) was heated to 100°C in a sealed tube for 12 h. The reaction was cooled to room temperature and diluted with dichloromethane (40 mL). The organic solution was washed with 10% aq. citric acid (20 mL), satd. aq. NaHCθ3, and brine (20 mL). The organic solution was dried over MgSθ4, filtered, and concentrated. The residue was purified by flash chromatography (95:5 to 90:10 hexanes/EtOAc) to give the acrylate ester 13-2 as a white solid.
TLC Rf = 0.44 (10% ethyl acetate/hexanes).
3-rBenzyl-(l(R)-phenylethyl)-aminol-3-(2-fluoro-biphenyl-4-yl)-propionic acid ethyl ester (13-3) A cooled (0°C) solution of N-benzyl-(R)-α- methylbenzylamine (8.9 mL, 42.6 mmol) in THF (100 mL) was treated with n-butyllithium (26.6 mL of a 1.6 M soln in hexanes; 42.6 mmol). After stirring for 10 min, the purple solution was cooled to -78°C and treated with a solution of ester 13^2 (5.76 g, 21.3 mmol) in THF (10 mL). After stirring for 20 min, the solution was quenched with satd aq NH4CI soln (5 mL), and the cold bath removed. The reaction mixture was diluted with Et20 (100 mL), and washed with 10% aq citric acid (50 mL) , satd aq NaHCθ3 (50 mL), 5% aq acetic acid (30 mL), 10% aq K2Cθ3 (50 mL), and brine (50 mL). The solution was dried over MgSθ4, filtered and concentrated. The residue was purified by flash chromatography (90:10 hexanes/EtOAc) to give adduct 1 - TLC Rf = 0.48 (10% ethyl acetate/hexanes).
3-Amino-3-(2-fluoro-biphenyl-4-yl)-propionic acid ethyl ester (13-4) A solution of the dibenzylamine 13-3 (δ.65 gm, 11.75 mmol) in EtOH/HOAc (90/10 mL) was purged with argon and treated with Pd(OH)2 (3 g) and placed under 1 atm of H2 gas for 12 h. Additional portions (2.5 g) or Pd(OH)2 were added after 24 h, 48 h and 144 h. The reaction mixture was purged with argon, filtered through Celite, and the filtrate dissolved in aq HCl (pH=l). The aqueous solution was
- Ill - washed with EtOAc, neutralized with satd aq NaHCθ3, and extracted with EtOAc (3 x 30 mL). The combined organic solutions were washed with brine, dried over MgSθ4, filtered and concentrated to give the desired product 134. iH NMR (300 MHz, CD3OD) δ 7.41 (m, 8H), 4.10 (m, IH), 4.06 (m, 2H),
2.73 (m, 2H), 1.18 (m, 3H) ppm.
SCHEME 14
H F
3-(3-Hvdroxy-4-nitro-phenyl)-acrylic acid ethyl ester (14-2)
To a solution of aldehyde 144 (15.0 g, 98.0 mmol) in CH2C1
(300 mL) was slowly added carboethoxymethylenetriphenylphosphorane (34.1 g, 98.0 mmol). The orange solution was stirred for 12 h at ambient temperature. The solution was concentrated to a paste and purified by flash chromatography (10% EtOAc/CH2Cl ) to give 14- as a yellow solid.
TLC Rf = 0.51 (30% ethyl acetate/hexanes). iH NMR (300 MHz, CD3OD) δ 8.08 (d, J=8.4 Hz, IH), 7.63 (d, J=16.2 Hz, IH), 7.3δ (d, J=1.5 Hz, IH), 7.27 (dd, J=8.4, 1.5 Hz, IH), 6.65 (d, J=15.9 Hz, IH), 4.25 (q, J=7.2 Hz, 2H), 1.32 (t, J=6.9 Hz, 3H) ppm.
3-(2-Oxo-2.3-dihvdro-benzoxazol-6-yl)-acrylic acid ethyl ester (14-3)
To a solution of the nitrophenol 14-2 (12.0 g, 67.4 mmol) in warm (70°C) AcOH/H 0 (200 mL) was added iron dust (9.61 g, 172.2 mmol). The brown heterogeneous mixture was stirred for 30 min at 70- 80°C. The mixture was filtered hot through Celite, and the Celite bed washed with EtOAc (2 x 200 mL). The filtrate was cautiously neutralized with satd aq NaHCθ3 (3 x 100 mL). The solution was dried over MgSθ4, filtered, and concentrated. The residue was purified by flash chromatography (5% MeOH in CH C12) give an orange solid (9.6 g, 81%).
A portion of this solid (4.δ g, 21.7 mmol) was dissolved in THF (150 mL) and treated with 1,1-carbonyldiimidazole (3.87 g, 23.8 mmol) and the solution was stirred at ambient temperature for 24 h. The solution was diluted with EtOAc (100 mL) and washed with 10% HCl (δO mL) and brine (60 mL). The solution was dried over MgSθ4, filtered, and concentrated. The residue was purified by flash chromatography (δ% MeOH in CH2C12) to give 2M. as a yellow solid. TLC Rf = 0.49 (5% MeOH/CH2Cl2). iH NMR (300 MHz, CD3OD) δ 7.77 (d, J=15.9 Hz, IH), 7.65 (s, IH), 7.41 (d, J=8.4 Hz, IH), 7.09 (d, J=84 Hz, IH), 6.47 (d, J=15.9 Hz, IH), 4.22 (q, J=7.2 Hz, 2H), 1.31 (t, J=7.2 Hz, 3H) ppm.
3ιS-Amino-3-(2-oxo-2.3-dihvdro-benzoxazol-6-yl)-propionic acid ethyl ester (14-4)
A solution of N-benzyl-α-(R)-methylbenzylamine (4.08 g, 19.3 mmol) in THF (120 mL) at 0°C was treated with n-BuLi (7.72 mL of a 2.5 M soln in hexanes). The resulting solution was stirred at 0°C for 30 min and then cooled to -78°C. A solution of acrylate 14-3 (1.5 g, 6.43 mmol) in THF (20 mL) was added. After stirring for 15 min at -78°C, satd aq NH4CI soln (26 mL) was added and the cold bath removed. The mixture was warmed to room temperature, and extracted with Et20 (2 x 40 mL). The combined organic extracts were washed with brine (30 mL), dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography (30% ethyl acetate/hexanes) to give 2.74 g of the β- aminoester as a yellow oil. The aminoester was dissolved in
EtOH/H 0/AcOH (54 mL/4.8 mIJ1.2 mL), degassed with argon, and treated with Pd(OH)2 (2.74 g). The mixture was placed under 1 atm of
H2. After stirring for 18 h, the mixture was diluted with EtOAc, and filtered through Celite. The filtrate was concentrated to give ester 144 as an off-white solid.
TLC Rf = 0.10 (5% MeOH/CH2Cl2). iH NMR (300 MHz, CD3OD) δ 7.34 (s, IH), 7.26 (dd, J=l,2, 8.1 Hz, IH),
7.12 (d, J=8.1 Hz, IH), 4.6δ (t, J=7.2 Hz, IH), 4.13 (q, J=6.9 Hz, 2H), 2.98
(m, 2H), 1.20 (t, J=7.2 Hz, 3H) ppm.
SCHEME 15
3-(4-Hvdroxy-3-fluorophenyl)-acrylic acid ethyl ester (lδ-2)
A solution of 2-fluoro-4-bromophenol 15-1 (50 g, 261.8 mmol), ethyl acrylate (34 mL), Pd(OAc) (2.5 g), tri-o-tolylphosphine (5 g) and triethylamine (83 mL) was heated to 100°C in a sealed tube for 12 h. The reaction was cooled to room temperature and diluted with dichloromethane (100 mL). The organic solution was washed with 10% aq. citric acid (40 mL), satd aq NaHC03, and brine (40 mL). The organic solution was dried over MgSθ4, filtered and concentrated. The residue was purified by flash chromatography (60:50 hexanes/EtOAc to 100% EtOAc) to give acrylic acid lδ-2 as a white solid. TLC Rf = 0.4δ (50% ethyl acetate/hexanes).
3-rBenzyl-(l(R)-phenylethyl)-amino1-3-(4-ethoxy-3-fluorophenyl)- propionic acid ethyl ester (15-4)
To a stirred solution of Jj>2 (49.26 gm, 234.5 mmol) in DMF (600 mL) was added Cs2Cθ3 (84.1 gm, 257.9 mmol) and ethyl iodide (18.8 mL, 234.5 mmol). After stirring for 12 h at room temperature, the reaction mixture was diluted with EtOAc (1L) and washed with water (6 x 300 mL), 10% aq. citric acid (200 mL), satd. aq. NaHCθ3 (200 mL), and brine (300 mL). The organic solution was dried over MgSθ4, filtered, and concentrated to give 52.9 g (9δ%) of the product 15-3 as an orange oil which crystallized upon standing. A cooled (0°C) solution of N-benzyl- (R)-α-methylbenzylamine (71 mL, 339.4 mmol) in THF (650 mL) was treated with n-butylHthium (212 mL of a 1.6 M soln in hexanes; 339.4 mmol). After stirring for 10 min, the purple solution was cooled to -78°C and treated with a solution of ester 1J 3 (63.8 g, 226.3 mmol) in THF (100 mL). After stirring for 20 min, the solution was quenched with satd aq NH4CI soln (50 mL), and the cold bath removed. The reaction mixture was diluted with Et20 (1000 mL), and washed with 10% aq citric acid (300 mL) , satd aq NaHCθ3 (300 mL), 5% aq acetic acid (300 mL), 10% aq K2Cθ3 (300 mL), and brine (200 mL). The solution was dried over MgS04, filtered and concentrated. The residue was purified by flash chromatography (8δ:15 hexanes/EtOAc) to give the adduct 164. TLC Rf = 0.39 (25% ethyl acetate/hexanes). 3-Amino-3-(4-Ethoxy-3-fluorophenyl)-propionic acid ethyl ester (15-δ)
A solution of the dibenzylamine 154 (30.0 gm, 66.8 mmol) in EtOH/HOAc (340/30 mL) was purged with argon and treated with Pd(OH) (6 g) and placed under 1 atm of H2 for 12 h. Additional portions (2.5 g) of Pd(OH)2 were added after 24 h and 48 h. The reaction mixture was purged with argon, filtered through Celite, and the filtrate collected. The filtrate was concentrated to yield the desired amine 15-δ. iH NMR (300 MHz, CD3OD) δ 7.19 (m, 3H), 4.62 (m, IH), 4.07 (m, 4H),
2.99 (m, 2H), 1.39 (m, 3H) 1.18 (m, 3H) ppm.
SCHEME 16
16-1 16-2
5-Ethoxy-nicotinic acid ethyl ester (16-2)
A mixture of 3-hydroxy-nicotinic acid methyl ester 16-1 (15 g, 90.8 mmol), ethyl iodide (14.5 ml, 181.6 mmol), cesium carbonate (29.5 g, 90.8 mmol) and DMF (150 mL) was stirred at ambient temperture for 3 hours. The reaction mixture was diluted with Et 0 and then washed with 10% K2C03, brine, dried (MgSθ4), and concentrated to give the ester 16-2 as a red oil. TLC Rf = 0.52 (silica,75% EtOAc/hexanes) iH NMR (300 MHz, CDCI3) δ 8.82 (s, IH), 8.46 (s,lH), 7.75 (s, IH), 4.40 (q, 2H, J=7Hz), 4.12 (q, 2H, J=7Hz), 1.43 (m, 6H).
5-Ethoxy-A'-methoxy-Ar-methyl-nicotinamide ( 16-3 )
To a solution of 16__2 (15 g, 72 mmol) in EtOH (100 mL) was added IN NaOH (80 ml, 80 mmol). After stirring for 1 h, the solvents were evaporated and the residue was dissolved in IN HCl (80 ml, 80 mmol) and then concentrated, azeotroped with CH3CN to give the crude acid. The crude acid was suspended in DMF (200 mL) and then treated with HCl*HN(Me)OMe (13.9 g, 144 mmol), EDC (15. lg, 79.2 mmol), HOBT (9.6g, 72 mmol) and NMM (60 mL, 576 mmol). The mixture was stirred for 18 hours and then concentrated. The residue was dissolved in ethyl acetate, washed with 10% K Cθ3, brine, dried (MgSθ4), and concentrated to give amide 16-3 as a brown oil.
TLC Rf = 0.30 (silica, 70:25:5 chloroform/ ethyl acetate/ MeOH) 5-Ethoxy-pyridine-3-carbaldehvde (16-4)
To a stirred solution of J (14.0 g, 66.5 mmol) and CH2C12
(200 mL) at -78°C under argon was added DIBAL (1.0M hexanes, 90ml) dropwise over 30 minutes. After 30 minutes, the solution was warmed to 0°C for 1 hour. The reaction was quenched with 100 ml 1.0M Rochelle's salt, stirred for 1.0 hour and then extracted with Et20. The organic layer was dried (MgS04), and then concentrated to give the aldehyde 164 as a brown oil.
TLC Rf = 0.32 (silica, 70:25:5 chloroform/ethyl acetate/MeOH) iH NMR (300 MHz, CDCI3) δ 10.10 (s, 1H),8.65 (s,lH), 8.65 (s,lH), 7.59 (s, IH), 4.14 (q, 2H, J=7Hz), 1.43 (t, 3H, J=7Hz). 3-(5-Ethoxy-pyridin-3-yl)-acrylic acid tert-hπtyl ester (16-6)
A mixture of 164 (8.0 g, δl.6 mmol), 16J5 (20 g, 54.2 mmol), and benzene (150 mL) was heated to reflux for 30 minutes. The mixture δ was diluted with Et20 and then washed with 10% K2Cθ3, brine and dried (MgSθ4). Following evaporative removal of the solvent, the residue was chromatographed (silica gel, 30% EtOAc/hexanes) to give 16-6 as a yellow solid.
TLC Rf = 0.41 (silica, 70:26:5 chloroform/ ethyl acetate/ MeOH) 0 iH NMR (300 MHz, CDCI3) δ 8.31 (m, 2H),7.55 (d, IH, J=16Hz), 7.27 (s, IH), 6.40 (d, IH, J=16Hz), 4.10 (q, 2H, J=7Hz), 1.54 (s, 9H), 1.44 (m, 3H).
3(S)-Amino-3-(δjethoxy-pyridin-3-yl)-propionic acid fe -butyl ester (16-8) To a stirred solution of VX∑ (δOOmg, 2.38mmol) and THF at 5 0°C was added nBuLi (2.5 M THF, 0.95 ml) dropwise. After 20 minutes, the solution was cooled to -78°C and 16-6 (δOOmg, 1.98 mmol), dissolved in 3 ml THF, was added. After 15 minutes, the reaction was quenched with sat. NH4CI followed by the removal of the cooling bath. The solution was extracted with ethyl acetate. The organic portion was washed with 0 brine, dried (MgSθ4) and concentrated. The residue was dissolved in acetic acid (14 ml) and the solution was purged with argon for 30 minutes. 10% Pd/C (1.0 g) was added and the mixture was heated to 80°C. 1,4-Cyclohexadiene (6 ml) was added dropwise maintaining an internal temperature between 80°C and 90°C. After 5.0 hours, the δ mixture was filtered through a celite pad, concentrated and then azeotroped with toluene. The residue was chromatographed (silica gel, 5% [10:10:1 EtOH/NH4θH/H20]/ 70:26:5 chloroform ethyl acetate/
MeOH) to give 16-8 as a yellow solid. iH NMR (300 MHz, CDCI3) δ 8.18 (m, 2H),7.25 (s,lH,), 4.41 (m,lH,), 4.08 0 (q, 2H, J=7Hz), 2.69 (m, 2H, ), 1.87 (s, 2H), 1.40 (m, 12H). SCHEME X7
3(S)-Amino-3-(5-methoxy-pyridin-3-yl)-propionic acid tert-butyl ester
(17-2)
3-Bromo-δ-methoxy-pyridine 17-1 (prepared as described in J. Org.
Chem. 1990, 56, -69) was converted into 17-2 utilizing the procedure described for the conversion of 12^2 to 12_£. XH NMR (300 MHz, CD3OD) δ
8.20 (d, IH, J=3Hz), 8.18 (d, IH, J=2Hz),7.50 (s, IH,), 4.51 (m,lH,), 3.90 (s,
3H), 2.87 (m, 2H, ), 1.37 (m, 9H).
SCHEME 18
18-2
1≤4
3-Amino-pent-4-enoic acid ethyl ester (18-2)
A mixture of 5% PαVBaSθ4 (0.025 g) and quinoline (0.30 mL) was stirred under a balloon of hydrogen for 30 minutes. 3-Amino-pent-4-ynoic acid ethyl ester (18-1) (for preparation, see J.A. Zablocki, et al., J. Med. Chem., 1995, 38, 2378-2394) (1.77 g, 10.0 mmol) in EtOH (15 mL) was added and the solution stirred for an additional 2.5 hours. The solution was filtered through a pad of celite and concentrated in vacuo to provide 2.65 g of crude product J - iH NMR (CDCI3, 300 MHz): δ 8.40-7.60 (br s,
2H), 6.11-5.96 (m, IH), 5.58-5.53 (d, IH), 5.44-5.41 (d, IH), 4.31-4.16 (m, 3H), 3.12-2.86 (m, 2 H), 1.29-1.25 t, 3H). SCHEME 19
19-1 19-2
Pd(OAc)2, Et3N, tri-o-tolylphosphine ethyl acrylate, CH3CN
19-3
5-Bromo-2-methoxypyridine (19-2)
To a solution of KOH (4.2 g, 0.075 mol) in water (750 mL) was added 2-methoxypyridine 19-1 (16.4 g, 0.15 mol) followed by a dropwise addition of bromine (24 g, 0.15 mol) in IN aqueous KBr (750 mL) and the resulting solution was stirred at room temperature for 5 hr. Solid NaHC03 was added until basic and the solution was extracted with CHCI3 (3x500 mL). The organic layer was washed with 10% NaHSθ3, then brine, dried over Na Sθ4_ filtered and the solvent removed in vacuo. The resulting dark brown oil was predominantly the desired compound 19-2 and was used as such in the next step.
XR NMR (300 MHz, CDClg) δ 3.91 (3H, s), 6.66 (IH, d), 7.62 (IH, dd), 8.20 (IH, d).
Ethyl 3-(6-methoxypyridin-3-yl)acrylate (19-3) A solution of the δ-bromo-2-methoxypyridine 18-2 (74.3 g, 0.4 mol), ethyl acrylate (150 mL, 1.4 mol), triethylamine (150 mL, 1.08 mol), palladium acetate (10 g, 0.045 mol) and tri-o-tolylphosphine (20 g, 0.066 mol) in 100 mL acetonitrile was degassed with argon for 10 minutes. The mixture was heated at 90°C for 12 hr then the volatiles were removed in vacuo. Toluene (300 mL) was added and the mixture concentrated again. Diethyl ether (300 mL) was added and the mixture filtered through a pad of silica gel eluting with 800 mL of diethyl ether. After removal of the diethyl ether, the residue was chromatographed on silica gel eluting with EtOAc/hexane, 1:19 then 1:14 then 1:9, to give 19-3 as a yellow solid.
IH NMR (300 MHz, CDC13) δ 1.34 (3H, t), 3.97 (3H, s), 4.26 (2H, q), 6.34
(IH, d),6.76 (IH, d), 7.63 (IH, d), 7.77 (IH, dd),8.27 (IH, d).
N-Benzyl-(R)-α-methylbenzyl-3(S)-(6-methoχypyridin-3-yl)-β-alanine ethyl ester (19-4)
To a solution of N-benzyl-(R)-α-methylbenzylamine (97.δ g,
462 mmol) in THF (750 mL) at 0°C was added n-butyllithium (2.5M in hexanes; 178.6 mL, 446 mmol). The dark violet solution was stirred at 0°C for 20 minutes, cooled to -78°C and the ester 1 (63.7 g, 308 mmol) in THF (250 mL) was added over 60 minutes. The resulting solution was stirred at -78 °C for 1 hr then cannulated into saturated NH4CI and extracted with EtOAc, washed with water then brine, dried and concentrated in vacuo to give an oil. Column chromatography (silica 5 gel; hexane/EtOAc, 9:1 then 4:1) gave 194 as an oil contaminated with N- benzyl-(R)-α-methylbenzylamine . This oil was taken up in 5% AcOH in water and extracted with diethyl ether (4x). The organic layers were dried over MgSθ4 and the solvent removed to give the title compound 19;
4. X0 1H NMR (300 MHz, CDClg) δ 1.08 (3H, t), 1.27 (3H, d), 2.62 (IH, dd), 2.62
(IH, dd), 3.66 (IH, d), 3.70 (IH, d), 3.93 (3H, s), 3.95 (2H, m), 4.41 (IH, dd), 6.74 (IH, d), 745-7.46 (10H, m), 7.64 (IH, dd), 8.15 (IH, d).
3(S)-(2-methoxypyrid-5-yl)-β-alanine ethyl ester (19-5)
15 To a degassed (argon) solution of the ester 194 (70 g) in
EtOH (260 mL), HOAc (25 mL) and water (2 mL) was added 20% Pd(OH)2 on carbon. The mixture was placed under hydrogen gas using a balloon and the resulting mixture was stirred for 24 hr. After filtration through celite (washing with EtOAc), the solvent was removed in vacuo to afford 0 a waxy solid. This was dissolved in 200 mL water and extracted with diethyl ether (2x200 mL). The aqueous layer was then treated with solid K Cθ3 until fully saturated and extracted with 4x200 mL EtOAc. After drying over MgSθ4, the solvent was removed in vacuo to give the title compound 19-5 as an oil which solidified in the freezer. 5 τ NMR (300 MHz, CDClg) δ 1.23 (3H, t), 2.61 (IH, dd), 2.68 (IH, dd), 3.92
(3H, s), 4.15 (2H, q), 4.41 (IH, dd), 6.93 (IH, d), 7.62 (IH, dd), 8.13 (IH, d).
Scheme 20
2QA 2QzZ
Pd(OH)2, EtOH L UAIH4 , 2. Pd(OH)2, EtOH
3-Bromo-6-chloro-5-nitropyridine (20-2)
A suspension of CuCl2 (3.33 g, 24.8 mmol) in anhydrous CH3CN (200 mL) at 6δ° was treated with tert-butylnitrite (3.13 mL, 26.3 mmol), followed by the dropwise addition of a solution of 20-1 in 60 ml of CH3CN. The resulting mixture was stirred under an argon atomsphere at 65° for 2 h and concentrated at reduced pressure. The residue was partitioned between EtOAc (lδO mL) and 3% HCl (60 ml), and the organic layer washed successively with 3% HCl, water, and brine (60 mL), then dried, filtered and concentrated to afford a brown solid which was chromatographed on silica (25% EtOAc/Hexane) to afford 20-2 as a yellow crystalline solid. TLC Rf = 0.60 (25% EtOAc/ Hexane) iH NMR (300 MHz, CDCI3) δ 8.70 (d, J=2.4 Hz, XH), 8.37 (d, J=2.4 Hz, XH).
(3-Nitro-5-bromo-Pyridin-2-yloxy)-acetic acid methyl ester (20-3) Methyl glycolate (450 mg, 5.0δ mmol) was added to a suspension of 60% NaH (131 mg, 5δ mmol) in THF (20 mL) at 0°. The resulting solution was stirred under argon for 0.5 h, then treated with a solution of 20-2. After stirring at 0° for 0.5 h, the reaction was diluted with ethyl acetate, and washed with successively with sat. NaHCθ3, water and brine (80 mL each), then dried, filtered and concentrated to afford 20-3 as a yellow solid.
TLC Rf = 0.70 (25% EtOAc/ Hexane) iH NMR (300 MHz, CDCI3) δ 8.46 (d, J= 2.4 Hz, IH), 8.37 (d, J= 2.4 Hz,
IH) 5.15 (s, 2H), 3.78 (s, 3H).
2-Oxo-2.3-dihvdro-lH-4-oxa-1.5-diaza-7-bromo-naphthalene (20-4)
A mixture of 20-3 (1.5 g, 5.12 mmol) and powdered tin (1.37 g, 11.5 mmol) was treated with cone. HCl (10 mL). The mixture was heated to 80° for 2 h, then cooled and concentrated. The residue was partitioned betwen CHCI3 and sat. NaHCθ3, washed with brine, then dried, filtered and concentrated to afford a yellow solid.
Chromatography on silica gel (50% hexane/EtOAc) gave 204 as a yellow solid.
TLC Rf = 0.65 (50% EtOAc/ Hexane) iH NMR (300 MHz, DMSO-dβ) δ 10.81 (br,s, IH), 7.88 (d, J=2.4 Hz, IH), 7.25 (d, J=2.4 Hz, IH), 4.81 (s, 2H).
3-(2-Oxo-2.3-dihvdro-lH-4-oxa-1.5-diaza-naphthalen-7-yl)-acrylic acid fert-bu yl ester (20-5)
A mixture of 204 (1.12 g, 4.89 mmol), (o-toltøP (298 mg, 1.0 mmol), Pd(OAc) (110 mg, 0.49 mmol), and triethylamine (0.86 mL, 5.87 mmol) in DMF (20 mL) was placed in a 100-mL flask. The mixture was degassed with argon, then tert-butyl acrylate (752 mg, 5.87 mmol) was added and the tube sealed and heated to 100° for 12 h. The reaction mixture was diluted with ethyl acetate, filtered and washed with NaHC03, water, and brine, dried, filtered and concentrated.
Chromatography on silica gel (26% hex/EtOAc) gave 20-5 as a yellow solid.
TLC Rf = 0.60 (25% EtOAc Hexane) iH NMR (300 MHz, DMSO-dβ) δ 10.91 (br,s, IH), 8.15 (d, J=2.4 Hz, IH), 7.54 (d, J=16 Hz, 1 H), 7.42 (d, J= 2.4 Hz, IH), 6.35 (d, J=16 Hz, 1 H), 4.84 (s, 2H), 1.48 (s, 9H).
3(S)-rBenzyl-(l( )-phenylethyl)-aminol-3-(2-oxo-2.3-dihvdro-lH-4-oxa-1.5- diaza-naphthalen-7-yl)-propionic acid tert-butyl ester (20-6) A solution of N-benzyl-α-(β)-methylbenzylamine (0.82 g, 3.87 mmol) in THF (25 mL) at 0°C was treated with n-BuLi (1.6 mL of a 2.5 M soln in hexanes). The resulting solution was stirred at 0°C for 30 min and then cooled to -78°C. A solution of acrylate 20-5 (0.485 g, 1.76 mmol) in THF (5 mL) was added. After stirring for 15 min at -78°C, satd aq NH4CI soln (5 mL) was added and the cold bath removed. The mixture was warmed to room temperature, and extracted with Et20 (2 x 40 mL).
The combined organic extracts were washed with brine (30 mL), dried over MgSθ4, filtered, and concentrated. The residue was purified by flash chromatography (40% ethyl acetate/hexanes) to give the β- aminoester 20-6 as a yellow oil.
TLC Rf = 0.3 (40% ethyl acetate/hexanes) iH NMR (300 MHz, CDCI3) δ IH NMR 8.70 (br, s, IH), 7.91 (d, J=1.8 Hz, lH),7.4-7.2 (10H), 7.12 (d, J=1.8 Hz, IH), 4.80 (s, 2 H), 4.42 (m, IH), 3.91 (q, J=6.7 Hz, 1 H), 3.69 (d, J=7.2 Hz, IH, ), 3.62 (d, J =7.2 Hz, IH, ), 2.46 (m, 2H), 1.34 (d, J=7.0 Hz, 3H), 1.29 (s, 9H).
3(S)-Amino-3-(2-oxo-2.3-dihvdro-lH-4-oxa-1.5-diaza-naphthalen-7-yl)- propionic acid tert-butyl ester (20-7)
A mixture of the dibenzylamine 20-6 (0.22 g, 0.44 mmol) in EtOH/H20/AcOH (26 mL/3 mL/1.0 mL) was degassed with argon and treated with Pd(OH)2 (100 mg). The mixture was placed under 1 atm of H2. After stirring for 18 h, the mixture was diluted with EtOAc and filtered through celite. The filtrate was concentrated and the residue purified by flash chromatography (20% 20:1:1 EtOH/NH4θH/H20 - 80% EtOAc) to give the tert-butyl ester 20-7 as a white solid. TLC Rf = 0.5 (20% 20:1:1 EtOH/NH4θH/H20 - 80% EtOAc) iH NMR (300 MHz, CD3OD) δ 7.89 (d, J= 1.7 Hz, IH), 7.31 (d, J=1.7 Hz, IH), 4.81 (s, 2H), 4.38 (m, IH), 2.6, (m, 2H), 141 (s, 9H).
3(R)-rBenzyl-(l-ρhenylethyl)-amino1-3(S)-(2-thioxo-2.3-dihvdro-lH-4-oxa- 1.5-diaza-naphthalen-7-yl)-propionic acid tert. butyl ester (20-8)
A solution of 20JB (0.22 g, 0.44 mmol ) in anhydrous THF was treated with Lawesson's reagent (0.098 g, 0.243 mmol) and stirred at room temperature for l.δ h. Silica gel (600 mg) was added to the reaction mixture and the solvent was removed at reduced pressure and the product was eluted from silica using 25% EtOAc/hex to afford 20-8 as a yellow solid.
TLC Rf = (40% EtOAc/hexane) 0.7 iH NMR (300 MHz, CD3OD) δ 9.82 (br, s, IH), 7.9δ (d, J=1.8 Hz, 1H),7.4- 7.2 (11H), 5.08 (s, 2 H), 4.42 (m, IH), 3.91 (q, J=6.7 Hz, 1 H), 3.69(d, J=7.2
Hz, IH, ), 3.62 (d, J =7.2 Hz, IH), 2.46 (m, 2H), 1.34 (d, J=7.0 Hz, 3H), 1.29
(s, 9H).
3(S)-Amino-3-(2.3-dihvdro-lH-4-oxa-1.5-diaza-naphthalen-7-yl)-propionic acid tert. butyl ester (20-9)
A solution of 203 ( 1.0 g, 1.9 mmol) in anhydrous Et20 (10 mL) at 0° was treated dropwise with LiAlH4 (2.09 ml of a 1.0 M solution in Et20). The resulting solution was stirred at 0°C for 30 min and then quenched by the sequential addition of H20 (0.3 mL), 15 % NaOH (0.08 mL). Celite (1 g) was added and the mixture filtered through a Celite pad. The filtrate was evaporated and the residue was purified by flash chromatography (6δ% ethyl acetate/hexanes) to give the dibenzylamine intermediate as a yellow oil. TLC Rf = 0.4 (65% ethyl acetate/hexanes) iH NMR (300 MHz, CDCI3) δ IH NMR 7.61 (d, J=1.8 Hz, lH),7.4-7.2 (10H),
6.87 (d, J=1.8 Hz, IH), 4.41 (m, 2 H), 4.36 (m, IH), 3.91 (q, J=6.7 Hz, 1 H),
3.8 (brs, IH), 3.69 (m, 2H), 3.42 (m, 2H), 2.46 (m, 2H), 1.34 (d, J=7.0 Hz,
3H), 1.29 (s, 9H).
This material was deprotected with Pd(OH)2 to afford 20-9 as a white solid. TLC Rf = 0.5 (20% 20:1:1 EtOH/NH4θH H20 - 80% EtOAc) iH NMR (300 MHz, CD3OD) δ 7.59 (d, J=1.7 Hz, IH), 6.92 (d, J=1.7 Hz,
IH), 4.41 (m, 2H), 4.30 (m, IH), ), 3.41 (m, 2H), 2.6, (m, 2H), 1.41 (s, 9H).
Scheme 21
21 -3 21 -4
10
3-Oxo-3.4-dihvdro-2H-l-oxa-4.δ-diaza-7-bromo-naphthalene (21-2)
A solution of 214 (4.8 g, 32 mmol) in MeOH (160 mL) at -15° was treated dropwise with bromine (2δ.7 g, 161 mmol). After stirring at -lδ° for O.δ h, the mixture was warmed to ambient temperature and lδ stirred overnight. The resulting white precipitate was filtered and washed with cold MeOH to afford 21-2 as a white solid. TLC Rf = 0.65 (50% EtOAc/ Hexane) iH NMR (300 MHz,DMSO-d6) d 11.2 (br,s, IH), 8.05 (d, J= 2.4 Hz, IH), 7.66 (d, J= 2.4 Hz, IH), 4.76 (s, 2H).
3(S)-Amino-3-(3-oxo-3.4-dihvdro-2H-l-oxa-4.5-diaza-naphthalen-7-yl)- δ propionic acid tert-butyl ester (21-3)
Bromide 21-2 was converted to amino ester 21-3 as illustrated in Scheme 20.
TLC Rf = O.δ (12% 20:1:1 EtOH/NH4θH H20 - 88% EtOAc) iH NMR (300 MHz, CD3OD) δ 8.04 (d, J= 1.7 Hz, IH), 7.34 (d, J=1.7 Hz, 0 IH), 4.76 (s, 2H), 4.38 (m, IH), 2.6, (m, 2H), 1.41 (s, 9H).
3(S)-Amino-3-(3-oxo-3.4-dihvdro-2H-l-oxa-4.5-diaza-naphthalen-7-yl)- propionic acid tert-butyl ester (21-4)
Bromide 21-2 was converted to amino ester 214 as 5 illustrated in Scheme 20.
TLC Rf = 0.5 (20% 20:1:1 EtOH/NH4θH/H20 - 80% EtOAc) iH NMR (300 MHz, CD3OD) δ 8.04 (d, J= 1.7 Hz, IH), 7.34 (d, J=1.7 Hz,
IH), 4.76 (s, 2H), 4.38 (m, IH), 2.6, (m, 2H), 1.41 (s, 9H).
Scheme 22
H02C C02Et NH4Ac, EtOH
22-3
Furo-r2.3-blpyridine-5-carboxaldehvde (22-2)
A solution of alcohol 22-1 (M. Bhupathy, et al., JL Heterocvcl. Chem. 1996, 32, 1283-1287) was treated with excess Mn02 (10 eq) and the mixture stirred at room temperature for 16 h, then filtered through Celite and evaporated to afford 22-2 as a white solid.
TLC Rf = 0.40 (25% EtO Ac/Hex) iH NMR (300 MHz, CDCI3) δ 10.22 (s, IH), 9.05 (d, J= 1.8 Hz, IH), 8.27 (d,
J=1.7 Hz, IH) 8.08 (d, J=1.8 Hz, IH), 7.10 (d, J=1.7 Hz, IH).
3-Amino-3-(furor2.3-blpyridin-5-yl)-propionic acid ethyl ester (22-3)
A solution containing aldehyde 22-2 (1.5 g, 10 mmol), ethyl hydrogen malonate (1.6 g, 20 mmol), and ammomum acetate (3.8 g, 50 mmol) in anhydrous ethanol (125 mL) was heated at reflux for 8 h. After cooling to room temperature, the solvent was evaporated and the residue partitioned between sat. sodium bicarbonate and EtOAc, the organic layer removed, dried, and concentrated. Chromatography of the residue afforded the amino ester 22-3 as a waxy solid. TLC Rf = 0.5 (20% 20:1:1 EtOH/NH4θH/H20 - 80% EtOAc) iH NMR (300 MHz, CD3OD) δ 8.34 (d, J=1.7 Hz, IH), 8.04 (d, J=1.7 Hz, IH), 7.72 ( d, J- 1.7 Hz, IH), 6.78 (d, J = 1.7 Hz, IH), 4.62 (m, IH), 4.13 (q, J=7.5 Hz, 2H), 3.20 (br, s, 2H), 2.76 (m, 2H), 1.23 (t, J= 7.5 Hz, 3H).
Scheme 23
H02C^ C02Et NH4Ac, EtOH
23-3
Furor3.2-b1pyridine-5-carboxaldehvde (23-2)
A solution of alcohol 234 (J.M. Hoffman, Jr., US Patent No. 4,808,595) was treated with excess Mn02 (10 eq) and the mixture stirred at room temperature for 16 h, then filtered through Celite and evaporated to afford 23-2 as a white solid. iH NMR (300 MHz, CDCI3) δ 10.18 (s, IH), 8.92 (d, J= 1.8 Hz, IH), 8.17 (d,
J=1.7 Hz, IH) 7.89 (d, J=1.8 Hz, IH), 7.10 (d, J=1.7 Hz, IH).
3-Amino-3-(furor3.2-b1pyridin-5-yl)-propionic acid ethyl ester (23-3)
A solution containing aldehyde 23-2 (1.5 g, 10 mmol), ethyl hydrogen malonate (1.6 g, 20 mmol), and ammonium acetate (3.8 g, 50 mmol) in anhydrous ethanol (125 mL) was heated at reflux for 8 h. After cooling to room temperature, the solvent was evaporated and the residue partitioned between sat. sodium bicarbonate and EtOAc, the organic layer removed, dried, and concentrated. Chromatography of the residue afforded the amino ester 23-3 as a waxy solid.
TLC Rf = 0.5 (20% 20:1:1 EtOH/NH4θH/H20 - 80% EtOAc) iH NMR (300 MHz, CD3OD) δ 8.58 (d, J=1.7 Hz, IH), 7.89 (d, J=1.7 Hz,
1H),7.85( d, J- 1.7 Hz, IH), 6.98 (d, J = 1.7 Hz, IH), 4.62 (t, J= 7.2 Hz, IH),
4.09 (q, J=7.5 Hz, 2H), 2.76 (m, 2H), 2.20 (br, s, 2H), 1.21 (t, J= 7.5 Hz, 3H).
Scheme 24
BocHN 02Me NMM, DMF 24-3
1. HOAc, 65°
2. HCl, EtOAc
02Me
H
24-4 N-(S)-(2-Amino-phenyl)-3-£er -butoxycarbonylamino-succinamic acid methyl ester (24-3)
A mixture of Boc-L-aspartic acid-β-methyl ester 24-1 (5.0g, 20.2 mmol), o-phenylene diamine 2 . (2.2 g, 20.2 mmol), EDC (3.9 g, 20.2 δ mmol), HOAT (0.28 g, 2.02 mmol), and NMM (6.7 mL, 60.7 mmol) in DMF (δO mL) was stirred for 18 h at ambient temperature. The solution was diluted with EtOAc (2δ0 mL) and washed with sat. sodium bicarbonate, water, and brine (50 mL each), then dried and evaporated to afford 24-3 as a yellow solid. 0 TLC Rf = 0.50 (96% CHCl3/δ% isopropanol) iH NMR (300 MHz, CDCI3) δ 8.10 (br,s, IH), 7.23 (d, J= 7.8 Hz, IH), 7.08 (t, J=7.8 Hz, 1H)6.78 (m, 1H),5.8 (br d, IH), 4.66 (m, 1 H), 3.76 (s, 3H), 3.15 (dd, J=4.6, 16 Hz, IH), 2.90 (dd, J= 5.1, 16 Hz, IH), 1.48 (s, 9H).
5 3(S)-Amino-3-Benzimidazol-2-yl-propionic acid methyl ester (24-4)
Ester 24-3 (1.0 g, 3 mmol) was dissolved in acetic acid (50 mL) and heated to 65° for 2 h. The solvent was removed to afford the Boc- protected intermediate as a white solid. The crude material (920 mg, 2.43 mmol) was dissolved in EtOAc, cooled to 0°, and treated with HCl gas to 0 give 244 as a tan solid. iH NMR (300 MHz, CD3OD) δ 7.80 (m, 2H), 7.3δ (m,2H), 5.98 (m, IH),
3.80 (m, 2H), 3.76 (s, 3H).
Scheme 25
1. DEAD, Ph3P
THF 2. HCl, EtOAc
H,N-^ C°2Me
252.
N-(S)-(2-Hvdroxy-phenyl)-3- er£-butoxycarbonylamino-succinamic acid methyl ester (25-2)
A mixture of Boc-L-aspartic acid-β-methyl ester (24-1) (5.0g, 20.2 mmol), 2-amino phenol (2δ-l) (2.2 g, 20.2 mmol), EDC (3.9 g, 20.2 mmol), HOAT (0.28 g, 2.02 mmol), and NMM (6.7 mL, 60.7 mmol) in DMF (50 mL) was stirred for 18 h at ambient temperature. The solution was diluted with EtOAc (250 mL) and washed with sat. sodium bicarbonate, water, and brine (50 mL each), then dried, and evaporated and chromatographed on silica (EtOAc) to afford 25-2 as a white solid. TLC Rf = 0.56 (EtOAc)) iH NMR (300 MHz, CDCI3) δ 7.23 (d, J= 7.8 Hz, IH), 6.89 (t, J=7.8 Hz, IH), 6.78 (m, IH), 5.68 (br d, IH), 4.65 (m, 1 H), 3.76 (s, 3H), 3.15 (dd, J=4.6, 16 Hz, IH), 2.90 (dd, J= 5.1, 16 Hz, IH), 1.48 (s, 9H). 3(S)-Amino-3-Benzoxazol-2-yl-propionic acid methyl ester (25-3)
Ester 25-2 (2.0 g, 6.0 mmol) was dissolved in anhydrous THF (150 mL) along with PI13P (1.58 g, 6.0 mmol) . The resulting solution was cooled to 0°, and a solution of diethyl azodicarboxylate (1.53 g, 6.2 mmol) in THF (25 mL) was added dropwise. The cooling bath was removed and the solution stirred overnight at ambient temperature. The solution was concentrated and the residue chromatographed (75% EtOAc/Hexane) to afford the Boc-protected ester as a colorless glass. The crude material (1.8 g, 5.0 mmol) was dissolved in EtOAc, cooled to 0° and treated with HCl gas to give 25-3 as a tan solid. iH NMR (300 MHz, CD3OD) δ 7.81 (m, 2H), 7.40 (m,2H), 5.0δ (t, J= 7.4 Hz,
IH), 3.72 (s, 3H), 3.30 (m, 2H).
SCHEME 26
l-Methyl-4-bromopyrazole (26-2)
Methyl iodide (8.47 mL, 136 mmol) was added to a mixture of 4-bromopyrazole 26-1 (10 g, 38 mmol), and K2Cθ3 (18.9 g, 136 mmol) in CH3CN (150 mL) and the mixture stirred at room temperature for 16 h, then filtered and evaporated to yield 26-2 as a yellow oil. iH NMR (300 MHz, CDCI3) δ 7.44(s, 1H),7.38 (s, IH), 3.90 (s, 3H).
3 (S)-Amino-3-(l-methyl-lH-pyrazol-4-yl)-propionic acid ethyl ester (26-3)
The bromide 26-2 was converted to the amino ester 26-3 following the procedure depicted in Scheme 19. iH NMR (300 MHz, CD3OD) δ 7.81 (s, 1H),7.58 (s, 1H),4.80 (m, IH), 4.0δ
(q, J= 7.0 Hz, 2 H), 3.89 (s, 3H), 3.00 (m, 2 H), 1.24 (t, J = 7.0 Hz, 3 H). Additional examples of the present invention are listed below and can be prepared by the method shown in Scheme 2 using in place of 14 the various 3-substituted β-alanine derivatives prepared according to the procedures depicted in Schemes 9-26 above. These examples can be prepared in high optical purity substituting intermediate 7^5 or its enantiomer for intermediate 2-5.
3(S)-(6-Ethoxy-pyridin-3-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid; 0
3(S)-(6-Amino-pyridin-3-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(4-Methyl-3-oxo-3,4-dihydro-2H-benzo[l,4]oxazin-7-yl)-3-(2-oxo-3-[3- 6 (δ,6,7,8-tetrahydro-[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)- propionic acid;
3-(6-Methylamino-pyridin-3-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid; 0
3(S)-(2-Fluoro-biphenyl-4-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(2-Oxo-2,3-dihydro-benzoxazol-6-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- 5 [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(4-Ethoxy-3-fluorophenyl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
0 3(S)-(δ-Ethoxy-pyridin-3-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(δ-Methoxy-pyridin-3-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid; δ 3(S)-(Ethynyl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro-[l,8]naphthyridin-2-yD- propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(6-Methoxy-pyridin-3-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(2-Oxo-2,3-dihydro-lH-4-oxa-l,5-diaza-naphthalen-7-yl)-3-(2-oxo-3-[3- (5,6,7,8-tetrahydro-[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)- propionic acid;
3(S)-(2,3-Dihydro-lH-4-oxa-l,δ-diaza-naphthalen-7-yl)-3-(2-oxo-3-[3- (δ,6,7,8-tetrahydro-[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)- propionic acid;
3(S)-(2-Oxo-3,4-dihydro-2H-l-oxa-4,5-diaza-naphthalen-7-yl)-3-(2-oxo-3-[3- (δ,6,7,8-tetrahydro-[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)- propionic acid;
3(S)-(3,4-Dihydro-2H-l-oxa-4,δ-diaza-naphthalen-7-yl)-3-(2-oxo-3-[3- (5,6,7,8-tetrahydro-[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yD- propionic acid;
3-(Furo-[2,3-b]pyridin-6-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin- l-yl)-propionic acid;
3-(2,3-Dihydrofuro[2,3-b]pyridin-6-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3-(Furo-[3,2-b]pyridin-6-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3-(2,3-Dihydrofuro[3,2-b]pyridin-6-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid; 3(S)-(Benzimidazol-2-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(lH-Imidazo[4,δ-c]pyridin-2-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(Benzoxazol-2-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro-[l,8]naphthyridin- 2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(l-Methyl-lH-pyrazol-4-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro-
[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid; and
3(S)-{2-Oxo-3-[3- δ,6,7,8-tetrahydro-[l,8]naphthyridin-2-yl)-propyl]- pyrrolidin-l-yl}-pent-4-enoic acid.
SCHEME A
SYNTHESIS OF RADIOLIGAND FOR SPA ASSAY
A-1
H, dioxane
1. Br2) NaOH, H20
2. HCl
SCHEME A (CONTINUED)
A-5a
6NHCI SCHEME A (CONTINUED)
N-(4-Iodo-phenylsulfonylamino)-L-asparagine (A-2)
To a stirred solution of acid A4 (4.39 g, 33.2 mmol), NaOH (1.49 g, 37.2 mmol), dioxane (30 ml) and H 0 (30 ml) at 0°C was added pipsyl chloride (10.34 g, 34.2 mmol). After -5 minutes, NaOH (1.49, 37.2 mmol), dissolved in 15 ml H20, was added followed by the removal of the cooling bath. After 2.0 h, the reaction mixture was concentrated. The . residue was dissolved in H20 (300 ml) and then washed with EtOAc.
The aqueous portion was cooled to 0°C and then acidified with concentrated HCl. The solid was collected and then washed with Et 0 to provide acid A- 2 as a white solid. iH NMR (300 MHz, D20) δ 7.86 (d, 2H, J=8Hz ), 7.48 (d, 2H, J=8Hz) 3.70
(m, IH), 2.39 (m, 2H).
2(S)-(4-Iodo-phenylsulfonylamino)-β-alanine (A-3)
To a stirred solution of NaOH (7.14 g, 181.8 mmol) and H20 (40 ml) at 0°C was added Br (1.30 ml, 24.9 mmol) dropwise over a ten minute period. After ~5 minutes, acid A- 2 (9.9 g, 24.9 mmol), NaOH (2.00 g, 49.8 mmol) and H20 (35 ml) were combined, cooled to 0°C and then added in a single portion to the reaction. After stirring for
20 minutes at 0°C, the reaction was heated to 90°C for 30 minutes and then recooled to 0°C. The pH was adjusted to ~7 by dropwise addition of concentrated HCl. The solid was collected, washed with EtOAc, and then dried in vacuo to provide acid A- 3 as a white solid. iH NMR (300 MHz, D20) δ 8.02 (d, 2H, J=8Hz), 7.63 (d, 2H, J=8Hz), 4.36
(m, IH), 3.51 (dd, IH, J=5Hz, 13Hz) 3.21 (m, IH).
Ethyl 2(S)-(4-iodo-phenylsulfonylamino)-β-alanine-hvdrochloride (A-4) HCl gas was rapidly bubbled through a suspension of acid A- 3 (4.0 g, 10.81-mmol) in EtOH (50 ml) at 0°C for 10 minutes. The cooling bath was removed and the reaction was heated to 60°C. After 18 h, the reaction was concentrated to provide ester A-4 as a white solid. iH NMR (300 MHz, CD3OD) δ 7.98 (d, 2H, J=8Hz), 7.63 (d, 2H, J=8Hz),
4.25 (q, IH, J=5Hz), 3.92 (m, 2H), 3.33 (m, IH), 3.06 (m, IH), 1.01 (t, 3H, J=7Hz).
Ethyl 4-r2-(2-Aminopyridin-6-yl)ethvnbenzoate (A-5a)
A mixture of ester A- 5 (700 mg, 2.63 mmol), (for preparation, see: Scheme 29 of PCT International Application Publication No. WO 95/32710, published December 7, 1995) 10% Pd/C (350 mg) and EtOH were stirred under 1 atm H . After 20 h, the reaction was filtered through a celite pad and then concentrated to provide ester A-5a as a brown oil.
TLC Rf = 0.23 (silica, 40% EtOAc/hexanes) iH NMR (300 MHz, CDCI3) δ 7.95 (d, 2H, J=8Hz), 7.26 (m, 3H), 6.43 (d,
IH, J=7Hz), 6.35 (d, IH, J=8Hz), 4.37 (m, 4H), 3.05 (m, 2H), 2.91 (m, 2H), 1.39 (t, 3H, J=7Hz).
4-r2-(2-Aminopyridin-6-yl)ethyllbenzoic acid hvdrochloride (A-6)
A suspension of ester A-5a (62δ mg, 2.31 mmol) in 6N HCl (12 ml) was heated to 60°C. After ~20 h, the reaction was concentrated to give acid A- 6 as a tan solid. iH NMR (300 MHz, CD3OD) δ 7.96 (d, 2H, J=8Hz), 7.80 (m, IH), 7.33 (d, 2H, J=8Hz), 6.84 (d, IH, J=9Hz), 6.69 (d, IH, J=7Hz), 3.09 (m, 4H).
Ethyl 4-[2-(2-Aminopyridin-6-yl)ethyl]benzoyl-2(S)-(4-iodo- phenylsulfonylamino)-β-alanine (A-7)
A solution of acid lδ-6 (400 mg, 1.43 mmol), amine A-4 (686 mg, 1.57 mmol), EDC (358 mg, 1.86 mmol), HOBT (252 mg, 1.86 mmol), NMM (632 μl, 5.72 mmol) in DMF (10 ml) was stirred for -20 h. The reaction was diluted with EtOAc and then washed with sat. NaHCθ3, brine, dried (MgSθ4) and concentrated. Flash chromatography (silica, EtOAc then 5% isopropanol/EtOAc) provided amide A- 7 as a white solid. TLC Rf = 0.4 (silica, 10% isopropanol/EtOAc) iH NMR (300 MHz, CD3OD) δ 7.79 (d, 2H, J=9Hz) 7.61 (d, 2H, J=8Hz), 7.62 (d, 2H, J=9Hz), 7.29 (m, IH), 7.27 (d, 2H, J=8Hz), 4.20 (m, IH), 3.9δ (q, 2H, J=7Hz), 3.66 (dd, IH, J=6Hz, MHz), 3.49 (dd, IH, J=8Hz, 13Hz), 3.01 (m, 2H), 2.86 (m, 2H), 1.08 (t, 3H, J=7Hz).
4-[2-(2-Aminopyridin-6-yl)ethyl]benzoyl-2(S)-(4-iodophenyl- sulfonylaminoVβ-alanine (A-8)
A solution of ester j_ (200 mg, 0.3213 mmol) and 6N HCl (30 ml) was heated to 60°C. After -20 h, the reaction mixture was concentrated. Flash chromatography (silica, 20:20:1:1 EtOAc/EtOH/ NH4θH/H 0) provided acid A-8 as a white solid. TLC Rf = 0.45 (silica, 20:20:1:1 EtOAc/EtOH/NH4θH/H20) iH NMR (400 MHz, DMSO) δ 8.40 (m, IH), 8.14 (Bs, IH), 7.81 (d, 2H, J=8Hz), 7.62 (d, 2H, J=8Hz), 7.48 (d, 2H, J=8Hz), 7.27 (m, 3H), 6.34 (d, IH, J=7Hz), 6.25 (d, IH, J=8Hz), 5.85 (bs, 2H), 3.89 (bs, IH), 3.35 (m, 2H), 2.97 (m, 2H), 2.79 (m, 2H).
4-[2-(2-Aminopyridin-6-yl)ethyl)benzoyl-2(S)-(4-trimethylstannyl- phenylsulfonylamino-β-alanine (A-9)
A solution of iodide A^ (70 mg, 0.1178 mmol), [(CH3)3Sn] (49 μl, 0.2366 mmol), Pd(PPh3)4 (5 mg) and dioxane (7 ml) was heated to 90 °C. After 2 h, the reaction was concentrated and then purified by preparative HPLC (Delta-Pak Cχ8 15 μM 100A°, 40 x 100 mm; 95:δ then 5:9δ H20/CH3CN) to provide the trifluoroacetate salt. The salt was suspended in H20 (10 ml), treated with NH4OH (5 drops) and then δ lyophilized to provide amide A- 9 as a white solid. iH NMR (400 MHz, DMSO) δ 8.40 (m, IH), 8.18 (d, IH, J=8Hz), 7.67 (m, 5H), 7.56 (d, 2H, J=8Hz), 7.29 (d, 2H, J=8Hz), 6.95-7.62 (m, 2H), 6.45 (bs, 2H), 4.00 (m, IH), 3.δ0 (m, IH), 3.33 (m, IH), 2.97 (m, 2H), 2.86 (m, 2H).
10 4-[2-(2-Aminopyridm-6-yl)ethyl]benzoyl-2(S)-4-l25iodo- phenylsulfonylamino-β-alanine (A-10)
An iodobead (Pierce) was added to a shipping vial of 5 mCi of Nal^δl (Amersham, IMS30) and stirred for five minutes at room temperature. A solution of 0.1 mg of A^9 in O.Oδ mL of 10% H2Sθ4 MeOH lδ was made and immediately added to the Nal25l/jodobead vial. After stirring for three minutes at room temperature, approximately 0.04-0.05 mL of NH4OH was added so the reaction mixture was at pH 6-7. The entire reaction mixture was injected onto the HPLC for purification [Vydac peptide-protein C-18 column, 4.6 x 250 mm, linear gradient of
20 10% acetonitrile (0.1% (TFA):H20 (0.1% TFA) to 90% acetonitrile (0.1% TFA):H 0 (0.1% TFA) over 30 minutes, 1 mlJmin]. The retention time of A- 10 is 17 minutes under these conditions. Fractions containing the majority of the radioactivity were pooled, lyophilized and diluted with ethanol to give approximately 1 mCi of A- 10. which coeluted on HPLC δ analysis with an authentic sample of A-8.
Instrumentation: Analytical and preparative HPLC was carried out using a Waters 600E Powerline Multi Solvent Delivery System with 0.1 mL heads with a Rheodyne 712δ injector and a Waters 0 990 Photodiode Array Detector with a Gilson FC203 Microfraction collector. For analytical and preparative HPLC, a Vydac peptide-protein C-18 column, 4.6 x 250 mm was used with a C-18 Brownlee modular guard column. The acetonitrile used for the HPLC analyses was Fisher Optima grade. The HPLC radiodetector used was a Beckman 170 5 Radioisotope detector. A Vydac C-18 protein and peptide column, 3.9 x 250 mm was used for analytical and preparative HPLC. Solutions of radioactivity were concentrated using a Speedvac vacuum centrifuge. Calibration curves and chemical concentrations were determined using a Hewlett Packard Model 8452A UV/Vis Diode Array Spectrophotometer. Sample radioactivities were determined in a Packard A6530 gamma counter.
The test procedures employed to measure αvβ3 and αvβδ binding and the bone resorption inhibiting activity of the compounds of the present invention are described below.
10
BONE RESORPTION-PIT ASSAY
When osteoclasts engage in bone resorption, they can cause the formation of pits in the surface of bone that they are acting upon. Therefore, when testing compounds for their ability to inhibit lδ osteoclasts, it is useful to measure the ability of osteoclasts to excavate these resorption pits when the inhibiting compound is present.
Consecutive 200 micron thick cross sections from a 6 mm cylinder of bovine femur diaphysis are cut with a low speed diamond saw (Isomet, Beuler, Ltd., Lake Bluff, II). Bone slices are pooled, placed 0 in a 10% ethanol solution and refrigerated until further use.
Prior to experimentation, bovine bone slices are ultrasonicated twice, 20 minutes each in H20. Cleaned slices are placed in 96 well plates such that two control lanes and one lane for each drug dosage are available. Each lane represents either triplicate or δ quadruplicate cultures. The bone slices in 96 well plates are sterilized by UV irradiation. Prior to incubation with osteoclasts, the bone slices are hydrated by the addition of 0.1 ml αMEM, pH 6.9 containing 5% fetal bovine serum and 1% penicillin/streptomycin.
Long bones from 7-14 day old rabbits (New Zealand White 0 Hare) are dissected, cleaned of soft tissue and placed in αMEM containing 20 mM HEPES. The bones are minced using scissors until the pieces are <1 mm and transferred to a 50 ml tube in a volume of 25 ml. The tube is rocked gently by hand for 60 cycles, the tissue is sedimented for 1 min., and the supernatant is removed. Another 25 ml 5 of medium is added to the tissue and rocked again. The second supernatant is combined with the first. The number of cells is counted excluding erythrocytes (typically - 2 x 10? cells/ml). A cell suspension consisting of 5 x lθ6/ml in αMEM containing 5% fetal bovine serum, 10 nM l,25(OH)2D3, and pencillin-streptomycin is prepared. 200 ml aliquots are added to bovine bone slices (200 mm x 6 mm) and incubated for 2 hrs. at 37°C in a humidified δ% C02 atmosphere. The medium is removed gently with a micropipettor and fresh medium containing test compounds is added. The cultures are incubated for 48 hrs., and assayed for c-telopeptide (fragments of the al chain of type I collagen) by Crosslaps for culture media (Herlev, Denmark).
Bovine bone slices are exposed to osteoclasts for 20-24 hrs and are processed for staining. Tissue culture media is removed from each bone slice. -Each well is washed with 200 ml of H20, and the bone slices are then fixed for 20 minutes in 2.5% glutaraldehyde, 0.1 M cacodylate, pH 7.4. After fixation, any remaining cellular debris is removed by 2 min. ultrasonication in the presence of 0.25 M NH4OH followed by 2 X 15 min ultrasonication in H20. The bone slices are immediately stained for 6-8 min with filtered 1% toluidine blue and 1% borax. After the bone slices have dried, resorption pits are counted in test and control slices. Resorption pits are viewed in a Microphot Fx (Nikon) fluorescence microscope using a polarizing Nikon IGS filter cube. Test dosage results are compared with controls and resulting IC50 values are determined for each compound tested. The appropriateness of extrapolating data from this assay to mammalian (including human) disease states is supported by the teaching found in Sato, M., et al., Journal of Bone and Mineral Research. Vol. 5, No. 1, pp.31-40, 1990, which is incorporated by reference herein in its entirety. This article teaches that certain bisphosphonates have been used clinically and appear to be effective in the treatment of Paget's disease, hypercalcemia of malignancy, osteolytic lesions produced by bone metastases, and bone loss due to immobilization or sex hormone deficiency. These same bisphosphonates are then tested in the resorption pit assay described above to confirm a correlation between their known utility and positive performance in the assay.
EIB ASSAY 5 Duong et al., J. Bone Miner. Res., 8: S378 (1993) describes a system for expressing the human integrin αvβ3. It has been suggested that the integrin stimulates attachment of osteoclasts to bone matrix, since antibodies against the integrin, or RGD-containing molecules, such as echistatin (European Publication 382 4δl), can effectively block 10 bone resorption.
Reaction Mixture:
1. 175 μl TBS buffer (50 mM Tris »HC1 pH 7.2, 150 mM NaCl, 1% BSA, 1 mM CaCl2, 1 mM MgCl2). lδ 2. 26 μl cell extract (dilute with 100 mM octylglucoside buffer to give 2000 cpm/25 μl).
3. 12δτ-echistatin (25 μl/50,000 cpm) (see EP 382 461).
4. 25 μl buffer (total binding) or unlabeled echistatin (nonspecific binding). 0
The reaction mixture was then incubated for 1 h at room temp. The unbound and the bound αvβ3 were separated by filtration using a Skatron Cell Harvester. The filters (prewet in 1.5% poly- ethyleneimine for 10 mins) were then washed with the wash buffer (60 5 mM Tris HCl, ImM CaCl2/MgCl2, pH 7.2). The filter was then counted in a gamma counter.
SPA ASSAY
0 MATERIALS:
1. Wheat germ agglutinin Scintillation Proximity Beads (SPA): Amersham
2. Octylglucopyranoside: Calbiochem 5 3. HEPES: Calbiochem 4. NaCl: Fisher
5. CaCl2: Fisher
6. MgCl2: SIGMA
7. Phenylmethylsulfonylfluoride (PMSF): SIGMA δ 8. Optiplate: PACKARD
9. Compound A- 10 (specific activity 600-1000 Ci/mmole)
10. test compound
11. Purified integrin receptor: αγβ3 was purified from 293 cells overexpressing αvβ3 (Duong et al., J. Bone Min. Res., θ:S378, 0 1993) according to Pytela (Methods in Enzymology, 144:475,
1987)
12. Binding buffer: δO mM HEPES, pH 7.8, 100 mM NaCl, 1 mM Ca2+/Mg2+, 0.5 mM PMSF
13. 50 mM octylglucoside in binding buffer: 60-OG buffer 5
PROCEDURE:
1. Pretreatment of SPA beads: 0 500 mg of lyophilized SPA beads were first washed four times with 200 ml of 50-OG buffer and once with 100 ml of binding buffer, and then resuspended in 12.5 ml of binding buffer.
2. Preparation of SPA beads and receptor mixture δ In each assay tube, 2.5 μl (40 mg/ml) of pretreated beads were suspended in 97.5 μl of binding buffer and 20 μl of 50-OG buffer. 5 μl (-30 ng/μl) of purified receptor was added to the beads in suspension with stirring at room temperature for 30 minutes. The mixture was then centrifuged at 2,500 rpm in a 0 Beckman GPR Benchtop centrifuge for 10 minutes at 4°C. The pellets were then resuspended in 50 μl of binding buffer and 25 μl of 50-OG buffer. 3. Reaction
The following were sequentially added into Optiplate in corresponding wells: (i) Receptor/beads mixture (75 ml) 5 (ii) 25 μl of each of the following: compound to be tested, binding buffer for total binding or A-8 for non-specific binding (final concentration 1 μM) (iii) A- 10 in binding buffer (25 μl, final concentration 40 pM) 0 (iv) Binding buffer (125 μl)
(v) Each plate was sealed with plate sealer from PACKARD and incubated overnight with rocking at 4°C
5 4. Plates were counted using PACKARD TOPCOUNT
δ. % inhibition was calculated as follows: A = total counts B = nonspecific counts 0 C = sample counts
% inhibition = [{(A-B)-(C-B)}/(A-B)]/(A-B) x 100
OCFORM ASSAY
Osteoblast-like cells (1.8 cells), originally derived from δ mouse calvaria, were plated in CORNING 24 well tissue culture plates in αMEM medium containing ribo- and deoxyribonucleosides, 10% fetal bovine serum and penicillin-streptomycin. Cells were seeded at 40,000/well in the morning. In the afternoon, bone marrow cells were prepared from six week old male Balb/C mice as follows: 0 Mice were sacrificed, tibiae removed and placed in the above medium. The ends were cut off and the marrow was flushed out of the cavity into a tube with a 1 mL syringe with a 27.6 gauge needle. The marrow was suspended by pipetting up and down. The suspension was passed through >100 μm nylon cell strainer. The resulting suspension was centrifuged at 350 x g for seven minutes. The pellet was resuspended, and a sample was diluted in 2% acetic acid to lyse the red cells. The remaining cells were counted in a hemacytometer. The cells were pelleted and resuspended at 1 x 10^ cells/mL. δO μL was added to each well of 1.8 cells to yield 60,000 cells/well and 1,25-dihydroxy-vitamin D3 (D3) was added to each well to a final concentration of 10 nM. The cultures were incubated at 37°C in a humidified, δ% C02 atmosphere.
After 48 h, the medium was changed. 72 h after the addition of bone marrow, test compounds were added with fresh medium containing D3 to quadruplicate wells. Compounds were added again after 48 h with fresh medium containing D3. After an additional 48 h., the medium was removed, cells were fixed with 10% formaldehyde in phosphate- buffered saline for 10 minutes at room temperature, followed by a 1-2 minute treatment with ethanol: acetone (1:1) and air dried. The cells were then stained for tartrate resistant acid phosphatase as follows: The cells were stained for 10-15 minutes at room temperature with δO mM acetate buffer, pH δ.O containing 30 mM sodium tartrate, 0.3 mg/mL Fast Red Violet LB Salt and 0.1 mg/mL Naphthol AS -MX phosphate. After staining, the plates were washed extensively with deionized water and air dried. The number of multinucleated, positive staining cells was counted in each well.
αvβδ ATTACHMENT ASSAY
Duong et al., J. Bone Miner. Res., 11: S290 (1996), describes a system for expressing the human αvβδ integrin receptor.
Materials:
1. Media and solutions used in this assay are purchased from BRL/Gibco, except BSA and the chemicals are from Sigma. 2. Attachment medium: HBSS with 1 mg/ml heat-inactivated fatty acid free BSA and 2 mM CaCl2.
3. Glucosaminidase substrate solution: 3.75 mM p-nitrophenyl N-acetyl-beta-D-glucosaminide, 0.1 M sodium citrate, 0.25% Triton, pH 5.0. 4. Glycine-EDTA developing solution: 50 mM glycine, δ mM EDTA, pH lO.δ.
Methods: 5 1. Plates (96 well, Nunc Maxi Sorp) were coated overnight at
4°C with human vitronectin (3 ug/ml) in 60 mM carbonate buffer (pH 9/.6), using 100 μl/well. Plates were then washed 2X with DPBS and blocked with 2% BSA in DPBS for 2h at room temperature. After additional washes (2X) with 10 DPBS, plates were used for cell attachment assay.
2. 293 (αvβδ) cells were grown in MEM media in presence of 10% fetal calf serum to 90% confluence. Cells were then lifted from dishes with IX Trypsin EDTA and washed 3X with serum free MEM. Cells were resuspended in lδ attachment medium (3 X 10^ cells/ml).
3. Test compounds were prepared as a series of dilutions at 2X concentrations and added as δO μl/well. Cell suspension was then added as 60 μl well. Plates were incubated at 37°C with 65 C02 for 1 hour to allow attachment.
20 4. Non-adherent cells were removed by gently washing the plates (3X) with DPBS and then incubated with glucosaminidase substrate solution (100 μl/well), overnight at room temperature in the dark. To quantitate cell numbers, standard curve of glucosaminidase activity was 5 determined for each experiment by adding samples of cell suspension directly to wells containing the enzyme substrate solution.
5. The next day, the reaction was developed by addition of 18δ μl/well of glycine/EDTA solution and reading absorbance at 0 405 nm using a Molecular Devices V-Max plate reader.
Average test absorbance values (4 wells per test samples) were calculated. Then, the number of attached cells at each drug concentration was quantitated versus the standard curve of cells using the Softmax program. 5 EXAMPLE OF A PHARMACEUTICAL FORMULATION
As a specific embodiment of an oral composition, 100 mg of a compound of the present invention are formulated with sufficient 5 finely divided lactose to provide a total amount of 580 to 590 mg to fill a size O hard gel capsule.
Representative compounds of the present invention were tested and found to bind to human αvβ3 integrin. These compounds are generally found to have IC50 values less than about 100 nM in the SPA
10 assay.
Representative compounds of the present invention were tested and generally found to inhibit > 50% the attachment of αvβδ expressing cells -to plates coated with vitronectin at concentrations of about 1 μM. lδ While the invention has been described and illustrated in reference to certain preferred embodiments thereof, those skilled in the art will appreciate that various changes, modifications and substitutions can be made therein without departing from the spirit and scope of the invention. For example, effective dosages other than the preferred doses
20 as set forth hereinabove may be applicable as a consequence of variations in the responsiveness of the mammal being treated for severity of bone disorders caused by resorption, or for other indications for the compounds of the invention indicated above. Likewise, the specific pharmacological responses observed may vary according to and δ depending upon the particular active compound selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, 0 therefore, that the invention be limited only by the scope of the claims which follow and that such claims be interpreted as broadly as is reasonable.
- 162

Claims

WHAT IS CLAIMED IS:
1. A compound of the formula
wherein W is selected from the group consisting of
R 1 NT NR2
-C-NR1H2 — NR^C-NR^2
a δ- or 6-membered monocyclic aromatic or nonaromatic ring system having 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, 0, and S wherein the ring nitrogen atoms are unsubstituted or substituted with one Rl substituent and the ring carbon atoms are unsubstituted or substituted with one or two l substituents, and
a 9- to 14-membered polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system has 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, 0, and S, and wherein the ring nitrogen atoms are unsubstituted or substituted with one Rl substituent and the ring carbon atoms are unsubstituted or substituted with one or two Rl substituents;
X is selected from the group consisting of
-(CH2)v-, wherein any methylene (CH2) carbon atom is either unsubstituted or substituted with one or two Rl substitutents; and a 5- or 6-membered monocyclic aromatic or nonaromatic ring system having 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, O, and S wherein the ring nitrogen atoms are unsubstituted or substituted with one Rl substituent and the ring carbon atoms are unsubstituted or substituted with one or two Rl substituents;
Y is selected from the group consisting of -(CH2)m-,
-(CH2)m-0-(CH2)n-,
-(CH2)m-S-(CH2)n-,
-(CH )m-SO-(CH )n-, -(CH2)m-S02-(CH2)n-,
-(CH2)m-0-(CH2)n-0-(CH2)p-,
-(CH2)m-0-(CH2)I1-NR4-(CH2)p -,
-(CH2)m-NR4-(CH2)n-NR4-(CH2)p -,
-(CH2)m-0-(CH2)n-S-(CH2)p -, -(CH2)m-S-(CH2)n-S-(CH2)p -,
-(CH2)m-NR4.(CH2)n-S-(CH2)p -,
-(CH )m-NR4 -(CH2)n-0-(CH2)p -,
-(CH2 S-(CH2)n-0-(CH2)p -, and
-(CH2)m-S-(CH2)n-NR4-(CH2)p -,
wherein any methylene (CH2) carbon atom in Y, other than in R4, can be substituted by one or two R^ substituents;
Z is a 5 membered aromatic or nonaromatic mono- or bicyclic ring system having 0 to 3 heteroatoms selected from the group consisting of N, 0, and S, and wherein the ring system is either unsubstituted or substituted with 0, 1, 2, or 3 oxo or thio substituents, and either unsubstituted or substituted with one or more substituents independently selected from the group consisting of RlO, RU, and Rl2 ;
wherein Rland R2 are each independently selected from the group consisting of hydrogen, halogen, Ci-XO alkyl, C3-8 cycloalkyl, C3-8 cycloheteroalkyl, C3-8 cycloalkyl Cχ-6 alkyl, C3-8 cycloheteroalkyl Cχ-6 alkyl, aryl, aryl Cχ_8 alkyl, amino, amino Cχ-8 alkyl, Cχ-3 acylamino, Cχ.3 acylamino Cχ-8 alkyl, (Cχ-6 alkyDpamino, (Cχ-6 alkyDpamino Cχ-8 alkyl, Cχ-4 alkoxy, Cχ-4 alkoxy Cχ-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cχ-6 alkyl, Cχ.3 alkoxycarbonyl,
Cχ-3 alkoxycarbonyl Cχ.6 alkyl, hydroxycarbonyl- Cχ-6 alkyloxy, hydroxy, hydroxy Cχ-6 alkyl, Cχ-6 alkyloxy- Cχ-6 alkyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, Cχ-8 alkyl-S(0)p, (Cχ-8 alkyDpaminocarbonyl, Cχ-8 alkyloxycarbonylamino, (Cχ-8 alkyl )paminocarbonyloxy,
(aryl Cχ-8 alkyDpamino, (aryl)pamino, aryl Cχ-8 alkylsulfonylamino, and Cχ-8 alkylsulfonylamino; or two Rl" substituents, when on the same carbon atom, are taken together with the carbon atom to which they are attached to form a carbonyl group;
each R3 is independently selected from the group consisting of hydrogen, aryl, Cχ.χo alkyl, aryl-(CH2)r-0-(CH2)s-, aryl-(CH2)rS(0)p-(CH2)s-, aryl-(CH )r-C(0)-(CH2)s-, aryl-(CH )r-C(0)-N(R4)-(CH2)s-, aryl-(CH2)r-N(R4)-C(0)-(CH2)s-, aryl-(CH2)r-N(R4)-(CH2)s-, halogen, hydroxyl, oxo, trifluoromethyl,
Cχ-8 alkylcarbonylamino, aryl Cχ.5 alkoxy, Cχ-5 alkoxycarbonyl, (Cχ-8 alkyDpaminocarbonyl, Cχ-6 alkylcarbonyloxy, C3-8 cycloalkyl, (Cχ-6 alkyDpamino, amino Cχ-6 alkyl, arylaminocarbonyl, aryl Cχ.5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cχ-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cχ-6 alkyl,
HC≡C-(CH2)t-, Cχ-6 alkyl-C≡C-(CH2)t-, C3-7 cycloalkyl-C≡C-(CH2)t-, aryl-C≡C-(CH2)t-, Cχ-6 alkylaryl-C≡C-(CH2)t-,
CH2=CH-(CH2)t-. Cχ-6 alkyl-CH=CH-(CH )t-, C3.7 cycloalkyl-CH=CH-(CH2)t-, aryl-CH=CH-(CH2)t-, Cχ_6 alkylaryl-CH=CH-(CH2)t-,
Cχ-6 alkyl-S02-(CH2)t-, Cχ_6 alkylaryl-S02-(CH2)t-, Cχ-6 alkoxy, aryl Cχ-6 alkoxy, aryl Cχ-6 alkyl,
(Cχ-6 alkyDpamino Cχ-6 alkyl, ( aryl )p amino, (aryl)pamino Cχ-6 alkyl, (aryl Cχ-6 alkyDpamino, (aryl Cχ-6 alkyDpamino Cχ-6 alkyl, arylcarbonyloxy, aryl Cχ-6 alkylcarbonyloxy, (Cχ-6 alkyl )paminocarbonyloxy, Cχ-8 alkylsulfonylamino, arylsulfonylamino,
Cχ-8 alkylsulfonylamino Cχ-6 alkyl, arylsulfonylamino Cχ-6 alkyl, aryl Cχ-6 alkylsulfonylamino, aryl Cχ-6 alkylsulfonylamino Cχ-6 alkyl,
Cχ-8 alkoxycarbonylamino,
Cχ-8 alkoxycarbonylamino Cχ-8 alkyl, aryloxycarbonylamino Cχ-8 alkyl, aryl Cχ-8 alkoxycarbonylamino, aryl Cχ_8 alkoxycarbonylamino Cχ-8 alkyl,
Cχ-8 alkylcarbonylamino,
Cχ-8 alkylcarbonylamino Cχ-6 alkyl, arylcarbonylamino Cχ-6 alkyl, aryl Cχ-6 alkylcarbonylamino, aryl Cχ-6 alkylcarbonylamino Cχ-6 alkyl, aminocarbonylamino Cχ-6 alkyl,
(Cχ-8 alkyDpaminocarbonylamino,
(Cχ-8 alkyDpaminocarbonylamino Cχ-6 alkyl,
(aryl)paminocarbonylamino Cχ-6 alkyl, (aryl Cχ-8 alkyDpaminocarbonylamino,
(aryl Cχ-8 alkyDpaminocarbonylamino Cχ-6 alkyl, aminosulfonylamino Cχ-6 alkyl,
(Cχ-8 alkyDpaminosulfonylamino,
(Cχ-8 alkyDpaminosulfonylamino Cχ-6 alkyl, (aryl)paminosulfonylamino Cχ-6 alkyl,
(aryl Cχ-8 alkyDpaminosulfonylamino,
(aryl Cχ.8 alkyDpaminosulfonylamino Cχ-6 alkyl,
Cχ-6 alkylsulfonyl,
Cχ-6 alkylsulfonyl Cχ-6 alkyl, arylsulfonyl Cχ-6 alkyl, aryl Cχ-6 alkylsulfonyl, aryl Cχ-6 alkylsulfonyl Cχ-6 alkyl,
Cχ-6 alkylcarbonyl,
Cχ-6 alkylcarbonyl Cχ-6 alkyl, arylcarbonyl Cχ-6 alkyl, aryl Cχ-6 alkylcarbonyl, aryl Cχ-6 alkylcarbonyl Cχ-6 alkyl, Cχ-6 alkylthiocarbonylamino, Cχ-6 alkylthiocarbonylamino Cχ-6 alkyl, arylthiocarbonylamino Cχ-6 alkyl, aryl Cχ-6 alkylthiocarbonylamino, aryl Cχ-6 alkylthiocarbonylamino Cχ-6 alkyl, (Cχ-8 alkyDpaminocarbonyl Cχ-6 alkyl, (aryl)paminocarbonyl Cχ-6 alkyl, (aryl Cχ_8 alkyDpaminocarbonyl, and
(aryl Cχ-8 alkyDpaminocarbonyl Cχ-6 alkyl, or two R3 substituents, when on the same carbon atom are taken together with the carbon atom to which they are attached to form a carbonyl or a cyclopropyl group, wherein any of the alkyl groups of R^ are either unsubstituted or substituted with one to three Rl substituents, and provided that each i is selected such that in the resultant compound the carbon atom or atoms to which B is attached is itself attached to no more than one heteroatom;
each R4 is independently selected from the group consisting of hydrogen, aryl, aminocarbonyl, C3-8 cycloalkyl, amino Cχ-6 alkyl, (aryl)paminocarbonyl, (aryl Cχ.5 alkyDpaminocarbonyl, hydroxycarbonyl Cχ-6 alkyl, Cχ-8 alkyl, aryl Cχ-6 alkyl, (Cχ-6 alkyDpamino C2-6 alkyl, (aryl Cχ-6 alkyDpamino C2-6 alkyl, Cχ-8 alkylsulfonyl, Cχ-8 alkoxycarbonyl, aryl oxy carb onyl , aryl Cχ-8 alkoxycarbonyl,
Cχ-8 alkylcarbonyl, arylcarbonyl, aryl Cχ-6 alkylcarbonyl, (Cχ.8 alkyDpaminocarbonyl, amino sulfonyl, Cχ-8 alkylaminosulfonyl, (aryl)paminosulfonyl,
(aryl Cχ-8 alkyDpaminosulfonyl, arylsulfonyl, arylCl-6 alkylsulfonyl, Cχ.6 alkylthiocarbonyl, arylthiocarbonyl, and aryl Cχ_6 alkylthiocarbonyl, wherein any of the alkyl groups of R4 are either unsubstituted or substituted with one to three Rl substituents;
R5 and R6 are each independently selected from the group consisting of hydrogen, Cχ.χo alkyl, aryl, aryl-(CH2)r-0-(CH2)s-, aryl-(CH2)rS(0)p-(CH2)s-, aryl-(CH2)r-C(0)-(CH2)s-, aryl-(CH2)r-C(0)-N(R4)-(CH2)s-, aryl-(CH2)r-N(R4)-C(0)-(CH2)s-, aryl-(CH2)r-N(R4).(CH2)s-, halogen, hydroxyl,
Cχ-8 alkylcarbonylamino, aryl Cχ.5 alkoxy,
Cχ-5 alkoxycarbonyl, (Cχ-8 alkyDpaminocarbonyl, Cχ-6 alkylcarbonyloxy, C3-8 cycloalkyl, (Cχ-6 alkyDpamino, amino Cχ-6 alkyl, arylaminocarbonyl, aryl Cχ.5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cχ-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cχ-6 alkyl,
HC≡C-(CH2)t-,
Cχ-6 alkyl-C-≡C-(CH )t-,
C3-7 cycloalkyl-C≡C-(CH2)t-, aryl-C≡C-(CH2)t-,
Cχ-6 alkylaryl-C≡C-(CH2)t-,
CH2=CH-(CH2)t-,
Cχ_6 alkyl-CH=CH-(CH2)t-,
C3.7 cycloalkyl-CH=CH-(CH2)t-, aryl-CH=CH-(CH2)t-,
Cχ-6 alkylaryl-CH=CH-(CH2)t-, Cχ_6 alkyl-S02-(CH2)t-, Cχ-6 alkylaryl-S02-(CH2)t-, Cχ-6 alkoxy, aryl Cχ-6 alkoxy, aryl Cχ-6 alkyl,
(Cχ-6 alkyDpamino Cχ-6 alkyl, (aryl)pamino, (aryl)pamino Cχ-6 alkyl, (aryl Cχ-6 alkyDpamino,
(aryl Cχ-6 alkyDpamino Cχ-6 alkyl, arylcarbonyloxy, aryl Cχ-6 alkylcarbonyloxy,
(Cχ-6 alkyDpaminocarbonyl oxy, Cχ-8 alkylsulfonylamino, arylsulfonylamino,
Cχ-8 alkylsulfonylamino Cχ-6 alkyl, arylsulfonylamino Cχ-6 alkyl, aryl Cχ-6 alkylsulfonylamino, aryl Cχ-6 alkylsulfonylamino Cχ-6 alkyl,
Cχ-8 alkoxycarbonylamino,
Cχ-8 alkoxycarbonylamino Cχ-8 alkyl, aryloxycarbonylamino Cχ-8 alkyl, aryl Cχ-8 alkoxycarbonylamino, aryl Cχ-8 alkoxycarbonylamino Cχ-8 alkyl,
Cχ-8 alkylcarbonylamino,
Cχ-8 alkylcarbonylamino Cχ-6 alkyl, arylcarbonylamino Cχ-6 alkyl, aryl Cχ.β alkylcarbonylamino, aryl Cχ.6 alkylcarbonylamino Cχ-6 alkyl, aminocarbonylamino Cχ-6 alkyl,
(Cχ-8 alkyDpaminocarbonylamino,
(Cχ-8 alkyl )paminocarbonylamino Cχ-6 alkyl, (aryl)paminocarbonylamino Cχ-6 alkyl,
(aryl Cχ-8 alkyDpaminocarbonylamino,
(aryl Cχ-8 alkyDpaminocarbonylamino Cχ-6 alkyl, aminosulfonylamino Cχ-6 alkyl,
(Cχ-8 alkyDpaminosulfonylamino, (Cχ-8 alkyDpaminosulfonylamino Cχ-6 alkyl,
(aryl)paminosulfonylamino Cχ-6 alkyl,
(aryl Cχ-8 alkyDpaminosulfonylamino,
(aryl Cχ-8 alkyDpaminosulfonylamino Cχ-6 alkyl,
Cχ-6 alkylsulfonyl, Cχ-6 alkylsulfonyl Cχ-6 alkyl, arylsulfonyl Cχ-6 alkyl, aryl Cχ-6 alkylsulfonyl, aryl Cχ-6 alkylsulfonyl Cχ-6 alkyl,
Cχ-6 alkylcarbonyl, Cχ_6 alkylcarbonyl Cχ-6 alkyl, aryl carbonyl Cχ-6 alkyl, aryl Cχ-6 alkylcarbonyl, aryl Cχ-6 alkylcarbonyl Cχ-6 alkyl, Cχ-6 alkylthiocarbonylamino,
Cχ-6 alkylthiocarbonylamino Cχ_6 alkyl, arylthiocarbonylamino Cχ-6 alkyl, aryl Cχ-6 alkylthiocarbonylamino, aryl Cχ-6 alkylthiocarbonylamino Cχ_6 alkyl, (Cχ-8 alkyDpaminocarbonyl Cχ-6 alkyl,
(aryl)paminocarbonyl Cχ-6 alkyl,
(aryl Cχ-8 alkyDpaminocarbonyl, and
(aryl Cχ.g alkyDpaminocarbonyl Cχ-6 alkyl; or R5 and R6 are taken together with the carbon atom to which they are attached to form an oxo group, wherein any of the alkyl groups of BP or β are either unsubstituted or substituted with one to three Rl substituents, and provided that each B and R^ are selected such that in the resultant compound the carbon atom to which R^ and R^ are attached is itself attached to no more than one heteroatom;
R7 and R8 are each independently selected from the group consisting of hydrogen, Cχ.χo alkyl, aryl, aryl-(CH )r-0-(CH2)s-, aryl-(CH2)rS(0)p-(CH2)s-, aryl-(CH2)r-C(0)-(CH2)s-, aryl-(CH )r-C(0)-N(R4)-(CH2)s-, aryl-(CH2)r-N(R4)-C(0)-(CH2)s-, aryl-(CH2)r-N(R4)-(CH2)s-, halogen, hydroxyl,
Cχ-8 alkylcarbonylamino, aryl Cχ.5 alkoxy, Cχ-5 alkoxycarbonyl, (Cχ-8 alkyDpaminocarbonyl, Cχ-6 alkylcarbonyloxy, C3-8 cycloalkyl,
(Cχ-6 alkyDpamino, amino Cχ-6 alkyl, arylaminocarbonyl, aryl Cχ.5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cχ-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cχ-6 alkyl,
HC-≡C-(CH2)t-, Cχ-6 alkyl-C.sC-(CH2)t-,
C3-7 cycloalkyl-C=C-(CH2)t-, aryl-C-≡C-(CH2)t-,
Cχ-6 alkylaryl-C≡C-(CH2)t-,
CH2=CH-(CH2)t-, Cχ-6 alkyl-CH=CH-(CH2)t-,
C3-7 cycloalkyl-CH=CH-(CH2)t-, aryl-CH=CH-(CH2)t-,
Cχ-6 alkylaryl-CH=CH-(CH2)t-,
Cχ-6 alkyl-S02-(CH2)t-, Cχ-6 alkylaryl-S0 -(CH2)t-,
Cχ-6 alkoxy, aryl Cχ-6 alkoxy, aryl Cχ-6 alkyl,
(Cχ-6 alkyDpamino Cχ-6 alkyl, (aryl)pamino,
(aryl)pamino Cχ-6 alkyl,
(aryl Cχ-6 alkyDpamino,
(aryl Cχ-6 alkyDpamino Cχ-6 alkyl, arylcarbonyloxy, aryl Cχ-6 alkylcarbonyloxy,
(Cχ-6 alkyl )paminocarbonyloxy,
Cχ-8 alkylsulfonylamino, arylcarbonylamino, arylsulfonylamino,
Cχ-8 alkylsulfonylamino Cχ-6 alkyl, arylsulfonylamino Cχ-6 alkyl, aryl Cχ-6 alkylsulfonylamino, aryl Cχ-6 alkylsulfonylamino Cχ-6 alkyl, Cχ-8 alkoxycarbonylamino,
Cχ-8 alkoxycarbonylamino Cχ-8 alkyl, r.ryloxycarbonylamino Cχ-8 alkyl, aryl Cχ-8 -alkoxycarbonylamino, aryl Cχ-8 alkoxycarbonylamino Cχ.8 alkyl, Cχ-8 alkylcarbonylamino Cχ_6 alkyl, arylcarbonylamino Cχ-6 alkyl, aryl Cχ-6 alkylcarbonylamino, aryl Cχ-6 alkylcarbonylamino Cχ-6 alkyl, aminocarbonylamino Cχ.6 alkyl, arylaminocarbonylamino,
(Cχ-8 alkyDpaminocarbonylamino, (Cχ-8 alkyDpaminocarbonylamino Cχ-6 alkyl, (aryl)paminocarbonylamino Cχ-6 alkyl, (aryl Cχ-8 alkyDpaminocarbonylamino, (aryl Cχ-8 alkyDpaminocarbonylamino Cχ-6 alkyl, aminosulfonylamino Cχ-6 alkyl, (Cχ-8 alkyDpaminosulfonylamino, (Cχ-8 alkyDpaminosulfonylamino Cχ-6 alkyl, ( aryl )p aminosulfonylamino Cχ-6 alkyl, (aryl Cχ-8 alkyDpaminosulfonylamino,
(aryl Cχ-8 alkyDpaminosulfonylamino Cχ-6 alkyl,
Cχ-6 alkylsulfonyl,
Cχ-6 alkylsulfonyl Cχ-6 alkyl, arylsulfonyl Cχ-6 alkyl, aryl Cχ-6 alkylsulfonyl, aryl Cχ_6 alkylsulfonyl Cχ-6 alkyl,
Cχ-6 alkylcarbonyl,
Cχ-6 alkylcarbonyl Cχ_6 alkyl, arylcarbonyl Cχ-6 alkyl, aryl Cχ-6 alkylcarbonyl, aryl Cχ_6 alkylcarbonyl Cχ-6 alkyl,
Cχ-6 alkylthiocarbonylamino,
Cχ-6 alkylthiocarbonylamino Cχ-6 alkyl, arylthiocarbonylamino Cχ-6 alkyl, aryl Cχ_6 alkylthiocarbonylamino, aryl Cχ-6 alkylthiocarbonylamino Cχ-6 alkyl,
(Cχ-8 alkyDpaminocarbonyl Cχ-6 alkyl,
(aryl)paminocarbonyl Cχ-6 alkyl, (aryl Cχ-8 alkyl )paminocarbonyl,
(aryl Cχ-8 alkyDpaminocarbonyl Cχ-6 alkyl, and
C7-20 polycyclyl Cθ-8 alkyloxycarbonylamino; wherein any of the alkyl groups of R^and R^ are either unsubstituted or substituted with one to three Rl substituents, and provided that each R^and R^ are selected such that in the resultant compound the carbon atom to which R? and R^ are attached is itself attached to no more than one heteroatom;
R9 is selected from the group consisting of hydrogen,
Cχ-8 alkyl, aryl, aryl Cχ-8 alkyl,
Cχ-8 alkylcarbonyloxy Cχ-4 alkyl, aryl Cχ-8 alkylcarbonyloxy Cχ-4 alkyl,
Cχ-8 alkylaminocarbonylmethylene, and Cχ-8 dialkylaminocarbonylmethylene; RlO , Rll, and Rl2 are each independently selected from the group consisting of hydrogen,
Cχ-8 alkyl, aryl, halogen, hydroxyl, oxo, aminocarbonyl, C3-8 cycloalkyl, amino Cχ-6 alkyl, (aryl)paminocarbonyl, hydroxy carb onyl ,
(aryl Cχ-5 alkyDpaminocarbonyl, hydroxycarbonyl Cχ-6 alkyl, aryl Cχ-6 alkyl,
(Cχ-6 alkyDpamino Cχ-6 alkyl,
(aryl Cχ-6 alkyDpamino C2-6 alkyl,
Cχ-8 alkylsulfonyl, Cχ-8 alkoxycarbonyl, aryloxycarbonyl, aryl Cχ-8 alkoxycarbonyl,
Cχ-8 alkylcarbonyl, arylcarbonyl, aryl Cχ-6 alkylcarbonyl,
(Cχ-8 alkyDpaminocarbonyl, amino sulfonyl, Cχ-8 alkylamino sulfonyl, (aryl)paminosulfonyl, (aryl Cχ.8 alkyDpaminosulfonyl,
Cχ-6 alkylsulfonyl, arylsulfonyl, aryl Cχ-6 alkylsulfonyl, aryl Cχ-6 alkylcarbonyl, Cχ-6 alkylthiocarbonyl, arylthiocarbonyl, aryl Cχ.β alkylthiocarbonyl, aryl-(CH2)r-0-(CH2)s-, aryl-(CH2)rS(0)p-(CH2)s-, aryl-(CH2)r-C(0)-(CH2)s-, aryl-(CH2)r-C(0)-N(R4)-(CH )s-, aryl-(CH2)r-N(R4)-C(0)-(CH2)s-, aryl-(CH2)r-N(R4)-(CH )s-, HC≡C-(CH2)t-,
Cχ-6 alkyl-C≡C-(CH2)t- ,
C3-7 cycloalkyl-C≡C-(CH2)t-, aryl-C≡C-<CH2)t-,
Cχ-6 alkylaryl-C-≡C-(CH2)t-, CH =CH-(CH2)t-,
Cχ.6 alkyl-CH=CH-(CH2)t-,
C3.7 cycloalkyl-CH=CH-(CH2)t-, aryl-CH=CH-(CH2)t-,
Cχ-6 alkylaryl-CH=CH-(CH2)t-, Cχ-6 alkyl-S02-(CH2)t-,
Cχ-6 alkylaryl-S0 -(CH )t-, Cχ-8 alkylcarbonylamino, aryl Cχ.5 alkoxy, Cχ-5 alkoxycarbonyl, (Cχ-8 alkyDpaminocarbonyl,
Cχ-6 alkylcarbonyloxy, (Cχ-6 alkyDpamino, aminocarbonyl Cχ-6 alkyl, Cχ-6 alkoxy, aryl Cχ-6 alkoxy,
( aryl )p amino, (aryl)pamino Cχ-6 alkyl, (aryl Cχ-6 alkyDpamino, (aryl Ci-6 alkyDpamino Cχ-6 alkyl, arylcarbonyloxy, aryl Cχ-6 alkylcarbonyloxy, (Cχ-6 alkyDpaminocarbonyl oxy, Cχ-8 alkylsulfonylamino, arylsulfonylamino,
Cχ-8 alkylsulfonylamino Cχ-6 alkyl, arylsulfonylamino Cχ-6 alkyl, aryl Cχ-6 alkylsulfonylamino, aryl Cχ-6 alkylsulfonylamino Cχ-6 alkyl, Cχ-8 alkoxycarbonylamino,
Cχ-8 alkoxycarbonylamino Cχ-8 alkyl, aryloxycarbonylamino Cχ-8 alkyl, aryl Cχ-8 -alkoxycarbonylamino, aryl Cχ-8 alkoxycarbonylamino Cχ-8 alkyl, Cχ-8 alkylcarbonylamino,
Cχ-8 alkylcarbonylamino Cχ-6 alkyl, arylcarbonylamino Cχ-6 alkyl, aryl Cχ-6 alkylcarbonylamino, aryl Cχ-6 alkylcarbonylamino Cχ-6 alkyl, aminocarbonylamino Cχ-6 alkyl,
(Cχ-8 alkyDpaminocarbonylamino, (Cχ-8 alkyl )paminocarbonylamino Cχ-6 alkyl, (aryl)paminocarbonylamino Cχ-6 alkyl, (aryl Cχ-8 alkyDpaminocarbonylamino, (aryl Cχ-8 alkyDpaminocarbonylamino Cχ-6 alkyl, aminosulfonylamino Cχ-6 alkyl, (Cχ-8 alkyDpaminosulfonylamino, (Cχ-8 alkyDpaminosulfonylamino Cχ-6 alkyl, (aryl)paminosulfonylamino Cχ-6 alkyl, (aryl Cχ-8 alkyDpaminosulfonylamino,
(aryl Cχ-8 alkyDpaminosulfonylamino Cχ-6 alkyl,
Cχ-6 alkylsulfonyl,
Cχ-6 alkylsulfonyl Cχ-6 alkyl, arylsulfonyl Cχ-6 alkyl, aryl Cχ-6 alkylsulfonyl, aryl Cχ-6 alkylsulfonyl Cχ-6 alkyl,
Cχ-6 alkylcarbonyl,
Cχ-6 alkylcarbonyl Cχ-6 alkyl, arylcarbonyl Cχ-6 alkyl, aryl Cχ-6 alkylcarbonyl, aryl Cχ-6 alkylcarbonyl Cχ-6 alkyl,
Cχ-6 alkylthiocarbonylamino,
Cχ_6 alkylthiocarbonylamino Cχ-6 alkyl, arylthiocarbonylamino Cχ_6 alkyl, aryl Cχ_6 alkylthiocarbonylamino, aryl Cχ-g alkylthiocarbonylamino Cχ-6 alkyl,
(Cχ.8 alkyDpaminocarbonyl Cχ-6 alkyl,
(aryl)paminocarbonyl Cχ-6 alkyl,
(aryl Cχ-8 alkyDpaminocarbonyl, and (aryl Cχ-8 alkyDpaminocarbonyl Cχ-6 alkyl; wherein any of the alkyl groups of RlO, RU, and Rl2 are either unsubstituted or substituted with one to three Rl substituents;
wherein
each m is independently an integer from 0 to 6; each n is independently an integer from 0 to 6 each p is independently an integer from 0 to 2; each r is independently an integer from 1 to 3; each s is independently an integer from 0 to 3; each t is independently an integer from 0 to 3; and v is independently an integer from 0 to 6;
and the pharmaceutically acceptable salts thereof.
2. The compound of Claim 1 wherein
W is a 6-membered monocyclic aromatic ring system having 1 or 2 nitrogen atoms wherein each ring carbon atom is unsubstituted or substituted with one Rl substituent, or
a 9- to 14-membered polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system has 0, 1, 2, 3 or 4 heteroatoms selected from the group consisting of N,0, and S, and wherein the ring nitrogen atoms are unsubstituted or substituted with one Rl substituent and the ring carbon atpms are unsubstituted or substituted with one or two Rl substituents; and
Z is selected from the group consisting of
3. The compound of Claim2 wherein W is selected from the group consisting of
and Z is selected from the group consisting of
4. The compound of Claim 3 wherein W is
X is -(CH2)y-, wherein any methylene (CH2) carbon atom is either unsubstituted or substituted with one or two Rl substitutents; Y is selected from the group consisting of
-(CH2)m-, -(CH2)m-0-(CH2)n-,
-(CH2)m-S-(CH2)n-,
-(CH2)m-SO-(CH2)n-,
-(CH2)m-S02-(CH2)n-, -(CH2)m-0-(CH2)n-0-(CH2)p-,
-(CH2)m-0-(CH2)n-NR4-(CH2)p-,
-(CH2)m-NR4-(CH2)n-NR4-(CH2)p-, and
-(CH2)m-NR4.(CH2)n-0-(CH2)p-, wherein any carbon atom in Y, other than in 4, can be substituted by one or two R^ substituents;
and Z is
5. The compound of Claim 4 wherein Y is selected from the group consisting of
(CH2)m, (CH2)m-S-(CH2)n, and (CH2)m-NR4-(CH2)n,
wherein any carbon atom in Y, other than in R4, can be substituted by one or two R^ substituents, and m and n are integers from 0-3, and v is 0.
6. The compound of Claim 5 wherein each R^ is independently selected from the group consisting of hydrogen, fluoro, trifluoromethyl, aryl,
Cχ-8 alkyl, arylCχ-6 alkyl hydroxyl, oxo, aryl amino carb onyl , aryl Cχ-5 alkylaminocarbonyl, aminocarbonyl, and aminocarbonyl Cχ-6 alkyl; and
each R4 is independently selected from the group consisting of hydrogen, aryl,
C3-8 cycloalkyl, Cχ-8 alkyl,
Cχ-8 alkylcarbonyl, arylcarbonyl, Cχ-6 alkylsulfonyl, arylsulfonyl, arylCχ-6alkylsulfonyl, arylC χ-6alkylcarbonyl,
C χ-8alkylaminocarbonyl, arylCx-δalkylaminocarbonyl, arylCχ-8alkoxycarbonyl, and Cχ-8alkoxycarbonyl.
7. The compound of Claim 6 wherein R^, R?, and R$ are each hydrogen and R^ is selected from the group consisting of hydrogen, aryl,
Cχ-8 alkyl, aryl-C≡C-(CH2)t-, aryl Cχ-6 alkyl, δ CH2=CH-(CH2)t-, and
HC≡C-(CH )t-.
8. The compound of Claim 7 wherein B? is selected from the group consisting of hydrogen, methyl, and ethyl.
10
9. The compound of Claim 8 wherein R^ is hydrogen.
10. * The compound of Claim 6 wherein Bβ, R^, and R^ are each hydrogen and R? is selected from the group consisting of lδ hydrogen, aryl,
Cχ-8 alkylcarbonylamino,
Cχ-8 alkylsulfonylamino, arylcarbonylamino, 20 arylsulfonylamino,
Cχ-8 alkylsulfonylamino Cχ-6 alkyl, arylsulfonylamino Cχ-6 alkyl, aryl Cχ-6 alkylsulfonylamino, aryl Cχ-6 alkylsulfonylamino Cχ-6 alkyl, 5 Cχ-8 alkoxycarbonylamino,
Cχ-8 alkoxycarbonylamino Cχ-8 alkyl, aryloxycarbonylamino Cχ-8 alkyl, aryl Cχ-8 alkoxycarbonylamino, aryl Cχ-8 alkoxycarbonylamino Cχ-8 alkyl, 0 Cχ-8 alkylcarbonylamino Cχ-6 alkyl, arylcarbonylamino Cχ-6 alkyl, aryl Cχ-6 alkylcarbonylamino, aryl Cχ-6 alkylcarbonylamino Cχ-6 alkyl, aminocarbonylamino Cχ-6 alkyl, 5 (Cχ-8 alkyDpaminocarbonylamino,
- X74 - (Cχ-8 alkyDpaminocarbonylamino Cχ-6 alkyl, (aryl)paminocarbonylamino Cχ-6 alkyl, arylaminocarbonylamino,
(aryl Cχ-8 alkyDpaminocarbonylamino, 5 (aryl Cχ-8 alkyDpaminocarbonylamino Cχ-6 alkyl, aminosulfonylamino Cχ-6 alkyl,
(Cχ-8 alkyDpaminosulfonylamino,
(Cχ-8 alkyDpaminosulfonylamino Cχ-6 alkyl,
(aryl)paminosulfonylamino Cχ-6 alkyl, 10 (aryl Cχ-8 alkyDpaminosulfonylamino,
(aryl Cχ-8 alkyDpaminosulfonylamino Cχ-6 alkyl,
Cχ-6 alkylthiocarbonylamino,
Cχ-6 alkylthiocarbonylamino Cχ-6 alkyl, arylthiocarbonylamino Cχ-6 alkyl, lδ aryl Cχ-6 alkylthiocarbonylamino, and aryl Cχ-6 alkylthiocarbonylamino Cχ-6 alkyl.
11. The compound of Claim 10 wherein R^ is selected from the group consisting of 20 hydrogen, aryl,
Cχ-8 alkylcarbonylamino, aryl Cχ-6 alkylcarbonylamino, arylcarbonylamino, δ Cχ-8 alkylsulfonylamino, aryl Cχ-6 alkylsulfonylamino, arylsulfonylamino ,
Cχ-8 alkoxycarbonylamino, aryl Cχ-8 alkoxycarbonylamino, 0 arylaminocarbonylamino,
(Cχ-8 alkyDpaminocarbonylamino, (aryl Cχ-8 alkyl)paminocarbonylamino,
(Cχ-8 alkyDpaminosulfonylamino, and
(aryl Cχ-8 alkyDpaminosulfonylamino.
12. The compound of Claim 11 wherein R^ is selected from the group consisting of hydrogen, methyl, and ethyl.
13. The compound of Claim 12 wherein R^ is hydrogen.
14. The compound of Claim 6 selected from the group consisting of
Ethyl 3(S)-(3-fluorophenyl)-3-[2-oxo-3(S)-[3-(5,6,7,8-tetrahydro- [l,8]naphthyidin-2-yl)-propyl]-pyrrolidin-l-yl]-propionate;
Ethyl 3(S)-(3-flubrophenyl)-3-[2-oxo-3(R)-[3-(5,6,7,8-tetrahydro- [ 1 , 8]naphthyidin-2-yl )-propyl]-pyrrolidin- l-yl]-propionate ;
Ethyl 3(S)-(2,3-dihydro-benzofuran-6-yl)-3-(2-oxo-3(S)-[3-(5,6,7,8- tetrahydro-[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionate;
Ethyl 3(S)-(2,3-dihydro-benzofuran-6-yl)-3-(2-oxo-3(R)-[3-(δ,6,7,8- tetrahydro-[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionate;
Ethyl 3(S)-(quinoun-3-yl)-3-(2-oxo-3(R)-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionate;
Ethyl 3(S)-(quinonn-3-yl)-3-(2-oxo-3(S)-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionate;
3(S)-(3-Fluorophenyl)-3-[2-oxo-3(R)-[3-(5,6,7,8-tetrahydro- [l,8]naphthyidin-2-yl)-propyl]-pyrrolidin-l-yl]-propionic acid;
3(S)-(3-Fluorophenyl)-3-[2-oxo-3(S)-[3-(5,6,7,8-tetrahydro- [l,8]naphthyidin-2-yl)-propyl]-pyrrolidin-l-yl]-propionic acid; 3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(2-oxo-3(R)-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(2-oxo-3(S)-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(Quinolin-3-yl)-3-(2-oxo-3(R)-[3-(5,6,7,8-tetrahydro-[l,8]naphthyridin- 2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(Quinolin-3-yl)-3-(2-oxo(S)-3-[3-(5,6,7,8-tetrahydro-[l,8]naphthyridin- 2-yl)-propyl]-pyrroHdin-l-yl)-propionic acid;
2(S)-Benzenesulfonylamino-3-[3-(3-[l,8]naphthyridin-2-yl-propyD- [l,2,4]oxadiazol-5-yl]-propionic acid;
3(S)-(6-Ethoxy-pyridin-3-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(6-Amino-pyridin-3-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(4-Methyl-3-oxo-3,4-dihydro-2H-benzo[l,4]oxazin-7-yl)-3-(2-oxo-3-[3- (5,6,7,8-tetrahydro-[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yD- propionic acid;
3-(6-Methylamino-pyridin-3-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(2-Fluoro-biphenyl-4-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-p3τ*rolidin-l-yl)-propionic acid;
3(S)-(2-Oxo-2,3-dihydro-benzoxazol-6-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid; 3(S)-(4-Ethoxy-3-fluorophenyl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(5-Ethoxy-pyridin-3-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- 6 [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yD-propionic acid;
3(S)-(δ-Methoxy-pyridin-3-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphth3nridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
10 3(S)-(Ethynyl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro-[l,8]naphthyridin-2-yD- propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(6-Methoxy- yridin-3-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid; lδ
3(S)-(2-Oxo-2,3-dihydro-lH-4-oxa-l,δ-diaza-naphthalen-7-yl)-3-(2-oxo-3-[3- (δ,6,7,8-tetrahydro-[l,8]naphthyridin-2-yl)-propyl]-p5πτolidin-l-yl)- propionic acid;
0 3(S)-(2,3-Dihydro-lH-4-oxa-l,δ-diaza-naphthalen-7-yl)-3-(2-oxo-3-[3- (5,6,7,8-tetrahydro-[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)- propionic acid;
3(S)-(2-Oxo-3,4-dihydro-2H-l-oxa-4,5-diaza-naphthalen-7-yl)-3-(2-oxo-3-[3- 5 (5,6,7,8-tetrahydro-[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)- propionic acid;
3(S)-(3,4-Dihydro-2H-l-oxa-4,δ-diaza-naphthalen-7-yl)-3-(2-oxo-3-[3- (δ,6,7,8-tetrahydro-[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)- 0 propionic acid;
3-(Furo-[2,3-b]pyridin-6-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid; 3-(2,3-Dihydrofuro[2,3-b]pyridin-6-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3-(Furo-[3,2-b]pyridin-6-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- 5 [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3-(2,3-Dihydrofuro[3,2-b]pyridin-6-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
10 3(S)-(Benzimidazol-2-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro-
[l,8]naphthyridin-2-yl)-propyl]-pyrrolidin- l-yl)-propionic acid;
3(S)-(lH-Imidazo[4,δ-c]pyridin-2-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid; lδ
3(S)-(Benzoxazol-2-yl)-3-(2-oxo-3-[3-(δ,6,7,8-tetrahydro-[l,8]naphthyridin- 2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(l-Methyl-lH-pyrazol-4-yl)-3-(2-oxo-3-[3-(5,6,7,8-tetrahydro- 20 [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-{2-oxo-3-[3-(δ,6,7,8-tetrahydro-[l,8]naphthyridin-2-yl)-propyl]- pyrrolidin-l-yl}-pent-4-enoic acid;
5 and the pharmaceutically acceptable salts thereof.
15. The compound of Claim 14 selected from the group consisting of
0 3(S)-(3-Fluorophenyl)-3-[2-oxo-3(R)-[3-(5,6,7,8-tetrahydro-
[l,8]naphthyidin-2-yD-propyl]-pyrrolidin-l-yl]-propionic acid;
3(S)-(3-Fluorophenyl)-3-[2-oxo-3(S)-[3-(δ,6,7,8-tetrahydro- [l,8]naphthyidin-2-yl)-propyl]-pyrrolidin-l-yl]-propionic acid; 5 3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(2-oxo-3(R)-[3-(5,6,7,8-tetrahydro- [l,8]naphthyridin-2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(2-oxo-3(S)-[3-(δ,6,7,8-tetrahydro- δ [l,8]naphthyridin-2-yD-propyl]-pyrrolidin-l-yl)-propionic acid;
3(S)-(Quinolin-3-yl)-3-(2-oxo-3(R)-[3-(δ,6,7,8-tetrahydro-[l,8]naphthyridin- 2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
0 3(S)-(Quinolin-3-yl)-3-(2-oxo-3(S)-[3-(5,6,7,8-tetrahydro-[l,8]naphthyridin- 2-yl)-propyl]-pyrrolidin-l-yl)-propionic acid;
and the pharmaceutically acceptable salts thereof.
5 16. A pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier.
17. A pharmaceutical composition made by combining a 0 compound according to Claim 1 and a pharmaceutically acceptable carrier.
18. A process for making a pharmaceutical composition comprising combining a compound according to Claim 1 and a pharmaceutically acceptable carrier.
19. The composition of Claim 16 which further comprises an active ingredient selected from the group consisting of a) an organic bisphosphonate or a pharmaceutically acceptable salt or ester thereof, b) an estrogen receptor modulator, c) a cytotoxic/antiproliferative agent, d) a matrix metalloproteinase inhibitor, e) an inhibitor of epidermal-derived, fibroblast-derived, or platelet-derived growth factors, f) an inhibitor of VEGF, g) an inhibitor of Flk-1/KDR, Flt-1, Tck/Tie-2, or Tie-1, h) a cathepsin K inhibitor; and i) a prenylation inhibitor, such as a farnesyl transferase inhibitor or a geranylgeranyl transferase inhibitor or a dual farnesyl/geranylgeranyl transferase inhibitor; and mixtures thereof.
20. The composition of Claim 19 wherein said active ingredient is selected from the group consisting of a.) an organic bisphosphonate or a pharmaceutically acceptable salt or ester thereof, b.) an estrogen receptor modulator, and c. a cathepsin K inhibitor; and mixtures thereof.
21. The composition of Claim 20 wherein said organic bisphosphonate or pharmaceutically acceptable salt or ester thereof is alendronate monosodium trihydrate.
22. The composition of Claim 19 wherein said active ingredient is selected from the group consisting of a.) a cytotoxic/antiproliferative agent, b.) a matrix metalloproteinase inhibitor, c.) an inhibitor of epidermal-derived, fibroblast-derived, or platelet-derived growth factors, d. ) an inhibitor of VEGF, and e.) an inhibitor of Flk-1/KDR, Flt-1, Tck/Tie-2, or Tie-1; and mixtures thereof.
23. A method of eliciting an integrin receptor antagonizing effect in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound according to Claim 1.
24. The method of Claim 23 wherein the integrin receptor antagonizing effect is an αvβ3 antagonizing effect.
2δ. The method of Claim 24 wherein the αvβ3 δ antagonizing effect is selected from the group consisting of inhibition of bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation, viral disease, and tumor growth.
26. The method of Claim 2δ wherein the αvβ3 10 antagonizing effect is the inhibition of bone resorption.
27. The method of Claim 23 wherein the integrin receptor antagonizing effect is an αvβδ antagonizing effect.
lδ 28. The method of Claim 27 wherein the αvβδ antagonizing effect is selected from the group consisting of inhibition of restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation, and tumor growth.
20 29. The method of Claim 23 wherein the integrin receptor antagonizing effect is a dual αvβ3/αvβδ antagonizing effect.
30. The method of Claim 29 wherein the dual αvβ3/αvβδ antagonizing effect is selected from the group consisting of inhibition of 5 bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation, viral disease, and tumor growth.
31. The method of Claim 23 wherein the integrin antagonizing effect is an αvβ6 antagonizing effect. 0
32. The method of Claim 31 wherein the αvβ6 antagonizing effect is selected from the group consisting of angiogenesis, inflammatory response, and wound healing.
33. A method of eliciting an integrin receptor antagonizing effect in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of the composition of Claim 16.
34. A method of treating or preventing a condition mediated by antagonism of an integrin receptor in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of the composition of Claim 16.
35. A method of inhibiting bone resorption in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of the composition of Claim 16.
36. A method of inhibiting bone resorption in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of the composition of Claim 20.
37. A method of treating tumor growth in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of the composition of Claim 22.
38. A method of treating tumor growth in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound according to Claim 1 in combination with radiation therapy.
EP98962096A 1997-12-17 1998-12-14 Integrin receptor antagonists Withdrawn EP1047425A4 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US6991097P 1997-12-17 1997-12-17
US8325198P 1998-04-27 1998-04-27
US83251P 1998-04-27
GB9810182 1998-05-13
GBGB9810182.7A GB9810182D0 (en) 1998-05-13 1998-05-13 Vitronectin receptor antagonists
GB9811283 1998-05-26
GBGB9811283.2A GB9811283D0 (en) 1998-05-26 1998-05-26 Vironectin receptor antagonists
US9258898P 1998-07-13 1998-07-13
US92588P 1998-07-13
PCT/US1998/026539 WO1999030709A1 (en) 1997-12-17 1998-12-14 Integrin receptor antagonists
US69910P 2008-03-19

Publications (2)

Publication Number Publication Date
EP1047425A1 true EP1047425A1 (en) 2000-11-02
EP1047425A4 EP1047425A4 (en) 2009-04-22

Family

ID=27517457

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98962096A Withdrawn EP1047425A4 (en) 1997-12-17 1998-12-14 Integrin receptor antagonists

Country Status (5)

Country Link
EP (1) EP1047425A4 (en)
JP (1) JP2002508323A (en)
AU (1) AU736026B2 (en)
CA (1) CA2315370A1 (en)
WO (1) WO1999030709A1 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
EP1105389A4 (en) * 1998-08-13 2001-10-17 Merck & Co Inc Integrin receptor antagonists
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
WO2000047207A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company LACTAM INHIBITORS OF FXa AND METHOD
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
IL146378A0 (en) 1999-06-02 2002-07-25 Merck & Co Inc Alpha v integrin receptor antagonists
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
JP2003510360A (en) 1999-10-04 2003-03-18 メルク エンド カムパニー インコーポレーテッド Integrin receptor antagonist
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
WO2001053297A1 (en) 2000-01-20 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
AU2001227046A1 (en) * 2000-01-24 2001-07-31 Sagami Chemical Research Center . 5h-quinoxalino(2,3-b)naphtho(2,1)(1,4)oxazin-5-one and intermediate for the preparation thereof
ATE375330T1 (en) 2000-04-17 2007-10-15 Ucb Pharma Sa ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
EP1289983A2 (en) 2000-06-15 2003-03-12 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
IT1317049B1 (en) 2000-06-23 2003-05-26 Sigma Tau Ind Farmaceuti USEFUL COMPOUNDS FOR THE PREPARATION OF MEDICATIONS FOR PHOSPHODIESTERASE INHIBITING ACTIVITIES IV.
US6740654B2 (en) 2000-07-07 2004-05-25 Celltech R & D Limited Squaric acid derivatives
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
CA2417059A1 (en) 2000-08-02 2002-02-07 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
WO2002022123A1 (en) * 2000-09-13 2002-03-21 Merck & Co., Inc. Alpha v integrin receptor antagonists
US20040254211A1 (en) 2000-09-14 2004-12-16 Arison Byron H Alpha v integrin receptor antagonists
PL363311A1 (en) 2001-04-24 2004-11-15 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and tnfalpha
US20030171368A1 (en) * 2002-02-06 2003-09-11 Werner Seitz Pyrimidinonesulfamoylureas`
JP2006516144A (en) 2002-12-20 2006-06-22 ファルマシア・コーポレーション Thiazole compounds as integrin receptor antagonist derivatives
JP4980715B2 (en) 2003-05-30 2012-07-18 ジェミン エックス ファーマシューティカルズ カナダ インコーポレイテッド Tricyclic heterocyclic compounds, compositions and methods for treating cancer or viral diseases
ES2433466T3 (en) 2004-02-27 2013-12-11 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in the treatment of metabolic disorders
US8710232B2 (en) 2004-04-22 2014-04-29 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives used as TAFIa inhibitors
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US20070299114A1 (en) * 2004-10-05 2007-12-27 Shionogi & Co., Ltd. Biaryl Derivatives
JP2009523813A (en) 2006-01-18 2009-06-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Specific therapies using integrin ligands to treat cancer
EA017864B1 (en) 2007-01-18 2013-03-29 Мерк Патент Гмбх Specific therapy and medicament using integrin ligands for treating cancer
SG176103A1 (en) 2009-05-25 2011-12-29 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
BR112013011244A2 (en) 2010-11-11 2017-10-24 Sanofi Sa Process for the preparation of 3- (6-amino-pyridin-3yl) -2-acrylic acid derivatives
LT2953948T (en) 2013-02-07 2018-01-10 Scifluor Life Sciences, Inc Fluorinated integrin antagonists
US8901144B2 (en) 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
CA2961935C (en) 2013-09-24 2020-09-08 Hirofumi Fukunaga Nitrogen-containing compound or salt thereof, or metal complex thereof
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
RU2017132433A (en) 2015-02-19 2019-03-19 Сайфлуор Лайф Сайенсиз, Инк. FLUORIATED DERIVATIVES OF TETRAHYDRONAFTHYRIDINYL NANOIC ACID AND THEIR APPLICATION
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
RS61453B1 (en) 2016-11-08 2021-03-31 Bristol Myers Squibb Co Pyrrole amides as alpha v integrin inhibitors
MX2019005234A (en) 2016-11-08 2019-08-12 Squibb Bristol Myers Co Azole amides and amines as alpha v integrin inhibitors.
ES2925173T3 (en) * 2016-11-08 2022-10-14 Bristol Myers Squibb Co Propionic acids substituted in position 3 as inhibitors of integrin alpha V
CN110167934B (en) 2016-11-08 2022-06-10 百时美施贵宝公司 Cyclobutane-and azetidine-containing monocyclic and spiro compounds as alpha V integrin inhibitors
MA46745A (en) 2016-11-08 2021-03-31 Bristol Myers Squibb Co INDAZOLE DERIVATIVES AS AN ALPHA V INTEGRIN ANTAGONISTS
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP3589627A4 (en) 2017-02-28 2020-08-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
KR20200084879A (en) * 2017-11-07 2020-07-13 브리스톨-마이어스 스큅 컴퍼니 Pyrrolopyrazine derivatives as alpha V integrin inhibitors
MX2021002181A (en) 2018-08-29 2021-07-15 Morphic Therapeutic Inc Inhibiting î±v î²6 integrin.
EP3843728A4 (en) * 2018-08-29 2022-05-25 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
JP6768868B2 (en) * 2019-03-29 2020-10-14 健裕生技股▲分▼有限公司 Compounds for promoting myocardial regeneration, methods for preparing them, and their use
US11124472B2 (en) 2019-04-08 2021-09-21 Genhealth Pharma Co., Ltd. Myocardial regeneration promoting compounds, preparation method thereof, and pharmaceutical composition
JP2020164528A (en) * 2020-04-28 2020-10-08 健裕生技股▲分▼有限公司 Myocardial regeneration promoting compounds, preparation method thereof, pharmaceutical composition, and their use
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1025439A (en) * 1963-10-09 1966-04-06 Abbott Lab Nitrofuryl substituted oxadiazoles
DE1620057A1 (en) * 1965-12-13 1970-03-19 Miles Lab Process for the preparation of omega (5-substituted-2-tetrazolyl) alkanoic acids
DE1946638A1 (en) * 1968-09-13 1970-09-03 Ici Ltd Heterocyclic compounds
WO1995006038A1 (en) * 1993-08-24 1995-03-02 G.D. Searle & Co. Platelet aggregation inhibitors
WO1995017397A1 (en) * 1993-12-20 1995-06-29 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1995032710A1 (en) * 1994-05-27 1995-12-07 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5295661A (en) * 1976-02-04 1977-08-11 Yoshitomi Pharmaceut Ind Ltd 5-alkoxy-4-oxazolealkanoic acid derivatives
US4480106A (en) * 1981-10-28 1984-10-30 Ciba-Geigy Corporation Process for the preparation of asymmetrically substituted maleic anhydrides, and asymmetrically substituted maleic anhydrides
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
JPH09165370A (en) * 1995-10-13 1997-06-24 Fuji Yakuhin Kogyo Kk Lactam derivative and its salt
AU1354097A (en) * 1995-12-29 1997-07-28 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1997024122A1 (en) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1997024124A1 (en) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
PT796855E (en) * 1996-03-20 2002-07-31 Hoechst Ag INHIBITION OF REABSORCAO IN BONES AND ANTAGONISTS OF VITRONECTIN
JP4289688B2 (en) * 1996-04-03 2009-07-01 武田薬品工業株式会社 Oxazole derivatives, production methods and agents thereof
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
EP0946587A2 (en) * 1996-12-16 1999-10-06 Fujisawa Pharmaceutical Co., Ltd. New amide compounds
EE200000360A (en) * 1997-12-17 2001-12-17 Merck & Co., Inc. Integrin receptor antagonists, a pharmaceutical composition and a process for its preparation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1025439A (en) * 1963-10-09 1966-04-06 Abbott Lab Nitrofuryl substituted oxadiazoles
DE1620057A1 (en) * 1965-12-13 1970-03-19 Miles Lab Process for the preparation of omega (5-substituted-2-tetrazolyl) alkanoic acids
DE1946638A1 (en) * 1968-09-13 1970-09-03 Ici Ltd Heterocyclic compounds
WO1995006038A1 (en) * 1993-08-24 1995-03-02 G.D. Searle & Co. Platelet aggregation inhibitors
WO1995017397A1 (en) * 1993-12-20 1995-06-29 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1995032710A1 (en) * 1994-05-27 1995-12-07 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9930709A1 *

Also Published As

Publication number Publication date
EP1047425A4 (en) 2009-04-22
AU1725799A (en) 1999-07-05
JP2002508323A (en) 2002-03-19
AU736026B2 (en) 2001-07-26
WO1999030709A1 (en) 1999-06-24
CA2315370A1 (en) 1999-06-24

Similar Documents

Publication Publication Date Title
US6066648A (en) Integrin receptor antagonists
US6017926A (en) Integrin receptor antagonists
EP1040111B1 (en) Integrin receptor antagonists
US6090944A (en) Alkanoic acid derivatives as αv integrin receptor antagonists
AU736026B2 (en) Integrin receptor antagonists
EP1040098B1 (en) Integrin receptor antagonists
US6048861A (en) Integrin receptor antagonists
US6040311A (en) Integrin receptor antagonists
EP1044001B1 (en) Integrin receptor antagonists
US6413955B1 (en) Integrin receptor antagonists
US6358970B1 (en) Integrin receptor antagonists
US20020037889A1 (en) Alpha V integrin receptor antagonists
US6211191B1 (en) Integrin receptor antagonists
CZ20002269A3 (en) Integrin receptor antagonizing substances

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000717;LT PAYMENT 20000717;LV PAYMENT 20000717;MK PAYMENT 20000717;RO PAYMENT 20000717;SI PAYMENT 20000717

A4 Supplementary search report drawn up and despatched

Effective date: 20090325

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 519/00 20060101ALI20090319BHEP

Ipc: C07D 401/14 20060101ALI20090319BHEP

Ipc: C07D 401/06 20060101ALI20090319BHEP

Ipc: C07D 471/04 20060101ALI20090319BHEP

Ipc: C07D 413/06 20060101ALI20090319BHEP

Ipc: C07D 207/26 20060101ALI20090319BHEP

Ipc: A61K 31/40 20060101ALI20090319BHEP

Ipc: A61K 31/435 20060101AFI19990706BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERCK SHARP & DOHME CORP.

17Q First examination report despatched

Effective date: 20090721

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100701